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ABSTRACT 
Despite intensive research, cancer remains one of the major causes of worldwide morbidity. 
It is widely believed, however, that if currently available anti-cancer drugs could be 
delivered specifically to tumours then the disease would have been mastered. The delivery 
of prodrug converting enzymes by clostridial spores specifically to the anoxic centres of 
tumours is one potential delivery mechanism. This is due to the extreme selectivity of spores 
to germinate solely in the hypoxic regions of tumours. Once germinated, the expression of a 
prodrug converting enzyme converts a systemical1y administered prodrug to a highly toxic 
drug only in the tumour. Previous studies using Clostridium acetobutylicum and Clostridium 
beijerinckii as the delivery vehicle highlighted that prodrug converting enzyme expression is 
only found in tumours. However, no significant anti-tumour affect was observed. Two 
possible reasons were evolved. Firstly, expression of the prodrug converting enzyme may be 
low, and/or, secondly, the tumours may not be colonised sufficiently to promote an anti-
tumour effect. 
Preliminary studies identified that Clostridium sporogenes NCIMB 10696 may represent a 
more suitable host. Higher spore titres could be prepared and, once administered, higher cell 
counts are found in the colonised tumours. Prodrug converting enzymes with improved 
kinetics over pre-existing enzymes have also been identified. Once effective gene transfer 
systems and expression systems had been developed, suitably high levels of several different 
prodrug converting enzymes, in particular nitroreductases, were obtained. Initial in vivo 
studies on one of the early recombinant strains identified a definite anti-tumour effect. Since 
those initial studies, further improvements to expression have been made. It is hoped that a 
more significant anti-tumour affect would result from using these improved strains. 
It is the ultimate aim of CDEPT to have the prodrug converting enzymes integrated into the 
host genome so as to negate the use of antibiotics. Towards this, studies on the use of both 
classical and novel integrative technologies have been investigated. 
.. 
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CHAPTER! 
INTRODUCTION 
1.1 THE GENUS CLOSTRIDIUM 
The genus Clostridium comprises one of the largest prokaryotic genera (Minton and Clarke, 
1989). Characterised as anaerobic Gram-positive rods they are unified by their ability to 
form spores. As a grouping, they have achieved greatest prominence as a consequence of 
their more notorious representatives, Clostridium botulinum, Clostridium tetani, Clostridium 
perfringens and Clostridium difficile. In this context, spore production represents one of the, 
if not the most important, virulence factor. Thus, the capacity of C. botulinum spores to 
survive extreme adversity has meant that this organism has been the principal target in food 
processing for almost a century. Similarly, within the healthcare setting, the ability of 
C. difficile spores to survive in the hospital and nursing home environment makes this 
particular clostridia one of the major causes of nosocomial infection. It is also one of the 
most difficult examples of microbial contamination to eradicate. 
Paradoxically, it is the very ability to form spores that presents the genus with perhaps its 
greatest potential to benefit mankind, through the exploitation of clostridial spores as a 
delivery system for treating cancer. This is because intravenously administered spores 
localise to, and then exclusively germinate in, the hypoxic centres of solid tumours. The net 
result is the establishment of an actively growing population of vegetative cells, specifically 
restricted to the anaerobic environment within the tumour mass. This unique feature 
provides the opportunity to selectively deliver therapeutic agents to solid tumours, by 
endowing the clostridial species used with appropriate genes capable of directing the 
production of the desired therapeutic. 
1.2 CLOSTRIDIAL TUMOUR ONCOLYSIS 
The notion of using bacteria to treat tumours has been around for nearly 140 years. The first 
documented case of a cancer patient being purposefully injected with I ive bacteria as a form 
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of cancer treatment was undertaken by the German physician W. Busch in 1868 (Hall, 1988). 
The patient, who had an inoperable sarcoma, was infected with Streptococcus pyogenes by 
placing her into a bed previously occupied by a patient with as. pyogenes infection. Within 
a week the primary tumour had decreased by 50%, and the lymph nodes in the neck had also 
shrunk in size. This provided the first indication that tumours can be reduced by bacterial 
infection. Treatment with S. pyogenes was also performed by William B. Coley at New 
York Hospital, and Friedrich Fehleisen in Germany around 1880 - 1890 who achieved some 
degree of tumour regression and patient survival (Pawelek et al., 2003). Subsequent animal 
studies indicated that the results were in part attributed to the infection and in part to the 
stimulation of the host immune response. 
The concept of using bacteria as tumour vectors has, however, been most vigorously pursued 
using Clostridium species. As early as 1813, Vautier reported that cancer patients who 
suffered gas gangrene (c. perfringens) were apparently cured of their cancer following the 
clostridial infection (cited in Hall, 1988). The potential of deliberately using clostridia was 
explored in 1935, when Connell (I935) used sterile filtrates of Clostridium histolyticum for 
the treatment of advanced cancers. The clinical improvements observed were attributed to 
the production of proteolytic enzymes that preferentially degraded cancerous tissue without 
affecting normal tissue. These observations subsequently led to several experiments in 
which proteolytic enzymes were produced in situ by deliberately infecting tumours with 
clostridial spores. Thus, Parker and colleagues (Parker et al., 1947) demonstrated that 
intratumoural injection of spores of C. histolyticum into the transplanted sarcomas of mice 
resulted in germination of the clostridia and a noticeable lysis of the tumour tissue. These 
studies gave the first suggestion of the potential to use clostridial spores to induce the lysis of 
tumours. 
Following on from Parker's work, Malmgren and Flanigan (I955) further demonstrated the 
extreme selectivity of clostridia for the hypoxic areas of tumours. Systemic administration 
of C. tetani into mice bearing a variety of tumours resulted in the mice succumbing to 
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tetanus within 48 hours. The healthy control mice, which were not transplanted with a 
tumour, remained unaffected, demonstrating no signs of disease over the entire time of the 
study. This observation demonstrated that spore germination and production of the tetanus 
toxin occurred exclusively in the hypoxic cores of tumours. 
Mose and Mose (1959) were the first to consider using non-pathogenic clostridial spores as a 
means of treating cancer via clostridial-induced lysis. For this purpose they isolated 
Clostridium butyricum M55, a strain they later termed Clostridium oncolyticum M55 (now 
reclassified as Clostridium sporogenes ATCC 13732). The intravenous injection of 
C. butyricum M55 spores into mice transplanted with solid Ehrlich tumours resulted in the 
softening of tumours followed by the spontaneous discharge of a "brownish liquid necrotic 
mass". Of the few animals that survived, most had recurrence of the tumour at the same site, 
indicating the presence of an outer viable rim of cells from which tumour re-growth could 
occur. The results were confirmed with studies that used other rodent tumour models and 
non-pathogenic Clostridium species (Gericke and Engelbart, 1964; Mose and Mose, 1964; 
Thiele et al., 1964). 
The data obtained in these early studies was sufficient for the initiation of clinical studies. 
These were undertaken by Mose and Mose using C. oncolyticum M55. In the study, they 
demonstrated that this organism lacked human pathogenicity by administering a spore 
suspension to themselves (cited in Carey et aI., 1967). Initial trials were performed with 36 
patients, who received a dose of 106 to 109 spores either intratumourally or intravenously. 
The injections were well tolerated, but were followed by a high-grade fever that then 
decreased to a low-grade fever for 1-3 days. Oncolysis occurred in the largest of the 
tumours 5-8 days later, but was not evident in the smaller tumours, metastases, and the 
surrounding tissues. Trials were also performed in the USA (Carey et al., 1967) with five 
patients with advanced neoplastic disease. Oncolysis occurred in three cases only in the 
largest of tumours, and in one case a transient clinical benefit was attributed to clostridial-
induced oncolysis. Several clinical trials have assessed the use of clostridia for the treatment 
of inoperable malignant brain tumours (Heppner and Mose, 1978; Heppner et al., 1983; 
Kretschmer, 1972). Oncolysis of the glioblastomas did occur, but complications arose 
before the completion of oncolysis and the tumours had to be removed via conventional 
surgery. These clinical trials showed that most patients could tolerate Clostridium well, 
although the presence of an outer viable rim of cells hampered progress. 
Experiments with wild type clostridial species clearly demonstrated that spore treatment is 
remarkably well tolerated and that vegetative growth frequently leads to the destruction of 
large parts of the tumour. Invariably, however, an outer viable rim remains from which 
tumour regrowth occurs. This led to the concept of combining drug treatment with spore 
administration to enhance the already observed therapeutic effect. In early studies, 
alkylating agents of the ethyleneimino type (such as tetramin, E-39, trenimon and mitomycin 
C) were shown to produce positive results when the dose and timing of drug/spore 
administration was adjusted to optimum levels (Thiele et al., 1964). The concept of 
enhancing the therapeutic properties of the clostridial cells used through genetic 
manipulation was first suggested by Schlechte and Elbe (1988). These workers attempted to 
make a recombinant strain of C. butyricum M55 that produced Colicin E3, an E. coli 
bacteriocin suggested to possess canceriostatic properties. At the time the methodology 
required to generate such a recombinant strain was not available, and the evidence presented 
to support the creation of such a strain was not convincing. It has only been since the 
advances made in clostridial gene transfer systems in the late 1980s and early 1990s 
(Mauchline et al., 1999; Minton et aI., 1993), that the desired genetic changes could be 
reproducibly made. As these gene systems were developed for non-pathogenic saccharolytic 
strains, the initial experiments were undertaken with Clostridium acetobutylicum and 
Clostridium beijerinckii. 
1.3 USE OF SACCHAROLYTIC STRAINS 
As a prelude to the enhancement of the therapeutic properties of clostridial strains through 
recombinant approaches, the ability of the various saccharolytic clostridial species to 
colonise tumours was assessed. Lemmon et al (1997) systemically applied 108 spores of 
C. beijerinckii NCIMB 8052 to mice bearing mammary EMT6 tumours and showed that 
vegetative Gram-positive clostridial rods were only present in the hypoxic and necrotic 
regions of the tumour. Histological samples of brain, heart, kidney, lung, and spleen tissues 
indicated the complete absence of spores. In another study (Lambin et at., 1998), the 
colonisation of four different saccharolytic clostridia: C. beijerinckii A TCC 17778, 
C. limosum DSM 1400, C. acetobutylicum ATCC 824 and NI-4082 (now reclassified as 
C. saccharoperbutylacetonicum), were compared to C. oncolyticum. It was found that a 
spore titre of at least 107 was required for colonisation of the W AG/Rij rats, and that 
C. acetobutylicum colonised better than the other three saccharolytic strains obtaining a 
similar population level to that obtained by C. oncolyticum. Heat treatment of the tumours 
indicated that the numbers of colony forming units (cfu) obtained (up to 109 cfu per gram of 
tissue after 4 - 5 days) was due to vegetative cells. 104 to 106 cfu were found in normal 
tissues. These colonies were proven to be entirely due to spores, as heat treatment had no 
effect on colony counts. This result was confirmed with Gram-staining and histochemical 
staining of the tumour and normal tissues. No clostridial spores were present in urine 
samples taken at 4 and 8 days after spore injection. 
Having established that saccharolytic clostridial strains are able to colonise tumours, efforts 
have focussed on the introduction of genes encoding anti-cancer agents. To date, the 
introduction of two classes of recombinant therapeutic protein have been explored: 
(i) proteins that are antitumourogenic in their own right such as toxins and cytokines, and; 
(ii) enzymes which turnover a prodrug to a toxic drug, so-called prodrug converting 
enzymes. 
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1.3.1 Tumour necrosis factor (TNFa) 
TNFa acts as a therapeutic agent in several ways. These include selective destruction of the 
neovasculature leading to thrombosis and necrosis of tumours, stimulation of T-cel1 
immunity, and direct cytotoxicity to tumour cells, mainly via apoptosis (Fiers, 1991; Larrick 
and Wright, 1990; Laster et al., 1988; Zheng et aI., 1995). Furthermore, enhancement of the 
anti-tumour effect of TNFa has been demonstrated when combined with irradiation 
(Hallahan et aI., 1995; Sersa et al., 1988). The downside to its use, however, is the systemic 
toxicity that ensues from direct administration. Delivery via recombinant clostridia therefore 
provides an opportunity for the localised production, thereby minimising any toxic side 
effects. 
In the investigations of Theys et al (1999), mouse TNFa (mTNFa) was placed under the 
control of the eglA promoter and eglA signal sequence for secretion of mTNFa into the 
tumour mass. Biologically active mTNFa was detected by spectrophotometric assay and the 
presence of mTNFa in both the culture supernatants and cell lysates was demonstrated by 
Western blot. The cleaved processed form of mTNFa was detectable in culture 
supernatants, with both the precursor and processed forms of mTNFa detectable in cell 
lysates. Lysates and supernatants were taken at various times throughout bacterial growth 
and added to the highly TNFa sensitive WEHIl64 clone 13 cells. Up to 1055 U TNFa per 
ml of lysate and approximately 104 U TNFa per ml of supernatant was detectable. However, 
it was noted that the TNFa activity in the supernatant decreased after 20 hours. This is 
unlike the TNFa activity in the cel1lysates, which was maximal at mid-log growth phase and 
maintained at that level for at least 20 hours. Acidification of the media during growth was 
attributed to be influencing TNFa stability, as this phenomenon was not seen in pH buffered 
media. 
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1.3.2 Prodrug converting enzymes 
Greatest attention has focussed on the use of prodrug converting enzymes. These represent 
the crucial component of Directed Enzyme Prodrug Therapy (DEPT). In DEPT strategies 
the anti-cancer drug is introduced into the bloodstream as a harmless "prodrug". This is 
subsequently converted into the active drug by an "enzyme" that is specifically targeted 
("directed") to tumour cells, prior to injection of the prodrug. Specific targeting of the 
enzyme ensures that high therapeutic doses of the drug are exclusively achieved within the 
vicinity of the tumour, and not elsewhere in the body. As each enzyme molecule is able to 
catalyse the generation of large quantities of therapeutic drug, not every tumour cell needs to 
be specially targeted, i.e. the 'bystander effect'. 
In order for enzyme/prodrug therapy to be effective, both the enzyme and prodrug should 
meet certain requirements. The enzyme should be either of a non-human origin or a human 
protein that is absent or expressed only at a low concentration in normal tissues (Rainov et 
aI., 1998; Rigg and Sikora, 1997). The protein must achieve a sufficient level of expression 
in the tumours and have high catalytic activity (Niculescu-Duvaz et aI., 1998). The prodrug 
should be a good substrate for the expressed enzyme and not be activated by exogenous 
enzymes present in normal tissue. Additionally, the prodrug must be able to pass through the 
tumour cell membrane in order for it to take its effect on the tumour cell. It is also 
preferential to have a high as possible cytotoxicity differential between the prodrug and toxic 
drug. Finally, it is beneficial if the drug is highly diffusible or is actively taken up by non-
expressing cancer cells in order to elicit a 'bystander effect' (Niculescu-Duvaz et aI., 1998). 
The first DEPT strategy was proposed by Bagshawe (1987). Here, enzyme delivery is 
mediated by the fusion of the prodrug converting enzyme to a monoclonal antibody raised 
against a tumour-specific antigen, i.e. Antibody-Directed Enzyme Prodrug Therapy 
(ADEPT). Whilst such an approach remains under investigation (Francis et aI., 2002; 
Spooner et aI., 2003), ADEPT suffers from a number of fundamental drawbacks. Tumours 
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exhibit great heterogeneity with regard to the type of antigen present, necessitating the 
generation of a multitude of different antibodies for different forms of cancer. Moreover. in 
some instances tumours do not possess an enriched antigen, and so may not be targeted by 
this approach. This has led, in part, to a greater emphasis in recent years on strategies which 
seek to deliver the gene encoding the prodrug converting enzyme, most often through the use 
of a viral vector (Green et at., 2003; Okabe et at., 2003); in so-called Gene-Directed or 
Viral-Directed Enzyme Prodrug Therapy (G/VDEPT). However, GDEPT/VDEPT 
approaches also exhibit fundamental deficiencies, most notably a lack of tumour specificity, 
poor levels of transgene expression and inefficient distribution of the vector throughout the 
tumour mass (Xu and McLeod, 2001). 
The suggested (Minton et at., 1995) delivery of prodrug converting enzymes through the use 
of clostridial spores (Clostridial-Directed Enzyme Prodrug Therapy, CDEPT) would 
overcome many of these problems. The strategy does not rely on the presence or absence of 
a particular antigen. Rather, it achieves its specificity through the existence of the hypoxic 
environment present in the centre core of the majority of solid tumours. Two prodrug 
converting enzymes have been explored to date, based on the bacterial enzymes 
nitroreductase (NTR) and cytosine deaminase (CD). Both enzymes essentially have no 
human equivalent. 
1.3.2.1 Nitroreductase 
The first prodrug-converting enzyme to be cloned and expressed in clostridia was the E. coli 
B nitroreductase NfnB (Michael et at., 1994), which was introduced into C. beijerinckii 
NCIMB 8052 (Minton et at., 1995). Nitroreductase reduces the prodrug CB 1954 (5-
(aziridin-l-yl)-2,4-dinitrobenzamide) into either a 2-hydroxylamine, or 4-hydroxylamine 
product (Knox et at., 1988b) (see Figure 1.1). The 4-hydroxylamine product (5-(aziridin-l-
yl)-4-hydroxylamine-2-nitrobenzamide) is known to be particularly toxic (104_ to 105 -fold 
more cytotoxic than the CB 1954 progenitor). A further non-enzymatic conversion of the 
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4-hydroxylamine derivative by Acetyl CoA to a 4-acetoxy derivative results in the formation 
of DNA cross-links. The DNA cross-links lead to apoptosis of the cancer cell (Knox et al., 
1988a; Knox et al., 1991). 
CB1954 
2-nitroso 
Derivative 
\7 
N 
;74 NHOH H2N I ~ ~2 
o N02 
4-hydroxylamine 
Derivative 
2-hydroxylamine 
Derivative 
Figure 1.1: Nitroreductase reduction of CB 1954 to the 4-hydroxylamino (4-HX) toxic drug. The 
arrows represent the nitroreductase enzyme catalysed two electron reduction. NfnB converts CB 1954 
to the 4-HX plus a less toxic 2-HX derivative. Most other nitroreductases studied, except NfnB, 
convert CB 1954 to the toxic 4-HX only. The numbered positions in the benzene ring are indicated. 
Adapted from AbuKhader et al (AbuKhader et aI., 2005). 
The nfnB gene was efficiently expressed in C. beijerinckii NCIMB 8052, where recombinant 
NfnB was estimated to represent 8% of the cells soluble protein. Following the intravenous 
injection of the recombinant spores into mice bearing EMT6 tumours, tumour lysates were 
shown, by Western blots, to contain the E. coli-derived enzyme (Minton et aI., 1995). 
Subsequently, Lemmon et al (1997) confirmed the result obtained with C. beijerinckii and 
measured a 22-fold increase in killing in EMT6 tumours treated with CB 1954. However, 
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despite the fact that recombinant nitroreductase could be detected In tumours, enzyme 
activity could not be detected in tumour tissue. 
1.3.2.2 Cytosine deaminase 
The other type of prodrug converting enzyme to be expressed in clostridia is the E. coli 
cytosine deaminase CodA. This enzyme converts the non-toxic prodrug 5-fluorocytosine (5-
FC) into the cytotoxic drug 5-fluorouracil (5-FU). 5-FU acts as an anticancer agent as it is 
further metabolised into 5-fluorouridine-5'-triphosphate and 5-fluoro-2'-deoxyuridine 5'-
monophosphate, which inhibit DNA and RNA synthesis (Polak et aI., 1976). This enzyme is 
of particular interest in DEPT strategies as the difference in toxicity between prodrug (5-FC) 
and drug (5-FU) is large (104). Moreover, both 5-FU and 5-FC are currently approved for 
clinical applications in the treatment of breast and gastrointestinal cancers. Fox et al (1996) 
were the first to report expression of codA in C. beijerinckii. Supernatants taken from the 
genetically modified C. beijerinckii culture increased the sensitivity of murine EMT6 
carcinoma cells to 5-FC 500-fold, a level comparable to other studies where the codA gene is 
transfected into mammalian cells. 
More recently, C. acetobutylicum was engineered to secrete CodA specifically at the site of 
the tumour by fusion of the clostripain (closJ) signal sequence to the 5' end of codA (Theys 
et al., 2001a). Western blot analysis revealed the 52-kDa CodA enzyme in both culture 
filtrates and cell lysates from early-logarithmic growth phase samples. In vitro and in vivo 
tests ascertained a maximal enzyme activity of 700 pmol 5-FC converted to 5-FU per ml in 
recombinant bacterial supernatants during early-log phase. This level would equate to a 3% 
conversion efficiency of 5-FC to 5-FU in vivo, an effectiveness considered to be 
therapeutically viable. The level of CodA activity decreased after early-log phase possibly 
due to denaturation of the enzyme from acidification of the media or by proteolytic 
breakdown from extracellular proteases produced by the bacterial host. 
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1.4 USE OF PROTEOLYTIC STRAINS 
The lack of anti-tumour effects seen following administration of prodrug to animals 
colonised with engineered saccharolytic clostridia may have been due to a number of factors, 
including segregational instability of the expression vector used and insufficient production 
of the recombinant prodrug converting enzyme gene. The latter could most simply be 
accounted for by the attainment of relatively low cell densities of saccharolytic clostridia in 
the colonised tumour, compared to, for instance C. sporogenes. Indeed, it was apparent that 
the bacterial cell numbers in tumours colonised by C. beijerinckii NCIMB 8052 was two 
orders of magnitude lower than comparable tumours colonised by C. sporogenes M55 (Liu 
et aI., 2002). 
These experiments suggest that a strain such as C. sporogenes M55 may represent a more 
effective delivery vehicle for anti-cancer agents. As this strain initially proved recalcitrant to 
gene transfer, another C. sporogenes (NCIMB 10696) was identified into which plasmid 
DNA could be transformed. Accordingly, an expression plasmid (pMTL540CD) carrying 
codA was successfully introduced into strain NCIMB 10696 and its in vivo effectiveness 
assessed as follows (Liu et aI., 2002): cell extracts taken from CodA recombinant C. 
sporogenes increased the cytotoxicity of 5-FC to SCCVII cells by a factor of 104. Western 
blot analysis of CodA and detection of enzyme activity in vitro were performed both 7 and 
14 days post-intravenous injection of 108 spores of recombinant C. sporogenes into SCCVII 
tumour-bearing mice. CodA was detected by Western blot analysis in both the 7 and 14 day 
tumour samples. Also, extracts from tumours from mice injected with recombinant spores 
increased the cytotoxicity of 5-FC by a factor of 103 with no increase observed for mice 
injected with wild-type spores. The exquisite selectivity of the process was highlighted by 
Western blot of several different tissue homogenates. CodA was found to be confined to the 
tumour and could not be found in any of the other tissues screened (brain, heart, lung, liver, 
kidney and spleen). 
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To further confirm that C. sporogenes was producing sufficient CodA to convert 5-FC to 
5-FU at a clinically relevant rate, colonised mice were injected with either 5-FC or 5-FU at 
maximally tolerated doses. Control groups of animals received either recombinant spores 
alone, or saline as a negative control. Injection of spores alone caused a small amount of 
tumour lysis as seen in other experiments, whereas a combination of 5-FC and recombinant 
spores produced a greater growth delay than that given by the maximally tolerated dose of 
5-FU. However, in both cases, the tumours became mildly resistant to 5-FU after the first 
week of injections. 
The benefits of a more aggressive coloniser have additionally been shown in a study that 
utilised a non-toxinogenic, proteolytic strain of C. novyi, C. novyi-NT (Dang et al., 2001). 
These authors assessed a variety of anaerobic bacteria for their capacity to grow extensively 
and uniquely in the anoxic zones of transplanted tumours. Of the 26 bacterial species tested, 
15 species were of the non-pathogenic anaerobe Bifidobacterium, 2 species were 
Lactobacillus and 9 were members of the genus Clostridium. Intravenous injection of 
Bifidobacterium species resulted in tight clusters of bifidobacteria uniquely in the tumour, 
rather than dispersed throughout the necrotic regions as preferred. Intratumoural injection of 
clostridia, in particular C. novyi and C sordellii, resulted in an extensive spread of vegetative 
cells throughout the poorly vascularised area of the tumour mass. Toxicity of C. novyii and 
C. sordellii is a barrier when injected intravenously. Injection of up to 1 08 spores led to the 
death of all tumour-bearing mice within 16-18 hours, due to the release of potent lethal 
bacterial toxins. To overcome this toxicity, the lethal toxin gene was eliminated from 
C. novyi by heat shock, the toxin gene being located within a phage episome. The result was 
confirmed by PCR and led to a new strain, C. novyi-NT. C. sordellii was not chosen due to 
the presence of two homologous toxin genes. Intravenous injection of spores of C. novyi-NT 
led to germination of the spores in the tumour, and resulted in greatly expanded areas of 
necrosis, without the toxicity side effects observed earlier. However, as in earlier studies, a 
viable rim of tumour cells still existed at the periphery of the tumour. 
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1.5 COMBINATION THERAPIES 
At an early stage in the evolution of clostridial-based strategies, it was recognised that 
procedures that enhance tumour hypoxia might increase oncolysis. Thus, Dietzel et at 
(1978) looked at increasing hypoxia in tumours by raising the temperature within the tumour 
using microwaves (High-Frequency Hyperthermia, H-FH). When this was combined with 
irradiation in repeated cycles, a larger reduction in tumour weight in animal tumour models 
was noticed (Gericke et aI., 1979). Increasing the degree of hypoxia through restriction of 
the oxygen level in the respiratory air supplied to animals has also been investigated. A 
reduction of between 11 and 12% in the air supplied to animals carrying both Ehrlich and 
Hardy Passey melanomas dramatically improved the extent of tumour lysis, resulting in 
complete tumour eradication in 30% of cases (Mose, 1979). More recently, an effective 
route to increasing tumour hypoxia has been demonstrated using vascular targeting agents. 
1.5.1 Vascular targeting agents 
It had been observed that the efficiency with which tumours are colonised following spore 
inoculation was directly proportional to tumour volume (Theys et at., 2001 b). A tumour size 
of approximately 3 cm3 is necessary to guarantee colonisation. This size constraint is 
directly linked to the degree of hypoxia and necrosis present, i.e. the larger the tumour the 
greater the extent of hypoxia and necrosis within the centre. This led to the hypothesis that 
the use of angiogenesis inhibitors and/or vascular targeting agents would increase the level 
of hypoxia and thereby lead to more effective colonisation by clostridia. Moreover, it would 
allow smaller, more aerobic tumours to be colonised. 
This hypothesis was tested in W AGlRij rats bearing rhabdomyosarcomas USing 
Combretastatin A4-phosphate (CombreAp, OXIGENE, Lund, Sweden), an example of a new 
class of tumour vasculature targeting agent. CombreAp selectively attacks and destroys 
tumour-specific blood vessels formed by angiogenesis (Dark et aI., 1997) leaving normal 
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vasculature unharmed, due to the morphologically and functionally abnormal tumour blood 
vessels (Denekamp, 1993). Systemic administration of CombreAp was shown to result in 
severe tumour vascular shutdown some 3 to 6 hours after administration, leading to obvious 
necrosis within 1 to 3 days (Landuyt et aI., 2000). Moreover, if administration of Comb reAp 
was preceded 4 hours earlier by an intravenous dose of clostridial spores then smalI tumours 
« 1 cm3) were colonised. Equivalent sized tumours in the control animals that did not 
receive any CombreAp were not colonised (Theys et aI., 200 1 b), indicating a strong 
relationship between the level of hypoxia/necrosis and the likelihood of tumour colonisation. 
The benefits of vascular targeting agents were also shown in the studies of Dang et al (200 I) 
using C. novyi-NT. In this case the vascular targeting agent employed was dolastatin-10 
(D I 0), which was also used in combination with the DNA damaging agent mitomycin C 
(MMC). Treatment with spores, D 1 0, and MMC resulted in dramatic effects on the large 
subcutaneous tumours of the colorectal cancer celI line HCT116 in nude mice. 24 hours 
post-administration of the spores the tumour mass swelled. D 10 was then given 
intravenously and folIowed by MMC 24 hours later. 6 hours after D 1 0 treatment a zone of 
necrosis could be seen. This zone increased in size over 24 hours and often completely 
enveloped the tumour. The necrotic masses then shrunk over the following 2 to 4 weeks. In 
the control mice, which received only D10 and MMC, no reduction in tumour mass was 
noted. The downside to this combination bacteriolytic therapy (termed 'COBALT') is the 
association of significant toxicity: 15-45% of animals died depending on tumour size, when 
C. novyi-NT spores were combined with chemotherapy. A possible explanation could be 
tumour lysis syndrome, a phenomenon seen in other cases where large tumours are rapidly 
destroyed by antineoplastic agents. 
1.5.2 Temporal regulation of gene expression 
A further avenue that is under investigation is to position the gene encoding the therapeutic 
agent under the control of a radiation-inducible promoter. This would place the production 
15 
of the desired therapeutic protein, In combination with the appropriate dose of ionising 
irradiation, under both temporal and spatial control. In bacteria, DNA damage is restored by 
a number of systems, the most important of which is the SOS repair mechanism (Miller and 
Kokjohn, 1990). The recA gene is a central component of this system. Using both Northern 
blot analysis and promoter systems, the expression of the recA gene of C. acetobutylicum has 
been shown to be induced by some 30% following irradiation at clinically relevant doses of 
2 Gy (Nuyts et al., 2001 a; Nuyts et al., 2001 b). The feasibility of using the recA promoter to 
regulate mTNFa production was tested by Nuyts and co-workers (Nuyts et al., 2001c). To 
enable secretion of the protein, the eglA signal sequence was fused to mTNFa. Secretion of 
mTNFa was shown to increase by 44% 3.5 hours after a single irradiation dose of2 Gy. As 
radiotherapy is usually given in smaller fractionated doses, a second dose of 2 Gy was given 
3 hours after the first. This lead to a 1.33- to 1.36-fold increase in TNFa production. The 
level of induction achieved correlates well with the increase seen after a single dose 
indicating that the recA promoter can be reactivated by a second dose of radiotherapy (N uyts 
et al., 2001c). 
Radioinducibility is mediated by binding of DinR (equivalent to LexA in E. coli) to operator 
sequences in the recA promoter, termed 'Cheo boxes'. In the original experiments, 
expression from the recA promoter was not completely repressed, as TNFa was produced 
even in the absence of irradiation (Nuyts et al., 2001c). To exert greater regulatory control, a 
second Cheo box was subsequently incorporated into the recA promoter (Nuyts et aI., 
200 I d). This resulted in an increase in mTNFa secretion from 44% for the wild-type 
promoter to 412% for the promoter with an extra Cheo box after a single irradiation dose of 
2 Gy. Moreover, these authors were able to show that the constitutive endo-f3-1 A-glucanase 
(egIA) promoter could be converted to an ionising irradiation responsive promoter through 
the introduction of a Cheo box. Thus, the presence of a Cheo box resulted in a 242% 
increase in mTNFa secretion. The increase in mTNFa secretion. from irradiated and non-
irradiated control cultures, was confirmed by RT-PCR to be caused by enhanced 
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transcription. 
Radiation-inducible promoters show promise for use in CDEPT strategies as the therapeutic 
protein is only induced in response to irradiation. Therefore, radiation may be employed as a 
'molecular switch', activating transcription/expression of the therapeutic gene only In 
tumour tissues rather than in other non-tumoural hypoxic tissues, such as abscesses or 
infarcted tissues. 
1.6 OTHER BACTERIAL DELIVERY SYSTEMS 
Whilst clostridia have been under the greatest scrutiny, other bacterial-based tumour delivery 
systems are under investigation, including the facultative anaerobe Salmonella typhimurium 
and the obligate anaerobe Bifidobacterium. Growth of S. typhimurium within tumours is 
mediated by severe disablements that both reduce toxicity (by alteration of the 
lipopolysaccharide) and impose a requirement for adenine. The latter is presumed not to be 
readily available in normal healthy tissues, but is enriched in the tumour environment as a 
consequence of cellular breakdown. This attenuation allows the organism to accumulate and 
persist in tumours and exert an inherent anti-tumour efficacy in their own right. However, 
whilst this efficacy has been observed in animal models (Low et aI., 1999; Pawelek et aI., 
1997), it was not seen in human trials (Toso et aI., 2002). As with clostridia, the use of 
S. typhimurium has been combined with DEPT approaches, most notably with codA, where 
appropriately manipulated strains have been shown, in combination with 5-FC, to cause 
significant tumour regression in rodent models (Zheng et al., 2000). This particular system 
has been taken into a Phase I clinical trial (Cunningham and Nemunaitis, 200 I), but the final 
outcome has yet to be published. 
The obligate anaerobe Bifidobacteriul71 longum has also been shown to selectively colonise 
solid tumours (Yazawa et aI., 2000). Compared to clostridia, the population densities 
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achieved in tumours are significantly less, i.e. less then 103 cfu g-l tumour tissue compared 
to 109 cfu g-l in the case of C. sporogenes. Given the result obtained with saccharolytic 
clostridial species, these low numbers might be predicted to be insufficient for the 
production of effective levels of a recombinant therapeutic protein. Surprisingly, however, 
recent studies have shown that a strain engineered to produce CodA caused significant 
regression of DMBA-induced mammary tumours in rats following administration of 5-FC 
(Fujimori et at., 2002). Similarly, Bifidobacterium adolescentis has been used to deliver an 
endostatin gene to solid tumours in mice, where a strong inhibition of angiogenesis stemmed 
tumour growth (Li et at., 2003). 
1.7 GENETIC MANIPULATION OF CLOSTRIDIA 
Anti-tumour effects have been demonstrated usmg recombinant clostridia to target 
expressIOn of prodrug converting enzymes and cytotoxic agents to the hypoxic areas of 
tumours. Nevertheless, further improvements to the current rudimentary genetic 
manipulation systems available for the clostridia would enable even greater enzyme 
expression and therefore superior anti-tumour effects. 
1.7.1 Introduction 
Natural bacterial competence has been reported in several bacteria, most notably in 
Streptococcus pneumoniae, Haemophilus injluenzae, and Bacillus subtilis. However, there 
has never been reported natural competence in the clostridia. Therefore, to introduce foreign 
DNA into clostridia, transformation procedures that rely on induced competence via the 
alteration of the cell envelope need to be devised. It has been some 20 years since the 
development of the first plasmid transformation procedure for clostridia. Cryptic 
C. perfringens plasm ids were introduced into a plasmid cured derivative of C. perfringens 
11268, strain 11268 CDR (Heefner et at., 1984; Squires et at., 1984). In this early work. L-
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phase variants (protoplasts unable to regenerate to the bacillary form) of C. perfringens 
11268 CDR were generated by growth in the presence of penicillin G and 0.4 M sucrose. 
Being osmotically sensitive, it was thought that L-phase variants would be susceptible to 
polyethylene glycol (PEG) mediated transformation. Protoplasts were transformed with the 
tetracycline resistance encoding cryptic plasmid pJU 124 from C. perfringens 12502 and 
tetracycline resistant transform ants arose at a frequency of approximately 102 transform ants 
per J.lg of plasmid DNA. The plasmid was also introduced by a filter mating technique using 
C. perfringens 12502 as the donor and C. perfringens 11268 as the recipient at a frequency 
of 10-5 cells per donor. 
Included in the publication on the work on transformation procedures was the development 
of a variety of E. coli/c. perfringens shuttle vectors (Squires et aI., 1984). A series of 
plasmid vectors were constructed based on small « 4 kb) cryptic plasmids from 
C. perfringens fused to pBR322 into which had been inserted a tetracycline resistant 
determinant to allow for antibiotic selection in both E. coli and C. perfringens. The plasm ids 
contained restriction sites to allow the insertion of additional heterologouslhomologous 
DNA. Transformation of C. perfringens occurred at a frequency of 102 transformants per J.lg 
of the chimeric plasmids. Following this initial work there have been numerous reports on 
the improvement of clostridial transformation. 
1.7.2 Transformation procedures 
PEG mediated transformation has had limited success mainly due to the difficulty in 
improving the regeneration step such that the L-form cells can regenerate to bacillary form. 
This difficulty was finally overcome using the partially autolysin deficient C. acetobutylicum 
NI-4081 (Azeddoug et al., 1989; Truffaut et aI., 1989). Transformation frequencies of 
around 1 x 106 transform ants per J.lg plasmid DNA were obtained in this strain. However. 
the inherent difficulty in transforming and regenerating protoplasts led to the development of 
transformation of vegetative cells by electric field permeabilisation of the cell membrane, a 
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process now termed electrotransformation or alternatively electroporation. 
1. 7.2.1 Electroporation 
There have been several reports of the successful introduction of plasmid DNA at a high 
frequency to a variety of clostridial species including C. beijerinckii (Oultram et aI., 1988), 
C. acetobutyiicum (Mermelstein et ai., 1992), proteolytic (Zhou and Johnson, 1993) and non-
proteolytic (Davis et aI., 2000) C. botulinum, C. perfringens (Allen and Blaschek, 1988), 
C. celluioiyticum (Jennert et ai., 2000) C. sporogenes (Liu et aI., 2002) and C. thermocellum 
(Tardif et ai., 2001). In summary, a pulse of high-intensity electrical field is applied to the 
cell that induces the temporary formation of pores in the cell membrane through which 
exogenous DNA can enter the cell. The protocols have been optimised for each species with 
variations at the stage of cell preparation and in the buffers utilised, the electroporation 
parameters, and at the stage of cell rescue post-electroporation. 
1. 7.2.2 Conjugation 
As an alternative to electroporation, the conjugal transfer of plasm ids from E. coli to a 
clostridial host has been documented for several species including C. beijerinckii (Williams 
et aI., 1990), C. botulinum (Bradshaw et ai., 1998), C. celluioyticum (Jennert et aI., 2000), 
C. difficile (Purdy et ai., 2002), and C. perfringens (Lyras and Rood, 1998). In all the 
reported cases, plasmid transfer from the donor to the recipient was dependent on the transfer 
mechanism of the broad host range IncP family of plasmids. A transfer origin (ori1) 
provided on the shuttle vector, and several trans-acting functions (Tra functions) supplied by 
the E. coli donor are required for conjugal transfer. The Tra functions may be either 
plasmid-encoded, as is the case for the IncP-type helper plasmid R 702, or integrated into the 
chromosome as is the case with the donor E. coli SM 1 O. , 
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1. 7.2.3 Restriction modification 
During the early development of genetic systems for C. acetobutylicum it was found that 
C. acetobutylicum ATCC 824 contains a restriction system designated Cac824I, that greatly 
reduces the electroporation efficiency of plasmid DNA that lacks the appropriate methylation 
signature (Mermelstein and Papoutsakis, 1993). The cognate methylase M.Cac824I protects 
host DNA from restriction digestion by the Cac8241 endonuclease. The Cac8241 restriction 
system endonuclease recognises the sequence 5'-GCNGC-3', which is prevalent in E. coli 
plasm ids but occurs infrequently in the C. acetobutylicum genome. Protecting plasmid DNA 
by methylation with the <l>3TI methyltransferase encoded by Bacillus subtilis phage <l>3T, was 
shown to protect plasmid DNA from restriction by Cac8241 and the isoschizomer Fnu4HI. 
Since these findings, restriction modification systems have been found in the non-proteolytic 
group II strain of C. botulinum, A TCC 25765 (Davis et al., 2000), where the restriction 
endonuclease CboI cleaves the palindrome 5'-CCGG-3'. Restriction is overcome by 
methylation of the shuttle vector in an E. coli host containing the B. subtilis M.BsuFI 
methylase which is equivalent to M.Cbo!. The CceI (5'-CCGG-3') restriction activity has 
been found to exist in C. cellulolyticum ATCC 35319 (Jennert et aI., 2000), with methylation 
of the external C by M.MspI (MspI is an isoschizomer of CceI) affording protection of 
transformed plasmid DNA. Finally, C. difficile strains CD3 and CD6 were also found to 
possess restriction modification systems ~ ~ (Purdy et al., 2002). In the case of CD3 no 
methylase exists to protect against the enzyme present (Cdi! cleaves 5'-CATCG-3') so all 
restriction sites need to be removed from shuttle vectors prior to transformation (Purdy et al., 
2002). In strain CD6 the two restriction systems, CdiCD6I (cleaves 5'-GGNMCC-3', 
equivalent to Sau96I) and CdiCD6II (cleaves 5'-GATC-3' equivalent to MboI) exist (Purdy 
et at., 2002). It was found that methylation by M.Sau961 protected against the CdiCD61 
restriction activity, and the resident dam methylation system of E. coli protected against 
CdiCD6II. 
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Additional to the restriction modification system, some clostridial species contain 
extracellular endonucleases, in particular, DNases. These have been reported to be present at 
low levels in C. thermohydrosulfuricum DSM 568 (Soutschek-Bauer et aI., 1985) and 
putatively in C. sporogenes NClMB 10696 (Liu et af., 2002). PEG-mediated transfonnation 
in the case of C. thermohydrosulfuricum, and the addition of DNase inhibitors to the 
electroporation buffer in the case of C. sporogenes NClMB 10696, negated the activity of 
extracellular DNases on the introduced plasmid DNA allowing successful transformation. 
1.7.3 Plasmid replicons and antibiotic selection 
Two decades have elapsed since the development of gene transfer technology for clostridia. 
During this time an arsenal of vectors has been developed to allow manipulation of the 
clostridia at the genetic and protein level. Despite this, the clostridial genus as a whole 
remains relatively intractable to in vitro derived genetic transfer such that the use of more 
genetically amenable organisms like E. coli and B. subtilis as intermediates is required for 
plasmid construction. This has led to the exclusive use of 'shuttle' vectors, which can 
replicate in the intermediate, normally E. coli, by the provision of a second replication 
region. Shuttle vectors therefore require a Gram-negative replication signal and antibiotic 
resistance marker for selection and maintenance in E. coli. Equivalent signals also need to 
be present for the Gram-positive host. 
1. 7.4 Shuttle vectors 
Native plasmids have been identified in several clostridia, for example in C. acetobutylicum 
ATCC 824 the pSOLI megaplasmid encodes the genes necessary for acetone and butanol 
production by this organism (ComiIIot et af., 1997). In addition to house keeping genes, 
some clostridia have plasmid-encoded virulence factors. These include the tetanus toxin of 
C tetani (Finn et af., 1984) and several toxins produced by C. perfringens (Katayama et af., 
1996). Native plasmids are one source of replication functions that have been utilised in the 
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construction of shuttle vectors since they are known to be functional in the host species and 
should be relatively segregationally stable. Several native plasm ids have been extensively 
characterised, including pCB 1 Oland pCB 1 02 from C. butyricum (Minton and Morris, 1981), 
pCD6 from C. difficile (Purdy et al., 2002) and pIP404 from C. perfringens (Garnier and 
Cole, 1986). As well as these well defined plasmids, several other clostridial plasm ids have 
been utilised in the construction of shuttle vectors, namely pCS86 from C. acetobutylicum 
strain No. 86 (Yoshino et al., 1990), and the C. perfringens plasm ids pHBIOI, pJU121, and 
pIU 122 (Blaschek and Solberg, 1981; Squires et aI., 1984). 
The replication regions of the well-defined clostridial plasm ids were identified by cloning 
putative minimal replication regions into otherwise non-replicative vectors. The vectors 
constructed were then transformed into either B. subtilis in the case of pCB 1 Oland pIP404 
(Collins et al., 1985; Garnier and Cole, 1988), or C. beijerinckii in the case ofpCBI02 and 
pCD6 (Collins et al., 1985; Purdy et al., 2002). Analysis of the replication regions from 
these plasm ids identified several different modes of replication. Firstly, pCB 101 displays 
many of the characteristics of other Gram-positive plasmids which replicate via a rolling 
circle mechanism (Brehm et aI., 1992). Sequence analysis of the replication protein of 
pCB 1 02 on the other hand revealed no homology to any currently known plasmid, thus it is 
unclear as to the mechanism by which this plasmid replicates. The replication mechanisms 
of pCD6 and pIP404 are also not definitely known, although they do both share features 
found in plasm ids that replicate via the theta replication method. These are a large putative 
replication protein and an extensive region of AT rich DNA repeats (Purdy et aI., 2002). 
An alternative to the use of clostridial plasm ids to construct shuttle vectors is the use of 
replicons derived from other Gram-positive bacteria. The B. subtilis plasmid pIM13 (Monod 
et at., 1986) has been widely used. It replicates via a single stranded DNA (ssDNA) 
intermediate and putatively based on that, a rolling circle mechanism. The Enterococcus 
faecalis plasmid pAMP 1 (Clewell et aI., 1974) has also been extensively employed. It 
replicates via a unidirectional theta replicating mechanism. Other plasmids that have been 
23 
utilised to a lesser extent are pIP501 from E. faecalis (Saunders and Guild, 1980), pWVOl 
from Lactococcus lac tis (Otto et aI., 1982), and the Staphylococcus aureus plasm ids pT127 
and pUB 11 0 (Lacey and Chopra, 1974; Novick and Brodsky, 1972). Generally, plasmids 
from other Gram-positive bacteria are not as segregationally stable as their clostridial 
counterparts. This is in part due to these plasm ids replicating via a rolling circle mechanism, 
which generates highly recombinogenic ssDNA intermediates (Gruss and Ehrlich, 1989), 
and as such they are not as good a choice for the construction of stable shuttle vectors. The 
one exception to this rule is pAMf31 which is generally stable in the variety of clostridial 
hosts which have been tested (Allen and Blaschek, 1988; Jennert et al., 2000; Oultram et aI., 
1988; Reysset and Sebald, 1985). 
In the absence of a 100% segregationally stable plasmid, antibiotic selection is required for 
positive selection of transformants. Ampicillin is routinely used in E. coli for antibiotic 
selection of plasmids, the resistance being encoded by f3-lactamase (bla). However, Bla is 
not functional in Gram-positive bacteria. The erythromycin resistance genes ermB from 
pAMf31 (Clewell et aI., 1974) or ermC from pIM13 (Monod et aI., 1986) are the most widely 
used selective marker to screen for clostridial transformants. Other antibiotic resistance 
markers that are frequently used include the tetracycline resistance gene tetM from Tn916 
(Franke and Clewell, 1981) and the C. perfringens Tn4451 chloramphenicol resistance gene, 
chloramphenicol acetyl transferase (catP) (Abraham and Rood, 1987). In the case of CatP, 
thiamphenicol is used instead of chloramphenicol for the selection of clostridial 
transform ants. 
1. 7.5 Expression vectors 
Expression vectors have been used in clostridia to obtain both expression of a particular 
protein and the expression of antisense RNA as a means of down-regulating protein 
expressIon. 
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For the over expressIOn of prodrug converting enzymes it is desirable to have strong 
constitutive expression such that the maximal level of protein is produced all throughout the 
growth cycle of the bacterium. Also, as the prodrug converting enzyme genes are not native 
to clostridia it is unlikely that the native prodrug converting enzyme promoter signals will 
function efficiently in clostridia. Therefore, the gene cannot be cloned with its own 
promoter, a technique often used for the expression of clostridial genes. 
Clostridial species produce a variety of sigma factors throughout growth and in response to 
different growth and environmental conditions. These alter the promoter recognition by 
RNA polymerase allowing coordinate transcription of different gene sets for a variety of 
bacterial responses. Furthermore, numerous transcriptional regulators exist leading to 
activation or repression of transcription. For this reason, most of the promoters that have 
been characterised are unsuitable for CDEPT due to their temporal expression. For example, 
in C. acetobutylicum these are promoters related to solventogenesis or acidogenesis, or to 
sporulation (Boynton et al., 1996a; Boynton et al., 1996b; Harris et al., 2002; Mermelstein et 
al., 1992; Nair et al., 1999; Papoutsakis and Bennett, 1993). As a consequence, only a few 
promoters have been isolated and utilised to promote prodrug converting enzyme production. 
These are the promoters preceding the ~ - 1 , 4 - e n d o g l u c a n a s e e (egIA) region of 
C. acetobutylicum P262 (Zappe et al., 1988), the clostripain gene (closJ) gene of 
C. histolyticum DSM 1126 (Dargatz et al., 1993), and the C. pasteurianum ferredoxin (jdx) 
gene (Graves and Rabinowitz, 1986). These promoters all generally conform to the 
promoter consensus sequence recognised by the major form of Clostridium RNA 
polymerase, which shows homology to other bacteria (see Figure 1.2). 
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-35 
-10 
eglA AAAAA TTATTA ATGTAAAAATATACTAAG TATAGA ATATTTA 
C/osl AATAA TGTAAA ACTTTAAATAATAACTCT TATAAT GGTTTTT 
fdx ACACT TTTAAA AAGTTTAAAAACATGA TACAAT AAGTTAT 
Consensus TTGACA (17 bp) TATAAT 
Figure 1.2: Putative promoter sequences of the p-1,4-endoglucanase (eglA), clostripain (closJ) and 
ferredoxin (jdx) genes used within clostridial prodrug converting enzyme expression vectors. The 
consensus sequence for the -35 and -10 is based on that recognized by the vegetative RNA polymerase 
holoenzyme. The -35 and -10 regions are underlined; bold characters within the consensus sequence 
indicate the highly conserved nucleotides, modified from Van Mellaert et al (Van Mellaert et aI., 
2005). 
As well as expressing the prodrug converting enzyme, it is desirable in some circumstances 
that the clostridial cells secrete the enzyme into the tumour mass. This can be obtained by 
fusing a signal sequence in frame to the 5' end of the gene of interest. The signal sequence 
encodes a signal peptide that consists of an NH2-terminal extension of the secretory peptide, 
which is required for successful translocation of the cell membrane. The signal peptide is 
cleaved by a signal peptidase once the protein is in the extracellular environment. The native 
signal peptide that is encoded by a secreted prodrug converting enzyme is usually not 
recognised by clostridial cells such that secretion is not very effective, if it occurs at all. 
Therefore, to enable efficient secretion of the prodrug converting enzyme from the clostridial 
cell two such signal peptides have been successfully developed, based on either the 
C. histolyticum DSM 1126 closI gene, or on the eglA gene of C. acetobutylicum P262 
(Dargatz et al., 1993; Zappe et al., 1988). Both signal peptides proved functional and 
secreted protein was detectable in the culture medium when the signal peptides were fused to 
either cytosine deaminase (codA) (Theys et al., 2001a) or tumour necrosis factor (m-TNFu) 
(Theys et at., 1999), respectively. 
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1.7.6 Gene integration in clostridia 
The recent and dramatic increase in antibiotic resistance and the rise in the occurrence of 
multidrug resistant bacteria in both community and hospital settings has led to the reduction 
in the use of antibiotic markers for clinical applications such as CDEPT. It is therefore 
necessary to have the prodrug converting enzyme integrated into the clostridial chromosome. 
This negates the use of plasmid-borne expression systems that are reliant on antibiotic 
selective markers. 
1.7.6.1 Homologous recombination 
The most common way of introducing genes into the bacterial chromosome is vIa 
homologous recombination, a process that results in genetic exchange between homologous 
DNA sequences from different sources. If the homologous DNA that is being inserted is 
interrupted in the middle with an antibiotic resistance marker (or other gene of interest) then 
following recombination, the target gene will be inactivated and the presence of the 
antibiotic resistance marker will allow selection of appropriate clones. Usually this 
technique IS used to inactivate a gene of interest in a process called allelic exchange 
mutagenesis. This process involves the exchange of the wild type chromosome encoded 
copy of the gene with a non-functional truncated copy of the gene. This is usually achieved 
by introducing the non-functional copy of the gene onto a replication deficient suicide vector 
such that once introduced the only antibiotic resistant clones will be ones where the gene of 
interest has been mutated. The preferable way of introducing the non-functional copy of the 
gene is on a conditionally replicative vector, for example a vector containing a temperature 
sensitive replicon. This would result in a plasmid that replicates only at the permISSIve 
condition. Changing to the non-permIssIve condition would inhibit plasmid replication 
thereby forcing segregational loss of the plasmid from the bacterial cell. The only way 
antibiotic resistant bacteria can be recovered is if the antibiotic resistance marker has 
integrated into the chromosome. The advantage to this approach is that a suitably high 
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number of cells will contain the plasmid prior to selecting for the rare integration event. 
Gene inactivation by allelic exchange can occur in two ways: 
1) Single crossover integration 
This process involves genetic exchange between a chromosomal copy of a gene and a 
plasmid-borne copy of the same gene that is truncated at the 5' and 3' ends (see Figure 1.3). 
Homologous recombination between the two DNA sequences results in the integration of the 
entire plasmid into the chromosome. The final outcome being the presence of two 
dysfunctional truncated copies of the target gene, one truncated at the 5' end the other 
truncated at the 3' end. However, mutations achieved in this way are intrinsically unstable 
due to the presence of large repeated flanking regions that may recombine to revert to the 
parent genotype. 
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2) Double crossover integration 
The more desired situation is double crossover integration as there is less chance of reversion 
to the wild type genotype and only the antibiotic resistance marker persists in the host. 
Allelic exchange by double crossover relies on the exchange between the target gene and a 
plasmid-borne copy of the target gene disrupted with a selectable marker, which is usually an 
antibiotic resistance marker (see Figure 1.4). The process of double crossover can occur 
either directly or indirectly. Direct double crossovers occur in one recombination event such 
that a correct mutant can be directly selected. Alternatively, the process of double crossover 
integration can be split into a two-stage event. Initially the process is identical to single 
crossover integration, in that the entire plasmid integrates into the host chromosome. 
However, a second recombination event occurs between two homologous stretches of DNA 
resulting in two possibilities. In 50% of cases there is resolution of the entire plasmid and 
disrupted target gene and reversion to the parent genotype. The alternative and desired event 
is re-excision of the plasmid leaving an interrupted dysfunctional target gene. 
Allelic exchange has been used successfully for the knock out of several genes in both 
C. acetobutylicum and C. perfringens. The first reported clostridial mutant was generated by 
Wilkinson and Young (1994), where both gutD and spoOA single crossover mutants were 
made in C. acetobutylicum NCIMB 8052 (now renamed C. beijerinckii NCIMB 8052) by 
conjugal transfer of a suicide plasmid from an E. coli donor. Since then, a variety of mutants 
have been made in C. acetobutylicum ATCC 824: a single crossover mutant in 
aldehyde/alcohol dehydrogenase (aad) (Green and Bennett, 1996), an uncharacterised 
mutant in the sporulation specific sigma E-processing enzyme (oriA) (Wong and Bennett, 
1996), and single crossovers in phosphotransacetylase (pta) and butyrate kinase (buk) (Green 
et aI., 1996). In C perfringens double crossover mutants were obtained in theta-toxin (PfoA) 
and alpha toxin (PIc) (Awad et aI., 1995), in the enterotoxin (cpe) (Sarker et at.. 1999), in 
collagenase (colA) (Awad et aI., 2000), and in the toxin regulator (virX) (Ohtani et aI., 2002). 
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Figure 1...f: Schematic representation of direct and indirect double crossover recombination. 
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Delivery of the single crossover or double crossover fragments to clostridia is usually by a 
replication deficient suicide plasmid. However, this method is somewhat unreliable and 
burdensome with sometimes several thousand colonies needing to be screened in order to 
obtain a correct knockout. Also, the experiment may need several attempts to obtain a 
knockout, and sometimes a knockout will not occur at all. 
Due to the problems experienced by Harris and colleagues in obtaining a spaDA knockout 
mutant in C. acetabutylicum ATCC 824 using the suicide method, they developed a 
replicative plasmid based approach (Harris et al., 2002). In order to disrupt spaDA, a 580 bp 
internal spaDA fragment was PCR amplified and cloned into a plasmid based on the Gram-
positive replicon from the B. subtilis plasmid pIM13. Serial passage of the recombinant C. 
acetabutylicum A TCC 824 harbouring the spaDA knockout plasmid on non-selective media 
was performed every 24 hours for 5 consecutive days with replica plating. Cells that grew 
on erythromycin (selects for integration event) but not on thiamphenicol (selects for plasmid) 
were isolated by comparing cultures that were replica plated onto medium containing either 
antibiotic. Isolates of C. acetabutylicum A TCC 824 that met the thiamphenicol sensitive and 
erythromycin resistant phenotype were then analysed by PCR amplification and sequencing. 
One isolate, SKOl, which was obtained in the first experiment with this method was 
analysed further by sequencing the interrupted region as the expected PCR product size for 
the interrupted gene was not obtained. From the sequencing data they determined that the 
following sequence of events occurred: first, the entire plasmid was apparently integrated 
into the chromosome at the spaDA gene, due to the presence of the duplicated internal spaDA 
fragment. It was expected that a second recombination event would occur somewhere in the 
duplicated region, resulting in either reversion to the parent phenotype or deletion of the 
plasmid DNA except for the marker resulting in an ideal double crossover. However, a 
second recombination event occurred between two 10 bp homologous sequences 
(5'-ACGACCAAAA-3') that were present in the 3' end of the Gram-positive replicon repL 
structural gene and upstream of the erythromycin resistance marker. The result \vas 
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inactivation of spaDA by insertion of a slightly larger fragment than predicted, an abnormal 
double crossover mutant. Potential reasons why a double crossover could occur on a 
replicative vector are due to the method of replication of the vector. pIM13 is known to 
replicate via a rolling circle method (Projan et al., 1987) that generates highly 
recombinogenic ssDNA intermediates. Secondly, by not implying selection, the resistance 
markers would only be maintained by the plasmid integrating due to the segregational 
instability of non-native rolling circle plasm ids. 
1. 7.6.2 Non-homologous recombination 
Recombination between DNA molecules can occur in a variety of other ways that are not 
dependent on regions of homologous DNA cloned onto a plasmid, or on the hosts 
recombination machinery. Mobile genetic elements, namely insertion sequences (IS) and 
transposons, are one such example of plasmid or chromosomally encoded genetic elements 
that perform non-homologous (illegitimate) recombination. 
Insertion sequences are the simplest type of mobile genetic element. Usually they consist of 
one or more transposase enzymes that are necessary for the movement of the element from 
one site to another. At the ends of most insertion sequences is an almost perfect inverted 
repeat (IR) sequence. The complementary nature of the IR sequences is in part responsible 
for the mobile nature of IS elements. Short duplicated target sequences are usually found 
flanking IS elements. This is not part of the IS element per se, but arises from the DNA at 
the site of insertion as a consequence of the molecular events involved. 
Transposons are similar to IS elements in that they consist of a transposase flanked with IR 
sequences and short duplicated target sequences. However, transposons also contain a 
resolution site, a resolvase and an identifiable genetic marker (usually an antibiotic resistance 
gene). More complex transposons, composite transposons, exist that consist of n\'o copies of 
an IS element in inverted orientation or as direct repeats (one usually contains a non-
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functional defective transposase) surrounding a set of resistance genes. Finally, a transposon 
can exist as an integron that is built up by insertion of additional antibiotic resistance genes 
within an existing transposon. 
Insertion sequences have been found in a variety of bacteria, although only a few have been 
reported in the clostridia. Several have been reported in C. perfringens (Brynestad et aI., 
1997; Daube et aI., 1993), and one, ISCbI, has been found in C. beijerinckii NCIMB 8052 
(Liyanage et aI., 2000a). To date, IS elements have not been utilised as a genetic tool for the 
manipulation of the clostridia. 
Transposons have also been found in a few clostridia, namely a Tn916-like tetracycline 
resistant determinant in C. difjicile (Hachler et aI., 1987), and two Tn3-like transposons, 
Tn4451 and Tn4452, in C. perfringens (Abraham and Rood, 1987). Although potentially 
useful, these transposons have not been shown to be capable of transposition. Among the 
several well characterised transposons, the 16.4 kb tetracycline resistance encoding 
conjugative transposon Tn916 from E. faecalis DS 16 (Franke and Clewell, 1981) has been 
shown to be successfully transferred by conjugation to C. acetobutylic;um (Woolley et aI., 
1989), C. botulinum (Lin and Johnson, 1991), C. tetani (Yolk et aI., 1988), C. difjicile 
(Mullany et al., 1991), and C. perfringens (Lyristis et aI., 1994). 
Utilising Tn916, several different mutants were obtained in a variety of clostridia. In 
C. perfringens, virulence gene sensor histidine kinase regulator (virS) (Lyristis et aI., 1994) 
and alpha, theta and kappa toxin mutants (Awad and Rood, 1997) were achieved. 
Granulose mutants (Mattsson and Rogers, 1994) and a tRNA mutant (Sauer and Durre, 
1992) were obtained in C. acetobutylicum. Finally, several different uncharacterised 
auxotrophic mutants have been obtained in C. botulinum (Lin and Johnson, 1991). 
Tn15.f5, originally isolated from Streptococcus pneumoniae, has also been used but to a 
lesser extent than Tn916, in the generation of mutants in C. beijerinckii (Evans et aI., 1998; 
Liyanage et al., 2000b). 
One major disadvantage to the use of Tn916 and transposons as a whole as a genetic tool is 
that integration is not targeted. Tn916 is reported to integrate into a hot spot in C. difficile 
CD37 (Mullany et al., 1991; Wang et al., 2000) and C. beijerinckii (Woolley et al., 1989). 
In other clostridial hosts, Tn916 was found to integrate at multiple host sites, namely in 
C. difficile 79-685 (Roberts et al., 2003), C. tetani (Volk et al., 1988), C. acetobutylicum 
(Babb et al., 1993) and C. botulinum (Lin and Johnson, 1991). Tn1545 is reported to 
integrate at multiple sites in C. beijerinckii (Woolley et al., 1989). From the perspective of 
CDEPT, non-targeted integration is not desired as integration in unknown genes may change 
the characteristics of the host such that the colonisation of the tumour may be affected, 
expression of the prodrug may be changed or the formation of spores reduced. 
1.8 CONCLUSIONS 
It is now over 10 years since the CDEPT concept was first proposed (Minton et al., 1995) as 
a means of treating solid tumours. In the intervening years a number of key steps have been 
taken towards proof of principle and the strategy now shows considerable promise as a novel 
therapy for treating solid tumours. Whilst concerns over the concept of deliberately 
'infecting' patients with a live clostridial species may surface, it is to be anticipated that 
clinical evaluations should dispel any such fears, allowing the full potential of CDEPT to be 
realised. However, there are still a number of additional refinements that have to be put in 
place before this approach can move into a clinical setting. 
Whilst proteolytic strains such as C. sporogenes and C. novyi are more effective in tumour 
colonisation and achieve higher population densities, these more aggressive tumour 
colonisers may cause toxicity (Dang et al.. 2001). The data obtained with B. longum has 
shown that high bacterial cell numbers are not necessarily required (Fujimori et at., 2002). 
The higher levels of therapeutic protein necessary could be achieved through the use of more 
effective transcription and translation signals. Therefore, to obtain the maximal benefit from 
CDEPT a suitable expression system needs to be employed. Regardless of the host used, for 
clinical evaluation, strains need to be generated which do not carry bacterial antibiotic 
resistance markers. This may be achieved through the integration of the therapeutic genes 
concerned into the genome. 
In addition to optimising the production of recombinant protein, the strategy may also 
benefit from maximising the catalytic activity of the enzyme utilised, through the use of the 
most effective enzyme and prodrug. The benefit of a more soluble nitroreductase prodrug 
has already been demonstrated (Liu et aI., 2002). The use of more effective enzymes is also 
likely to prove fruitful (Anlezark et aI., 2002). The deliberate secretion of the therapeutic 
protein may extend the area of drug generation away from the immediate vicinity of the foci 
of colonisation within the tumour. However, secreted enzymes are prone to proteolysis. 
This may present a particular problem with proteolytic clostridial strains. Moreover, a wider 
distribution of enzyme may give rise to a specific immune response directed against the 
protein. Immune responses in ADEPT prevent repeat therapies. On the other hand, recent 
studies have shown that the immunogenicity of specific enzymes can be attenuated (Spencer 
et al., 2002). 
1.9 PROJECT AIMS 
This study forms part of a European Union 5th Framework consortium consisting of six 
partners. The overall goal was to further develop the CDEPT strategy, ultimately to phase I 
clinical trial. 
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The specific aims of this study are: 
• To obtain over-expreSSIon of either of two prodrug converting enzymes. Both 
carboxypeptidase G2 and novel nitroreductase enzymes will be cloned and over-
expressed in an optim ised expression vector and transformed into an optimally 
colonising clostridial host. Once obtained, engineered strains will be assessed for 
the production of the prodrug converting enzyme both in vitro and in an in vivo 
mouse model. 
• To assess the tools currently available for gene integration in clostridia and modify 
them for integration of the promoter/prodrug converting enzyme fusion into suitable 
genome targets, such that the colonisation capabilities of the recombinant strain 
remain unaltered. 
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1 CHEMICALS AND KITS 
Invitrogen Ltd., Paisley, U.K. 
TOPO TA Cloning® Kit (with pCR2.1-TOPO or pCRII-Blunt vector), NuPAGE® 
gels and buffers, Zymogram gels and buffers 
New England Biolabs (U.K.) Ltd., Herts, U.K. 
Restriction endonuc1eases and buffers, Klenow DNA polymerase I fragment, 
T4 DNA polymerase, Antarctic phosphatase, T4 DNA ligase, 
Novagen, Merk Biosciences, Nottingham, U.K. 
Bugbuster protein extraction reagent, rLysozyme™ , Benzonase™ 
QIAGEN Ltd., West Sussex, U.K. 
QIAprep spin mini prep kit, QIAquick PCR purification kit, QIAquick gel extraction 
kit, RNeasy miniprep kit, One-Step RT-PCR kit, Hot Star Taq, DNeasy tissue kit. 
Sigma Aldrich Company Ltd., Dorset, UK 
All chemicals were supplied by Sigma Aldrich unless otherwise stated. 
Nucleic acids 
Oligonucleotides were synthesised by Sigma-Genosys Ltd., Haverhill, U.K .. 
Synthetic genes were supplied by Entelechon GmbH, Regensburg, Germany. 
Cambio 
Failsafe PCR system 
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2.2 BACTERIAL STRAINS AND PLASMIDS 
Strain Genotype Reference/source 
E. coli TOPI0 F mcrA l1(mrr-hsdRMS-mcrBC) Invitrogen Ltd.® 
~ 8 0 1 a c Z I 1 M 1 5 5 I1lacX74 deaR recAl 
araD139 l1(ara-leu)7697 galU galK rspL 
(StrR) endAl nupG 
E. coli TOPI 0 F' F' {lac!' TnlO (TetR)} mcrA l1(mrr- Invitrogen Ltd.® 
hsdRMS-mcrBC) ~ 8 0 1 a c Z I 1 M M 15 I1lacX74 
deaR recAI araD139 l1(ara-Ieu)7697 galU 
galK rpsL(StrR ) endA 1 nupG 
E. coli HMS 174 (DE3) F, recA,l hsdR(r K12 -m K12), Rif lambda Invitrogen Ltd.® 
(DE3) 
E. coli HB 1 0 1 thi-I hsdS20 (r-B, m-B) supE44 recAB ara- N. P. Minton 
14 leuB5proA2 lacYl galK rpsL20 (stl) 
xyl-5 mtl-l 
Bacillus subtilis BS34A Tn9l6 conjugative donor strain A. Roberts, UCL, 
London 
Clostridium sporogenes 
NCIMB 10696 
Variovorax paradoxus 
ATCC 25301 
Table 2.1 - Bacterial strains used in this study 
Vector Replicon(s) 
pMTL20 ColEI 
pMTL20E ColEI 
pCR2.I-TOPO ColEI 
pIMP! ColEI, 
pIM13 
Antibiotic 
selection 
Amp 
Amp, 
Erm 
Amp, 
Kan 
Amp, 
Erm 
N. P. Minton 
N. P. Minton 
Features Reference/ 
source 
E. coli cloning (Chambers et 
vector al., 1988a) 
E. coli cloning M. Young, 
vector University of 
Wales 
Aberystwyth 
E. coli PCR TI A Invitrogen 
cloning vector 
Clostridium (Mermelstein 
shuttle vector and 
Papoutsakis. 
1993) 
pMTL934I aLS2 CoIEI, Erm Clostridium (Carter et at., 
pCD6 shuttle vector, 2005) 
antisense 
expression vector 
pCR4-TOPO: jac2 ColEI Amp, E. coli PCR TI A Entelechon 
Kan cloning vector, GmbH 
fac2 promoter 
pMTL30 ColEI Amp, Mobilisable (Williams et 
Erm suicide plasmid al., 1990) 
pCR-Blunt 11-TOPO ColEI Kan, E. coli PCR blunt Invitrogen 
Zeocin cloning vector 
R702 I n c P ~ ~ Tet, Tra+, Mob+, (Hedges and 
conjugative Kan conjugative Jacob, 1974) 
plasmid 
pMTL93 0 1 CoIEI, Erm Clostridium (Purdy et al., 
pCD6 shuttle vector 2002) 
pHZl17 ColEI Amp eglA promoter (Abratt et al.. 
and coding 1993) 
sequence 
pMTL21 ColEI Amp E. coli cloning (Chambers et 
vector al., 1988a) 
pMTLI010 ColEI Tet E. coli expression R. Melton, 
vector Protherics, 
Salisbury 
pCR4-TOPO: :CPG2-synth ColEI Amp, E. coli PCR TI A Entelechon 
Kan cloning vector, GmbH 
synthetic CPG2 
pCR4-TOPO: :HinNTR-synth ColEI Amp, E. coli PCR TIA Entelechon 
Kan cloning vector, GmbH 
synthetic 
HinNTR 
pF25 ColEI Amp nfnB cloned into R. Naylor, 
pTrc99A Protherics, 
Salisbury 
pMTL9361gusA CoIEI, Erm GusA reporter J. Scott, 
pCD6 vector University of 
Nottingham 
pKNTl9-closlpcodA CoIEI, Erm Source of closI (Theys et al., 
pIM13 promoter 2001a) 
pMTL9361gusA:fac2p CoIEI, Erm fac2 promoter G. Carter, 
pCD6 gusA reporter Nottingham 
fusion 
pMTL93 61 gusA: :glnAp ColEI, Erm gInA promoter G. Carter, 
pCD6 gusA reporter Nottingham 
fusion 
pMTL93 61 gusA: :hydAp ColEI, Erm hydA promoter G. Carter, 
pCD6 gusA reporter Nottingham 
fusion 
pMTL9361gusA::egIAp ColEI, Erm eglA promoter G. Carter, 
pCD6 gusA reporter Nottingham 
fusion 
pMTL9361catP ColEI, Erm CatP reporter J. Scott, 
pCD6 vector University of 
Nottingham 
pMTL5200 ColEI Amp, HindlIIIXbaI N. Minton, 
Erm pBP 1 replicon University of 
Nottingham 
pMTL9401 ColEI, Erm Clostridium (Purdy et al., 
pCBI02 shuttle vector 2002) 
pMTL9511 ColEI, Erm Clostridium M. Herbert, 
p A M ~ l l shuttle vector HPA Porton 
Down, 
Salisbury 
pMTL9611 ColEI, Erm Clostridium (Purdy et al., 
pIP404 shuttle vector 2002) 
pJIR418 CoIEI, Erm,Cm Clostridium (S loan et al., 
pIP404 shuttle vector 1992) 
pMTLI015::NTR-N ColEI Tet E. coli J. Heap, 
overexpressJOn University of 
plasmid, source Nottingham 
ofNTR-N 
pCRScript::HinNTR-synthv2 ColEI Amp Synthetic gene - Entelechon 
HinNTR version GmbH 
2 
pCRScript: : NTR -N -synth ColEI Amp Synthetic gene - Entelechon 
NTR-N GmbH 
pMTL31 ColEI Amp, Mobilsable (Williams et 
Erm suicide vector al., 1990) 
-+1 
pMTL900 ColEI Amp, Tn916 integrative (Roberts et 
Cm suicide plasmid al.,2003) 
pWG3 ColEI Erm, Cm Suicide vector C. Schwarz, 
contains C. University of 
sporogenes Ulm, 
spoDA interrupted Germany 
with CatP 
pMTL4 ColEI Amp E. coli cloning This study 
vector 
pMTL4-Em ColEI Erm E. coli cloning This study 
vector 
pMTL5100 CoIEI, Erm Clostridium This study 
pIM13 shuttle vector 
pMTL20: fdxTfacaLS2:celAT ColEI Amp fac expression This study 
cartridge 
pMTL20: :ceIAT: fac2fdxT ColEI Amp fac2 expression This study 
cartridge 
pMTL5102 ColE!. Erm Clostridium This study 
pIM13 shuttle fac2 
expression vector 
PEOriT ColEI Amp, pCR2.1-TOPO This study 
Kan carrying RK2 
OriT region PCR 
amplified from 
pMTL30 
pMTL5112 CoIEI, Errn Mobilisable This study 
pIM13 Clostridium 
shuttle fac2 
expression vector 
pCR2.1 : :LacZ alpha ColEI Amp, PCR amplified This study 
Kan lacZ alpha 
pMTL5122 CoIEI, Erm Mobilisable This study 
pIM13 Clostridium 
shuttlefac2 
expression vector 
blue/white 
selection 
pCR2.1 ::CPG2 ColE! Amp, PCR amplified This study 
Kan wild type CPG2 
pCR2.1 ::egIASSCPG2S0E ColEI Amp, eglA signal This study 
Kan sequence fused to 
5' end ofCPG2 
pMTL21 : :egIASSCPG2 ColEI Amp eglA signal This study 
sequence fused to 
5' end of CPG2 
pMTLl 01 0::CPG2-synthvl ColEI Tet E. coli This study 
overexpression 
plasmid 
harbouring 
synthetic 
sequence CPG2 
version 1 
pMTL 1 0 1 0: :CPG2-synthv2 ColEI Tet E. coli This study 
overexpreSSIOn 
plasmid 
harbouring 
synthetic 
sequence CPG2 
version 2 
pCR2.1 : :HinNTR ColEI Amp, PCR amplified This study 
Kan wild type 
HinNTR 
pMTL5112: :CPG2 ColEI, Erm Clostridium fac2 This study 
pIM13 based expression 
vector expressing 
wild type 
sequence CPG2 
pMTL5112::CPG2-synth CoIEI, Errn Clostridium fac2 This study 
pIM13 based expression 
vector expressing 
synthetic 
sequence CPG2 
pMTL5122::HinNTR CoIEI, Errn Clostridium fac2 This study 
pIM13 based expression 
vector expressing 
wild type 
sequence 
HinNTR 
pMTL5122: : HinNTR -synth CoIEI, Erm Clostridium fac2 This study 
pIM13 based expression 
vector expressing 
synthetic 
sequence 
HinNTR 
-u 
pMTL5122: :nfnB CoIEI, Erm Clostridium fac2 This study 
pIM13 based expression 
vector expressing 
nfnB 
pMTL9361 gusA :closlp CoIEI, Erm closI promoter This study 
pCD6 gusA reporter 
fusion 
pCR2.1 ::botHallAfdxp ColEI Amp, PCR amplified This study 
Kan ferredoxin 
promoter from C. 
botulinum Hall A 
ATCC 3502 
pCR2.1 ::bot2916fdxp ColEI Amp, PCR amplified This study 
Kan ferredoxin 
promoter from C. 
botulinum A TCC 
2916 
pCR2.1 ::perst13fdxp ColEI Amp, PCR amplified This study 
Kan ferredoxin 
promoter from C. 
perfringens strain 
13 
pCR2.1 ::per8327fdxp ColEI Amp, PCR amplified This study 
Kan ferredoxin 
promoter from C. 
perfringens 
NCTC 8327 
pCR2.1 ::spofdxp ColEI Amp, PCR amplified This study 
Kan ferredoxin 
promoter from C. 
sporogenes 
NCIMB 10696 
pMTL93 61 catP: spofdxp CoIEI, Erm C. sporogenes This study 
pCD6 ferredoxin 
promoter catP 
reporter fusion 
pMTL9361catP:perstl 3f dxp CoIEI, Erm C. sporogenes This study 
pCD6 ferredoxin 
promoter catP 
reporter fusion 
pMTL5210 CoIEI, Amp, Mobilisable This study 
pBPl Erm Clostridium 
shuttle vector 
pIMPl::OriT CoIEI, Amp, Mobilisable This study 
pIM13 Erm Clostridium 
shuttle vector 
pMTL5612 CoIEI, Erm fae2 based This study 
pIP404 Clostridium 
expression vector 
pMTL5622::nfoB CoIEI, Erm Stable This study 
pIP404 Clostridiumfae2 
based expression 
vector expressing 
nfoB 
pMTL5123: :nfoB CoIEI, Erm C. sporogenes fdx This study 
pIM13 promoter based 
expression vector 
expressing nfoB 
pMTL5 623: :nfoB CoIEI, Erm Stable C. This study 
pIP404 sporogenes fdx 
promoter based 
expression vector 
expressing nfoB 
pMTL5622: : HinNTR -synth CoIEI, Erm Stable This study 
pIP404 Clostridium fae2 
based expression 
vector expressing 
synthetic 
sequence 
HinNTR 
pMTL5122: :NTR-N CoIEI, Erm Clostridiumfae2 This study 
pIM13 based expression 
vector expressing 
NTR-N 
pMTL5123::NTR-N CoIEI, Erm C. sporogenes fdx This study 
pIM13 promoter based 
expression vector 
expressing NTR-
N 
pMTL5623::NTR-N CoIEI, Erm Stable C. This study 
pIP404 sporogenes fdx 
promoter based 
expression vector 
expressing NTR-
N 
pMTLS122::HinNTR-synthv.2 ColEI, Enn Clostridium fac2 This study 
pIM13 based expression 
vector expressing 
synthetic 
sequence 
HinNTR version 
2 
pMTLS122::NTR-Nsynth ColEI, Erm Clostridium fac2 This study 
pIMl3 based expression 
vector expressing 
synthetic 
sequence NTR-N 
pCR2.1 : :CspopyrF ColEI Amp, PCR amplified C. This study 
Kan sporogenes pyrF 
crossover 
fragment 
pMTL31: :pyrF(Csp) ColEI Erm pyrF single This study 
crossover suicide 
plasmid 
pMTL900: :pyrF(Csp) ColEI Cm pyrF single This study 
crossover Tn916 
integrative 
plasmid 
pMTLS122::spoDA:catP oril ColEI, Enn spoDA double This study 
pIM13 crossover 
fragment cloned 
into rolling circle 
plasmid 
orientation 1 
pMTLS122:: spoDA:catP ori2 ColEI, Erm spoDA double This study 
pIM13 crossover 
fragment cloned 
into rolling circle 
plasmid 
orientation 2 
pIMP 1 OriT: :spoDA :catP ori 1 CoIEI, Amp, spoDA double This study 
pIM13 Erm crossover 
fragment cloned 
into rolling circle 
plasmid 
orientation 1 
46 
pIMP 1 OriT: :spaOA :catP ori2 ColEI, 
pIM13 
Table 2.2 - Plasmids used in this study 
2.3 GROWTH MEDIA 
2.3.1 Luria-Bertani medium 
Amp, 
Erm 
spaOA double This study 
crossover 
fragment cloned 
into rolling circle 
plasmid 
orientation 2 
Luria-Bertani (LB) broth was prepared as described by Sambrook et al. (1989) and consisted 
of 109 tryptone (Oxoid), 5 g yeast extract powder (Oxoid) and 5 g sodium chloride (NaCI) 
made up to 1 I with distilled water. Sterilisation was achieved by autoclaving at 120 DC and 
15 psi for 20 min. 
LB agar was prepared by addition of 1 % (w/v) Number 1 Bacteriological Agar (Oxoid). 
2.3.2 2 x YT medium 
2 x YT broth was prepared as described by Sam brook et al. (1989) and consisted of 16 g 
tryptone (Oxoid), 10 g yeast extract powder (Oxoid) and 5 g sodium chloride (NaCI) made 
up to 1 I with distilled water. 
2 x YT agar was prepared by addition of 1 % (w/v) Number 1 Bacteriological Agar (Oxoid). 
2.3.3 TYG medium 
TYG medium consisted of 30 g tryptone (Oxoid), 20 g yeast extract powder (Oxoid) and 1 g 
sodium thioglycolate (thioglycolic acid, HSCH 2COOH) made up to 1 I with distilled \\ater. 
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If required, glucose supplementation was added to a final concentration of 0.5% (wi\') after 
sterilisation. 
TYG agar was prepared by addition of 1 % (w/v) Number 1 Bacteriological Agar (Oxoid). 
2.3.4 Spizizen's minimal salts medium (SMM) [pH7.0] 
SMM consisted of 14 g dibasic potassium phosphate (K2HP04), 6 g monobasic potassium 
phosphate (KH2P04), 1 g sodium citrate and 0.2 g magnesium sulphate (MgS04.7H20) made 
up to 1 I with distilled water. The medium was filter sterilised prior to use. 
2.3.5 B. subtiUs competence medium 
B. subtilis competence medium consisted of 10 ml SMM (as described in Section 2.3.4), 
0.5 ml glucose (10% [w/v]), 5 fll calcium chloride (CaCh, 0.1 M stock solution), 0.1 ml 
magnesium sulphate (MgCh, 250 mM stock solution), 0.1 ml manganese chloride (MnCh, 
50 nM stock solution), 0.2 ml casamino acids 10% (w/v) and 0.25 ml tryptophan (10 mM 
stock solution). The individual components were filter sterilised prior to use. 
2.3.6 B. subtiUs transformation medium 
B. subtilis transformation medium consisted of 1 ml SMM (as described in Section 2.3.4), 
50 fll glucose, 10% (w/v), 20 fll magnesium sulphate (MgCh, 250 mM stock solution), 1 fll 
casamino acids, 10% (w/v) and 25 fll tryptophan (10 mM stock solution). The individual 
components were filter sterilised prior to use. 
2.4 SUPPLEMENTS 
Growth medium was supplemented at the following final concentrations as required: 
ampicillin (Amp), 100 J..lg mr': chloramphenicol (Cm), 25 J..lg mr' (for B. subtilis 5 flg mr'); 
folate (Fol) 0.1 % v/v; thiamphenicol (Thi), 20 ).lg mr!; tetracycline (Tet), 10 ).lg mr! (for 
clostridia 20 ).lg mr\ erythromycin (Erm), 300 ).lg mr! ,in liquid broth, 500 ).lg mr! on solid 
media (for clostridia 10 ).lg mr!); kanamycin (Kan), 100 ).lg mr!; trimethoprim (Tri), 
10 ).lg mr!; cycloserine, 250 ).lg mr!; i s o p r o p y l - l - t h i o - ~ - D - g a l a c t o p y r a n o s i d e e (IPTG), 
64 ).lg mr!; 5-bromo-4-chloro-3 i n d o l y l - ~ - D - g a l a c t o s i d e e (X-Gal), 40 ).lg mr!. Stock solutions 
were prepared as described by Sam brook et al. (1989) and stored according to the 
manufacturer's instructions. 
2.5 GROWTH CONDITIONS 
E. coli was grown aerobically at 37°C unless otherwise stated. Liquid cultures were grown 
in Luria Bertani broth, or 2 x YT broth, with gentle agitation at 200 rpm. Strains of E. coli 
were stored at -80°C using the Microbank™ system (Prolab Diagnostics). Stocks were 
revived by plating onto LB media supplemented with the appropriate antibiotics and 
incubated at 37°C. Cells were maintained at 4 °C on LB agar plates for up to 2 weeks. 
C. sporogenes was cultured and manipulated in a Mk 3 Anaerobic Work Station (Don 
Whitely Scientific Ltd, West Yorks, U.K.). The atmosphere of nitrogen (N2), carbon dioxide 
(C02), and hydrogen (H2) was maintained at a ratio of 80% (v/v): 10% (v/v): 10% (v/v) 
respectively and at a temperature of 37°C. Clostridial strains were stored in 10 ml cooked 
meat medium (Oxoid) and incubated anaerobically for 3 weeks at 37°C to enable 
sporulation to occur. After this time the cultures were removed from the anaerobic cabinet 
and stored in the laboratory at room temperature. TYG medium supplemented with 0.5% 
(w/v) glucose was used for the propagation of C. sporogenes. 
Variovorax paradoxus was grown aerobically at 30°C. Liquid cultures were grown in 
2 x YT broth with gentle agitation at 200 rpm. Plate cultures were grown on 2 x YT agar 
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supplemented with folate (0.1 % v/v) when appropriate. 
Bacillus subtilis was grown aerobically at 37°C. Liquid cultures were grown in LB broth 
with gentle agitation at 200 rpm. 
Growth of all bacterial cultures in liquid medium was monitored by measuring optical 
density at 600 nm (OD600) using a Pharmacia Novaspec II. 
2.6 DNA MANIPULATIONS AND ANALYSIS 
2.6.1 Chromosomal DNA preparation 
Chromosomal DNA was prepared using the QIAGEN DNeasy® Tissue kit (Qiagen Ltd., 
UK). For extraction of clostridial DNA, lysis was aided by the addition of rLysozyme 
(Novagen) (l0 KU mr! final concentration). 
2.6.2 Plasmid preparation 
Plasmid preparation was carried out by the alkaline lysis method described by Sambrook et 
al. (1989) using the QIAprep Spin Miniprep Kit (Qiagen Ltd., UK) as described in the 
manufacturer's instructions. 
2.6.3 Restriction digests 
Restriction enzymes were obtained from New England Biolabs, or Promega. Digests were 
performed as described in the manufacturer's instructions. Briefly, digests contained 
1 x buffer supplied by manufacturer, bovine serum albumin (l ~ g g mr! final concentration) 
was added if required, 0.5 - 2 ~ g g DNA, 5 - 20 U restriction endonuclease, unless the 
endonuclease exhibited star activity in which case 1 U was added. The final volume was 
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made up with water and maintained < 5% glycerol concentration to assist in minimising star 
activity. 
2.6.4 Blunt-ending of DNA fragments using Klenow polymerase 
DNA digested with restriction enzymes which resulted in 5' overhanging ends was blunt-
ended using DNA Polymerase I, Large (Klenow) Fragment, obtained from New England 
Biolabs or Prom ega as described in the manufacturer's instructions. Briefly, to a restriction 
digest (described above), 1 x DNA polymerase buffer (supplied by manufacturer), 2.5 U 
Klenow polymerase and 33 J.lM each dNTP was added, followed by incubation at 25°C for 
15 min. 
2.6.5 Blunt-ending of DNA fragments using T4 DNA polymerase 
DNA with 3' overhanging ends was blunt-ended using T4 DNA Polymerase, obtained from 
New England Biolabs, as described in the manufacturer's instructions. Briefly, to a 
restriction digest (described above), 1 x T4 DNA polymerase buffer (supplied by 
manufacturer), 5 U T4 DNA polymerase and 100 J.lM each dNTP was added, followed by 
incubation at 12°C for 15 min. 
2.6.6 Dephosphorylation of linearised DNA fragments 
Linearised DNA fragments were dephosphorylated usmg Antarctic Phosphatase (AP) 
obtained from New England Biolabs, as described in the manufacturer's instructions. 
Briefly, to a restriction digest (described above), 1 x AP buffer (supplied by manufacturer) 
and 5 U AP were added, followed by incubation at 37°C for 1 h. 
2.6.7 Ligation of DNA fragments 
Ligation of DNA fragments was carried out using T4 DNA ligase, obtained from NEB 
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according to manufacturer's instructions. Briefly, purified DNA fragment inserts were 
added to purified vector fragments at ratios of 1: 1, 3: 1 and 5: 1. Ligations were carried out in 
10/J1 volumes also containing 1 x T4 DNA ligase buffer (supplied by manufacturer) and 3 U 
T4 DNA ligase, followed by incubation at 16 DC overnight. 
2.6.8 Annealing of oligonucleotides prior to ligation 
Each oligonucleotide was diluted in sterile water to a concentration of I nM. 1 /JI of each 
was then added to 5 /JI REact buffer 3 (Invitrogen) and 5 /JI 100 mM MgCh. The solution 
was then made up to a final volume of 50 /JI with sterile water, and heated at 90 DC for 5 min 
before being allowed to slowly cool to room temperature over 45 min to 1 h. 
2.6.9 Ligation of annealed oligonucleotides and vector DNA 
The molarity of the annealed oligonucleotides and vector DNA was calculated and ratios of 
3: 1, 5: 1 and 0: 1 (oligonucleotides: vector) DNA were mixed. Ligations were carried out in 
10 /JI volumes also containing 1 x T4 DNA ligase buffer (supplied by manufacturer) and 3 U 
T4 DNA ligase. The reactions were incubated at 16 DC overnight. 
2.6.10 peR and restriction digest clean up 
DNA fragments from PCR reactions, restriction digests and blunt-ending reactions were 
routinely purified away from contaminating oligonucleotides and enzymes using Qiagen's 
QIAquick PCR Purification Kit (Qiagen Ltd., UK) as described in the manufacturer's 
instructions. 
2.6.11 Extraction of DNA fragments from agarose 
DNA fragments were visualised using ethidium bromide and the desired band excised from 
the agarose gel using a clean scalpel. The DNA was then extracted from the excised agarose 
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gel using Qiagen's QIAquick Gel Extraction Kit (Qiagen Ltd., UK) as described in the 
manufacturer's instructions. 
2.7 AGAROSE GEL ELECTROPHORESIS 
Agarose gels were prepared and run as described by Sambrook et al. (1989). Gels were 
prepared in 1 x T AE (40 mM Tris Acetate, 2 mM EDT A, pH 8.5) at a concentration of 1-
2% (w/v) agarose. Ethidium bromide was added to a final concentration of 10 )lg mr!. Gels 
were run in 1 x TAE buffer at 50 - 120 V. DNA was visualised using a UV transilluminator. 
2.8 POLYMERASE CHAIN REACTION 
2.8.1 Primers 
Primer Name Nucleotide Sequence (5' - 3') Primer 
Tm ~ o C ~ ~
ERMBF ATGACTGATATCACTGATGCTAGCGAAATGATAC 71 
ACCAATCAG 
ERMBR CTTAGTGTTAACACAGCTGTAGGCGCTAGGGACC 69 
TC 
ORITF CCTGCTTCGGGGTCATTATGC 56 
ORITR CCTGCTTCGGGGTCATTATAGC 57 
LACZALPHAF CTATGGCGTGCTGCTAGCG 55 
LACZALPHAR ACAGGAAACACATATGAC 43 
CPG2F ACCCGAACGAACAATGCGTAGA 58 
CPG2R GTGGCTTCCTGGTCTGCTGTC 56 
EGLASOEF GGGGGTATTCATATGTTTTC 56 
EGLASOER CGCGCTTCTGAGCTTCAGCTTTATAAGT 62 
CPG2S0EF CAGAAGCGCGACACAACG 58 
CPG2S0ER GCCGCCCTTGTCGTCG 56 
CPG2correction 1 CTAGGAGATTATATATGGCTGCAAGATTGATAAT 76 
GGATCTAGGTGCTGGTAAATAACTGCA 
CPG2correction2 GTTATTTACCAGCACCTAGATCCATTATCAATCTT 72 
GCAGCCATATATAATCTC 
HINNTRF GAGGAAATCATATGACTCAAC 51 
HINNTRR CTGCAGGCCTTTTTTAAT 50 
HINWTRTF ATGACTCAACTTACTCGTGAACAAG 54 
HINWTRTR TTACCCCACCCATTTCACC 51 
HINSYNTHRTF ATGACTCAATTAACAAGGGAACAA 51 
HINSYNTHR TR TTAACCAACCCATTTTACTACTTCATC 54 
NFNBF CATATGGATATCATTTCTGTCGCC 54 
NFNBR AGGCCTTCTAGATTACACTTCGGTTAAGGTGAT 63 
BOTFDXF GCGGCCGCGTGTAGTAGCCTGTGAAATAAGTAA 70 
BOTFDXR GTATGCCATATGTAACACACC 53 
PERFDXF GCGGCCGCTTAAATTTTTAATACGGTATAGGGGT 69 
PERFDXR CATATGAAAACACCTCCTAAAATG 57 
NMERTF ATGACAGTATTAAGCAAAGAGCAGG 54 
NMERTR TTATGCCCAAATAACGGTTTC 49 
PYRFF GCATGCCTTGATACGGATATAAGTTATCTACC 61 
PYRFR CAGCTGCTTGCACATTCTTCAAAGTTTTTTCCTTC 62 
TETMF GGGGACGCGTGATAGCGGGAACAAATAATTG 62 
TETMR GGGGACGCGTCAACATAAAATACACTAAG 44 
CATPR GCGGAGACGGAGAAAATC 50 
PYRCF GTAGATTGTATAGGGACGGATCATGCACC 62 
PYRKR GCTCTTATCATATAAAACTGTCCTGGCTTCC 60 
Table 2.3 Nucleotide sequence and melting temperatures of oligonucleotides used in this study. 
2.8.2 General PCR parameters 
PCR reactions were carried out using the Failsafe PCR system (Cambio) as described in the 
manufacturer's instructions. Briefly, on ice, 100 ng DNA template, 0.5 /11 of each primer 
(from 100 /1M stock), and 1.25 U of Failsafe PCR enzyme mix were mixed and the reaction 
was made up to a final volume of 25 /11 with sterile, nuclease free water. Finally, 25 /11 of 
2 x Failsafe PCR premix buffer was added bringing the final reaction volume to 50 /11. The 
mixture was then subjected to PCR in a thermal cycler block (Applied Biosystems Gene 
Amp PCR system 2400). 
Failsafe PCR premix buffer E was routinely used for all PCR reactions. Ifhowever. premix 
buffer E failed to yield a product, then the reaction was repeated with the remaining 
11 premix buffers (A-D & F-L); the one that gave the highest yield was used in subsequent 
repeat PCR's with identical template and primer pairs. 
Annealing temperatures (Ta) varied and were dependent upon the melting temperatures (Tm) 
of the primers used. Tm's for oligonucleotides shorter than 20 bases was calculated using 
the Wallace Rule: T m = 2(A + T) + 4(G + C). For oligonucleotides longer than 20 bases, Tm 
was calculated using the Nearest Neighbour formula (Breslauer et aI., 1986). The Ta used in 
the individual PCR's was 5 °c below the lowest calculated Tm of the primer pair. 
Extension times varied and were dependent on the size of the product being amplified. A 
1 min extension time was allowed for every kilobase of DNA amplified. 
2.8.3 Colony PCR 
A single colony was taken from an agar plate and resuspended in 20 /11 of sterile distilled 
water. The cell suspension was then lysed by heating to 98°C for 10 min in a thennal cycler 
block. The lysate was cleared by centrifugation at 16,000 x g in a bench top centrifuge. 4 /11 
was carefully removed (avoiding any cellular debris) and added to the PCR reaction. 
2.8.4 Gene splicing by overlap extension ("gene SOEing") 
Genes were spliced according to the method of Horton et al (1990). Briefly, a first round of 
PCR was performed with two primers, one of the primers containing a region of DNA 
sequence homologous to the region to which it is to be fused. This was followed by a second 
round of PCR using both fragments required to be fused together as templates, and the outer 
primers. This results in the common sequence between the two fragments allowing the 
strands from the two different fragments to hybridise to one another, forming an overlap. 
Extension of the overlap by DNA polymerase yields the required dsDNA recombinant 
molecule. Further amplification was achieved using the outer primers to obtain the full 
length PCR fusion product. 
2.9 TRANSFER OF PLASMID DNA INTO BACTERIAL CELLS 
2.9.1 Dialysis of DNA ligation reactions 
Ligation reactions were dialysed against water using 0.025 I-lm nitrocellulose dialysis filters 
(Millipore Corporation). The filter was allowed to float, reflective side up, in a petri dish 
containing sterile deionised water. The ligation reaction was then added to the uppermost 
surface by pipette and left to dialyse for 30 min. 
2.9.2 Preparation of electrocompetent E. coli 
Electrocompetent E. coli were prepared as follows: a 1 ml aliquot from a 10 ml overnight 
culture of E. coli (grown with selection if necessary) was used to inoculate 100 ml LB broth. 
The cells were grown at 37°C with shaking at 200 rpm to an OD600 nm of 0.5 - 1.0 (an optical 
density indicative of exponential growth). Cells were harvested by chilling on ice for 15 -
30 min followed by centrifugation at 4,000 x g for 15 min at 4 dc. The supernatant was 
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aspirated and the pellet resuspended in 100 ml ice-cold sterile deionised water. The cell 
suspension was centrifuged as before. The pellet was then resuspended in 2 ml of 10% 
glycerol, and centrifuged as before. The pellet was then resuspended to a final volume of 
0.5 m] in 10% (v/v) glycerol, resulting in a cell concentration of approximately 1 x 1010 cells 
mr!. The cells were stored at - 80°C in 40 J.lI aliquots. 
2.9.3 Electroporation of plasmid DNA into E. coli 
Plasmid DNA or dialysed ligation reactions were added to 40 J.lI of electrocompetent E. coli 
(as prepared in Section 2.9.2) that had been allowed to thaw on ice for 10 min. This mixture 
was then transferred to a pre-chilled 2 mm gap elecroporation cuvette (BioRad). A pulse of 
2.5 kV (25 J.lF, 200 0) was delivered to the cuvette using a BioRad Gene Pulsar according to • 
the manufacturer's instructions. 400 J.lI of SOC or 2 x YT recovery medium was 
immediately added, and the cell suspension was incubated at 37 DC for 1 h with shaking 
(200 rpm). Appropriate serial dilutions were then made from the cell suspension prior to 
spreading onto selective 2 x YT agar. 
2.9.4 Preparation of chemically competent E. coli 
A 1 ml aliquot from a 10 ml overnight culture of E. coli (grown with selection if necessary) 
was used to inoculate 100 ml LB broth. The cells were grown at 37°C with shaking at 200 
rpm to an OD6oo nm of 0.5 - 1.0 (an optical density indicative of exponential growth). To 
9 
harvest the cells the cells was chilled on ice for 15 to 30 minutes and centrifuged at , 
4,000 x g for 15 min at 4°C. The cell pellet was then resuspended in 25 ml of ice cold 
0.1 M MgC\:z The cells were harvested as before and the pellet gently resuspended in 2 ml 
of ice cold 0.1 M CaCho The cell suspension was then left on ice for a minimum of:2 h, to 
achieve chemical competence. 100 J.lI aliquots could then be used for chemical 
transformations for up to 48 h provided the cell suspension was kept chilled. 
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2.9.5 Transformation of plasmid DNA into chemically competent E. coli 
Plasmid DNA or ligation reactions were added to 1 00 ~ l l of competent E. coli cells that had 
been kept chilled on ice and gently mixed. The transformation reactions were then incubated 
for 30 min on ice, followed by heat-shock at 42°C for 30 sec. The mixture was then 
incubated on ice for a further minute, before the addition of 200 ~ l l SOC or 2 x YT recovery 
medium. The reaction was then incubated at 37°C for one hour with shaking at 200 rpm 
before plating onto 2 x YT agar containing the appropriate antibiotic selection. 
2.9.6 Transformation of plasmid DNA into B. subtilis 
Plasmid DNA was introduced into B. subtilis by transformation as follows: a heavy 
inoculum of fresh overnight growth was taken and added to 20 ml of competence medium 
(detailed in Section 2.3.5) with appropriate selection if necessary, followed by incubation at 
37°C with shaking (200 rpm), until an 00600 equivalent of 3.0 or more was achieved. The 
cells were then diluted ten-fold in transformation medium (detailed in Section 2.3.6). I ml 
aliquots were removed and added to I ~ g g of plasmid DNA, followed by incubation at 37°C 
with agitation, for a further 90 min. Aliquots were then spread onto LB agar plates 
containing the appropriate selection. 
2.9.7 Conjugation of plasmid DNA into C. sporogenes 
Plasm ids were introduced into C. sporogenes by conjugation from E. coli CA434 (E. coli 
HB I 0 I carrying the helper plasmid R 702) essentially as described by Purdy et at (2002). A 
I ml aliquot from a 5 ml overnight culture of the E. coli donor strain, grown in LB broth with 
appropriate selection, was taken and the cells harvested by centrifugation in a bench top 
microfuge at 5,000 x g for I min. The pellet was gently resuspended with a pipette tip in 
I ml sterile PBS and the cells harvested as before. The pellet was then transferred to the 
anaerobic cabinet and resuspended in 200 ~ I I of C. sporogenes that had been grown 
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anaerobically, overnight at 37 DC. The cell suspension was then spotted in 10 III volumes 
onto non-selective agar plates, followed by incubation at 37 DC for 7 h under anaerobic 
conditions. The cells were then harvested by flooding the agar plates with 0.5 - 1.0 ml of 
sterile PBS. The resulting cell slurry was removed, serially diluted and spread on selective 
agar plates, followed by incubation at 37 DC for 16 - 24 h in an anaerobic workstation. 
2.10 ESTIMATION OF PLASMID SEGREGATIONAL STABILITY 
The method utilised is a modification of experiments by Bron and Luxen (1985). 
Recombinant C. sporogenes was grown overnight in TYG medium supplemented with the 
appropriate selective antibiotic. A 30 III aliquot of the overnight culture was then 
subcultured into 3 ml non-selective TYG medium. Cultures were then incubated for 12 h 
before being subcultured as before into fresh non-selective medium and incubated for a 
further 12 h overnight. This subculturing regime was repeated four times. At the end of 
each 12 h growth period, cells were serially diluted in PBS up to 10-7 and plated to single 
colonies on TYG agar either with or without antibiotic selection. The colonies that arose on 
non-selective plates were picked onto fresh TYG agar without and then with antibiotic 
supplementation. 
Segregational stability was expressed as percentage cells having lost the plasmid after n 
generations. It can also be expressed as plasmid loss per generation and was calculated 
according to the formula: 
R=(I-xt 
Where R = fraction of plasmid containing cells, x = the rate of plasmid loss/generation, 
n = nllm ber of generations (Swinfield et al., 1991). 
Therefore, to calculate plasmid loss per generation (x): 
x = I - R1/n 
2.11 T/A CLONING 
PCR products were cloned into pCR2.1-TOPO (Invitrogen) as described in the 
manufacturer's instructions. PCR products were ligated directly into the vector due to the 
presence of precleaved ends in the vector, which have been treated with terminal 
deoxynucleotidyl transferase to create ddT overhangs on both 3' ends. The addition of 
TOPO isomerase to the TOPO reaction negates the need for DNA ligase and PCR products 
can be ligated directly into the vector due to the addition of 3' deoxyadenosine overhangs by 
the action of Taq polymerase during PCR. 
2.12 BLUEIWHITE SELECTION 
Blue/white selection was possible when DNA inserts were cloned into the E. coli lacZ alpha 
(lacZa) region present on many standard cloning vectors. This leads to disruption of the 
protein's function, giving rise to an easily identifiable phenotypic marker. Colonies were 
screened on agar plates containing 40 /lg mrl X-Gal and 1 mM IPTG. Colonies harbouring 
vector containing the insert grew white, whilst those without grew blue due to a functional 
~ - g a l a c t o s i d a s e e activity and hence uninterrupted gene. This screening process was only 
possible in E. coli strains that carry a mutation in the native lacZa region, namely TOPIO 
and TOP I OF'. Complementation of the mutant LacZa with the vector-borne copy of LacZa 
enables a functional enzymatic activity. 
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2.13 RNA ANALYSIS 
To minimise RNase contamination, all RNA work was carried out in a designated clean area, 
which had been thoroughly cleaned with RNaseZap (Ambion). Certified RNase clean tips 
and microfuge tubes (Eppendorf) were used and where possible all solutions were treated 
with 1% (v/v) diethyl pyrocarbonate (DEPC). In addition, all glassware and apparatus were 
wiped over with RNaseZap and rinsed with DEPC-treated water before use. 
2.13.1 Preparation of total RNA from C. sporogenes 
Prior to harvesting cells, 2 volumes (1 ml) of RNAprotect Bacteria Reagent (QIAGEN) was 
added to a bijou. 0.5 ml of an overnight culture of C. sporogenes cells grown in TYG 
medium ( ~ l l x 107 cells) was then added to the RNAprotect Bacteria Reagent and vortexed 
for 5 sec followed by incubation at room temperature for 5 min. The crude RNA prep was 
harvested by centrifugation at 5,000 x g for 10 min in a benchtop microfuge. The 
supernatant was thoroughly aspirated and the pellet loosened by briefly vortexing. The 
bacteria were then lysed by resuspended in 100 /-ll of TE containing 3 mg mrl lysozyme and 
incubating at room temperature for 10 min. 
Total RNA was then extracted from the C. sporogenes lysate using Qiagen's Rneasy Kit, as 
described in the manufacturer's instructions. Briefly, 350 /-ll of buffer RLT (supplied with 
kit) to which ~ - m e r c a p t o e t h a n o l l had been added, was mixed with the lysate, followed by the 
addition of 250 /-ll of cold absolute ethanol. This solution was then applied to an RNeasy 
column followed by the addition of 5U of Turbo DNase (Ambion) as a preliminary on-
column DNase digestion. The column was then incubated at room temperature for 5 minutes 
and centrifuged in a bench top microfuge at 8,000 x g for 15 sec. The flow-through was 
discarded and 700 III of buffer RWI (supplied with kit) was applied to the column for 5 min. 
The column was again centrifuged at 8,000 x g for 15 sec and the flow-through again 
discarded. The column was then washed by addition of 500 III of buffer RPE (supplied with 
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kit) and centrifuged as before. The column was then washed with 500 /-11 of buffer RPE for a 
second time and centrifuged at 8,000 x g for 2 min. The flow-through was again discarded 
and the RNA eluted by the addition of 50 /-11 of DEPC treated water and centrifugation at 
8,000 x g for 1 min. 
2.13.2 Removal of contaminating genomic DNA from total RNA 
Contaminating DNA was removed from RNA samples using Ambion's Turbo DNase as 
described in the manufacturer's instructions. The appropriate volume of lax Turbo DNase 
buffer was added to the RNA sample,S U of Turbo DNase per /-1g of RNA was then added 
and the final volume adjusted with DEPC-treated water. The reaction was incubated at 
37°C for 30 min. 
2.13.3 DNase I treated RNA sample clean up 
Total RNA that had been treated with DNase I was cleaned up prior to use in RT-PCR using 
Qiagen's RNeasy columns as described in the manufacturer's instructions. Briefly, the RNA 
sample was adjusted to 100 /-11 with DEPC-treated water and 350 /-11 of buffer RL T (supplied 
with kit) was added to the sample, followed by the addition of 250 /-11 of ice cold absolute 
ethanol. This solution was then applied to an RNeasy column and centrifuged in a bench top 
microfuge at 8,000 x g for 15 sec. The column was then washed by addition of 500 /-11 of 
buffer RPE (supplied with kit) and centrifuged as before. The column was washed for a 
second time by the addition of 500 /-11 of buffer RPE and was then centrifuged at 8,000 x g 
for 2 min. The flow-through was again discarded and the RNA eluted by the addition of 30 
/-11 of DEPC-treated water and centrifugation at 8,000 x g for 1 min. 
2.13.4 One-tube RT-PCR 
Before use in RT-PCR, RNA was treated with Turbo DNase (as described in Section 2.13.2) 
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and subsequently cleaned up as described in Section 2.13.3. RT-PCR was carried out using 
Qiagen's One-tube RT-PCR kit and HotStar Taq (QIAGEN), as described in the 
manufacturer's instructions. Briefly, RNA samples, buffers and reagents were allowed to 
thaw on ice. On ice, 10 ).!l 5 x QIAGEN One Step RT-PCR buffer, 400 ).!M of each dNTP, 
0.6 ).!M forward and reverse primer and 2 ).!l QIAGEN OneStep RT-PCR enzyme mix were 
added to lOng of RNA (quantified using a NanoDrop ND-lOOO spectrophotometer), and the 
final volume was adjusted to 50 ).!l with DEPC-treated water. Reverse transcription was then 
allowed to proceed at 50°C for 30 min. After which time, the reaction was then transferred 
to a nuclease free PCR tube and PCR amplification was carried out using an Applied 
Biosystems Gene Amp PCR system 2400 thermocycler (see Table 2.4). 
Step Time 
15 min 
2 1 min 
3 1 min 
4 x sec 
5 10 min 
6 hold 
Temperature (OC) 
95 
94 
x 
72 
72 
4 
Details 
Inactivation of Omnicsript and Sensiscript 
ReverseTranscriptases, denaturation of the cDNA 
template, and activation of the HotStarTaq DNA 
Polymerase 
Denaturation. 
Primer annealing. The temperature was calculated 
according to the primer pair used in the reaction, 
i.e. 5°C below the lowest Tm. 
Extension. (The time was dependant on the size 
of the product, with 60 sec extension allowed for 
every kilobase of DNA amplified). 
Final extension 
Table 2.-1: PCR programme utilised for RT-PCR amplification ofmRNA. 
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Control reactions were performed where the RNA template was exchanged for DEPC treated 
water to check for RNA contamination of RT-PCR buffers, dNTPs e.t.c. Also several 
HotStarTaq control peR reactions were performed with a variety of templates: DNA 
template as a positive control, RNA template to check for DNA contamination of the RNA 
, 
and water template to check for DNA contamination of HotStar Taq components. 
If the RT-PCR failed, the procedure was repeated with the inclusion of either Q-solution 
(changes the melting behaviour of DNA) and/or additional MgCI2. 
RT-PCR products were visualised with ethidium bromide by agarose electrophoresis as 
described in Section 2.7. 
2.14 PROTEIN EXPRESSION AND PURIFICATION 
2.14.1 Over-expression of proteins in E. coli 
5 ml cultures of E. coli harbouring the expression vectors were grown in LB broth under 
selective conditions at 37°C overnight with shaking (200 rpm). The culture was then diluted 
100-fold in sterile selective LB broth and grown at 37°C with shaking (200 rpm). 1.5 ml 
aliquots of cells were taken at the appropriate time (usually 4 h, 8 h, and 24 h) and harvested 
by centrifugation at 4,000 x g for 20 min, the supernatant discarded and the pellet stored at 
-20°C overnight. 
2.14.2 Preparation of celllysates and protein extraction from E. coli 
E. coli cell Iysates were prepared using BugBuster protein extraction reagent (Novagen) as 
described in the manufacturer's instructions. Briefly, cell pellets that had been stored at 
-20°C overnight were allowed to thaw on ice for approximately 15 min. The pellet was 
resuspended in BugBuster reagent, which had been previously diluted to 1 x by addition of 
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the appropriate buffer, by gentle vortexing. 300 ~ l l of reagent per 1.5 ml culture \\as used 
and 25 U of benzonase per ml of BugBuster was added in order to reduce the viscosity of the 
final lysate. The cel\ suspension was then incubated at room temperature with gentle 
shaking for 30 min. The insoluble cell debris was removed by centrifugation at 16,000 x g 
for 20 min at 4°C and the supernatant, which contains the soluble protein, was retained. 
To isolate insoluble proteins packaged in inclusion bodies, the pellet obtained after the 
BugBuster lysis was subjected to the following further modifications: the pellet was 
resuspended in the same volume of BugBuster reagent that was used to resuspend the 
original cell pellet, by pipetting up and down followed by vortexing to obtain an even 
suspension. Complete resuspension of the pellet is essential to ensure solubilisation and 
removal of any contaminating soluble proteins. 1 KU mr! rLysozyme was then added and 
the solution mixed by gentle vortexing followed by a 5 min room temperature incubation. 6 
volumes of a 1: 10 dilution BugBuster reagent (in deionized water) was then added to the 
suspension and mixed by vortexing for 1 min. The suspension was then centrifuged at 5,000 
x g for 15 min at 4°C to collect the inclusion bodies. The supernatant is removed with a 
pipette. The inclusion bodies were then resuspened in half the original culture volume (0.5 
volume) of 1: 10 diluted BugBuster reagent, mixed by vortexing, and centrifuged at 5,000 x g 
for 15 min at 4°C. This step is repeated twice. A final resuspension is followed by a 
centrifugation at 16,000 x g for 15 min at 4°C, and the supernatant removed. The final pellet 
of purified inclusion bodies is resuspended in the Tris buffer appropriate for the protein 
being studied. 
2.14.3 Over-expression of proteins in C. sporogenes 
5 ml cultures of C. sporogenes harbouring the expression vectors were grown in TYG broth 
under selective conditions anaerobically at 37°C overnight. The culture was then diluted 
100 fold in sterile selective TYG broth and grown at 37°C anaerobically. 1 ml aliquots of 
cells were taken at the appropriate time intervals (usually 4 h, 8 h, and 24 h), the OD6oo 
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recorded, and harvested by centrifugation at 5,000 x g for 5 mIn. The supernatant was 
discarded and the pellet stored at - 20°C overnight. 
2.14.4 Preparation of celllysates and protein extraction from C. sporogenes 
C. sporogenes cell lysates were prepared USIng BugBuster protein extraction reagent 
(Novagen) as described in the manufacturer's instructions. Briefly, cell pellets that had been 
stored at -20°C overnight were allowed to thaw on ice for approximately 15 min. The pellet 
was resuspended by gentle vortexing in l/Sth culture volume of BugBuster reagent that had 
been previously diluted from lOx stock to 1 x by addition of the desired enzyme assay 
buffer. If a larger volume of culture had been harvested then l/20th culture volume of 
1 x BugBuster was used. 25 U of benzonase per ml of BugBuster was added in order to 
reduce the viscosity of the final lysate. 1 KU rLysozyme per ml of 1 x BugBuster was added 
to the resuspended pellet. The cell suspension was then incubated at room temperature with 
gentle shaking for 30 min. The insoluble cell debris was removed by centrifugation at 
16,000 x g for 20 min at 4 °C and the supernatant, which contains the soluble protein, was 
retained. 
2.15 PROTEIN VISUALISATION 
2.15.1 NuPAGE gel electrophoresis 
NuPAGE 4 - 12% precast gels (Invitrogen) in MES runnIng buffer (50mM 2-(N-
morpholino)ethane sulphonic acid, 50 mM Tris, 0.1% (w/v) SDS, 1 mM EDTA, [pH 7.3]) 
were used for protein analysis by gel electrophoresis. Cell Iysates were diluted in 
4 x NuPAGE LDS sample buffer (106 mM Tris-HCI, 141 mM Tris-base, 2% (w/v) LOS, 
10% (w/v) glycerol, 0.51 mM EDTA, 0.22 mM Serva blue G2S0, 0.175 mM Phenol red [pH 
8.S]) and heated at 95°C for S min. Protein samples were then loaded into the wells of the 
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gel and run at 150 V for 90 min using the Novex XcellII minicell as described in the 
manufacturer's instructions. Pre-stained broad size range protein markers (BioRad) were 
used to estimate sizes of purified proteins. 
2.15.2 Novex Zymogram gel electrophoresis 
For the detection and characterisation of proteases, more specifically collagenases, Novex 
10% Zymogram gelatin gels (Invitrogen) were used. Proteases are visualised as clear bands 
against a dark blue background where the protease has digested the substrate, in this case 
gelatin. 5 ml overnight cultures of C. sporogenes NCIMB 10696 were centrifuged at 
5,000 x g. A 5 III aliquot of a 10-1 dilution of supernatant was diluted in 2 x Novex Tris-
Glycine SDS sample buffer. Culture supernatant samples were loaded into the wells of the 
gel and run in 1 x Tris-Glycine running buffer at 125 V for 1 h using the Novex XcellII 
minicell as described in the manufacturer's instructions. Pre-stained broad range protein 
markers (BioRad) were used to estimate the size of proteases. After electrophoresis, the gel 
was incubated in 1 x Zymogram renaturing buffer for 30 min at room temperature with 
gentle agitation. The buffer was decanted off and the gel was equilibrated prior to being 
developed by the addition of 1 x Zymogram developing buffer. The gel was equilibrated for 
30 min at room temperature with gentle agitation. The buffer was decanted and replaced 
with fresh I x Zymogram developing buffer followed by overnight incubation at 37°C. 
2.15.3 Simply blue staining 
After electrophoresis, NuPAGE gels were rinsed with 100 ml of deionised water for 5 min 
with gentle agitation three times, before being stained with 20 ml SimplyBlue for 1 - 3 h, 
again with gentle agitation. The stain was discarded and the gel destained with water for 
I - 3 h. Zymogram gels were stained after being developed by the addition of 20 ml of 
SimplyBlue. The gel was stained with gentle agitation until the zones of clearance \vere 
visible, usually after 1 - 2 hours. 
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2.15.4 Densitometry 
Overexpression of proteins was quantified by densitometry USIng a OS-SOO Calibrated 
Densitometer with Quantity One software (BioRad). 
2.16 QUANTIFICATION OF PROTEIN SAMPLES 
Protein concentration of cell lysates was determined using the Bradford assay (Bradford, 
1976). Briefly, bovine serum albumin (BSA) standards were prepared in 200 /-11 volumes 
ranging from 1 to 20 /-1g protein/200 /-11. The standards along with 200 /-11 of Iysates and serial 
dilutions up to 10-3 were added to 1 ml light path plastic cuvettes containing SOO /-11 Bradford 
Reagent (Sigma-Aldrich Company Ltd. Dorset, U.K.) which contains Coomassie Brilliant 
Blue 0-250, and incubated for 5 min. The absorbance at 595 nm (AS9S) was measured 
relative to a water blank. The data created from the BSA standards was used to create a 
standard curve, from which the concentration of the lysates could be calculated based on the 
AS9S obtained. 
2.17 ENZYME ASSAYS 
2.17.1 Chloramphenicol acetyl transferase assay 
C. sporogenes lysates were prepared as described previously (see Section 2.14.3 and 2.14.4). 
A 100 /-11 aliquot of lysate was added to 1 ml reaction buffer (10 mM 5.5'-dithio-bis(2-
nitrobenzoic acid) in 1 M Tris-HCl [pH 7.S], and 0.1 mM Acetyl-CoA) which had previously 
been equilibrated to 37°C for at least 30 min, in a clean plastic cuvette. The cuvette was 
then placed in a spectrophotometer, blanked, and 20 J-ll of 5 mM chloramphenicol added and 
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quickly mixed by inverting. The reaction was left to run for 1 min in the spectrophotometer, 
after which time the increase in absorbance at 412 nm was recorded. This process was 
repeated for each sample lysate, with appropriate dilutions made of the Iysates where 
necessary. 
Units per ml of CAT were calculated using the following equation, 
( ~ A 4 l 2 2 / min) / V 
13.6 
~ A 4 1 2 / / min = the increase in A4l2 per min 
V = the volume oflysate added (ml) 
In order to obtain Units mg- l protein the Units per ml were divided by the protein 
concentration (mg mrl) of the sample. 
2.17.2 ~ - G l u c u r o n i d a s e e assay 
~ - G l u c u r o n i d a s e e levels were measured by modification of the method described by Melville 
et at (1994). C. sporogenes was serially diluted into 3 ml of TYG medium and grown 
anaerobically at 37°C overnight. The lowest dilution showing growth was used to inoculate 
fresh sterile selective media 1 in 100 and grown anaerobically at 37°C. A 1 ml sample was 
removed every hour or at the appropriate time interval (usually 4 h, 8 h, and 24 h) and the 
OD600 recorded. Each sample was then centrifuged at 5,000 x g for 5 min, the supernatant 
aspirated and the pellet frozen at - 70°C overnight. The pellets were thawed on ice for 
5 min and resuspended in 0.8 ml Z buffer (60 mM Na2HP04.7H20 [pH 7.0], 40 mM 
NaH2P04.H20, 10 mM KCI, 1 mM MgS04.7H20 and 50 mM 2-mercaptoethanol). Cells 
were lysed by addition of 8 ~ l l of toluene followed by vigorous vortexing for 1 min. Each 
sample was incubated on ice for 10 min, and then with caps open for 30 min at 37°C in a 
fume hood. 150 ~ L l l from each sample was then transferred in duplicate to the wells of a flat 
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bottom 96 well plate and the enzyme reaction started by addition of a 6 mM solution of 
p - n i t r o p h e n y l - ~ - D D glucuronide. The plate was then immediately placed in a 37°C preheated 
ELISA plate reader (Wallac Victor2 1420 Multilabel counter). Absorbance at 405 nm was 
recorded every 30 sec until the reaction stopped. 
The specific activity was calculated based on the change in A405 while the reading was 
increasing linearly, using the following equation: 
A405 X 1,000 
OD600 X t (min) x 1.25 x sample vol (ml) 
In order to obtain specific activity per mg protein, the value for the specific activity was 
divided by the total protein concentration (mg mr!). 
2.17.3 Carboxypeptidase assay 
E. coli and C. sporogenes lysates were prepared as described previously (see Section 2.14.1, 
2.14.2,2.14.3 and 2.14.4). A quartz cuvette was prepared containing 0.1 ml of methotrexate 
solution (0.6 mM methotrexate [0.27 mg mr! methotrexate] in Tris buffer [0.1 M Tris-HCI 
pH 7.3, containing 0.2 mM ZnS04]) and 0.9 ml Tris buffer (0.1 M Tris-HCl pH 7.3, 
containing 0.2 mM ZnS04). The initial A320 was recorded (a value of at least 0.8 is required 
after zeroing with a Tris buffer blank). The cuvette was pre-warmed to 37°C, and the 
reaction initiated by the addition of 10 III of cell lysate. The decrease in absorbance at 320 
11m was recorded. 
To calculate Units mr! in the lysate: 
£: max for methotrexate is 8300 
~ ~ A320 X 100 x dilution factor 
8.3 
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2.17.4 Nitroreducatse menadione assay 
E. coli and C. sporogenes lysates were prepared as described previously (see Section 2.U.l, 
2.14.2, 2.14.3 and 2.14.4). A 1 ml quartz cuvette was prepared containing 780 IJ.I of Tris 
buffer (10 mM Tris-HCI pH7.5 at 37°C) preheated to 37 °C. Immediately prior to adding 
the lysate the following were added to the cuvette and mixed: 10 IJ.I 1 mM menadione, 100 IJ.I 
10 mM NADH, and 100 IJ.I 700 )lM cytochrome C. The cuvette was returned to the 
spectrophotometer and the absorbance zeroed. 10 IJ.I of lysate, or serial dilutions of the 
lysate, was then added to the cuvette and the reaction mixture immediately mixed. The 
increase in A550 being recorded. 
Units per ml of nitro reductase activity were calculated using the following equation, 
(.-1A550 f min) f ml 
14.79 
where .-1A550 fmin = the increase in A550 per min. 
In order to get Units mg-! protein, the Units per ml were divided by the protein concentration 
of the sample in mg mr!. 
2.18 PHENOTYPIC ASSAY 
2.18.1 Spore assay 
Sporulation efficiencies were calculated using a modification of the method described by 
Kamiya et at (1992). In essence, 5 ml overnight cultures of C sporogenes were used to 
inoculate (1: 1 00) 35 ml of selective TYG broth. Broths were incubated anaerobically at 
370C for 72 h. Following incubation, 500 IJ.I of cell culture was heat inactivated at 80°C for 
20 min. Dilutions of heat inactivated cells, and a non heat inactivated sample as a total cell 
count control, were plated out on selective TYG agar. Sporulation efficiency was recorded 
as % of spores relative to total cell count. 
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CHAPTER 3 
DEVELOPMENT OF A CLOSTRIDIAL 
EXPRESSION VECTOR AND GENE 
TRANSFER STUDIES IN 
c. SPOROGENES 
..,,, 
/ -' 
3.1 INTRODUCTION 
It is the ultimate aim of CDEPT to have the gene encoding the prodrug converting enzyme 
stably integrated into the genome, so as to negate the use of antibiotics in the clinic. In the 
interim, an effective segregationally stable plasmid-based expression system is required in 
order to assess the effectiveness of new enzyme/prodrug systems in the in vivo animal 
model. 
A variety of vectors are available for the manipulation of clostridia, however they could not 
be employed without becoming party to a restrictive materials transfer agreement. This 
would impose restrictions on the consortium's freedom to develop any process generated. 
Therefore, the required vectors needed to be reconstructed. In this chapter the construction 
of an E. coli/Clostridium shuttle expression vector will be described. 
For the initial expression studies, the ferredoxin promoter (fdxp) from C. pasteurianum was 
chosen for the shuttle expression vector. Ferredoxin (Fdx) is a low molecular weight 
electron carrier protein that functions as an electron acceptor in redox reactions. Clostridia 
grown in iron-rich media are capable of expressing Fdx at a level up to 2% total cellular 
protein (Marczak et aI., 1985; Rabinowitz, 1972). Also, considering that Fdx is a low-
molecular weight protein that is encoded by a single-copy gene (fdx) (Graves et al., 1985; 
Graves and Rabinowitz, 1986), clostridial jdx appears to be transcribed at high levels. 
Previous work (Minton et al., 1995) utilised the jdx promoter from C. pasteurianum to 
express the nitroreductase gene nfnB from E. coli to a level equivalent of 8% total cellular 
protein in a C. beijerinckii NCIMB 8052 host. If necessary, studies to identify an improved 
promoter wiII be performed at a later stage. 
An IPTG inducible ferredoxin promoter,jac, has been previously generated (CAMR, Porton 
Down, Salisbury). However, due to ownership issues, jac was resynthesised taking the 
opportunity to incorporate some improvements. These were enhancement to the spacing of 
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the ribosome binding site from the start codon and the alteration of the orientation of the lac 
operator. The resulting promoter was then utilised to generate an expression cartridge. 
3.2 RESULTS 
3.2.1 Construction of an E. coli/Clostridium shuttle vector 
Plasmid nomenclature was derived as follows. All plasmids constructed belong to the pMTL 
family of plasm ids. For plasmids generated for this work the prefix 5 was used therefore 
plasmids were called pMTL5xxx (i.e. 5 followed by three digits). A description of the 
nomenclature is shown in Appendix I. 
3.2.1.1 Vector backbone construction 
The first stage in the generation of an E. coli/Clostridium shuttle vector was to construct the 
basic plasmid backbone on which all future shuttle vectors could be based, that of pMTL4 
(Chambers et aI., 1988a). pMTL20 (Chambers et aI., 1988a; Oultram et aI., 1988), a 
derivative of pMTL4, was digested with the restriction endonuclease Haell in order to excise 
lacZa. This was performed so that lacZa could be recloned back into the shuttle vector in a 
more useful location at a later stage. Religation of the lacZa deleted plasmid yielded 
pMTL4 (see Figure 3.1). For antibiotic selection, erythromycin can be utilised as the sole 
antibiotic due to its selectivity in both E. coli and a variety of Clostridium species (Minton, 
N.P. personal communication). 
The next stage was to amplify up the erythromycin resistance marker, ermB, from pMTL20E 
(Oultram et al., 1988) using ERMF and ERMR primers. PCR amplified ermB was digested 
with EcoRV and HpaI and cloned into pMTL4 digested with EcoRV to generated pMTL-l-
Em (see Figure 3.1). To reduce the overall plasmid size, useful in generating as 
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bla 
segregationally stable a plasmid as possible, and due to the fact that erythromycin can be 
used as the sole resistance marker, the ampicillin resistance marker was excised on a BspHI 
(blunt-ended) fragment. In place of bia a Gram-positive replicon was cloned. 
Haell 
pMTL20 
2476 bp 
ColEI 
RNA II 
Haell 
bla 
Haell 
bla 
Hpa l ermS EcoRV 
\ ~ i = = = 0 4 4
~ ~
EcoRV 
pMTL4 
2004 bp 
pMTL4-Em 
3132 bp 
ColEI 
RNA II 
ColEI 
RNA II 
ermS 
EcoRV 
Figure 3. i: Schematic representation of the cloning strategy for the construction of pMTL-t.-Em. A 
partial H ae n digest was performed on pMTL20 in order to delete out I aeZ a (such that I aeZ a could be 
cloned into a more suitable location) to generate pMTL-t. (1) . ernIB was then peR amplified [roIll 
pMTL20E and cloned into the EcoRV site of pMTU (2) to generate pMTL-t.-Em (3). 
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3.2.1.2 Choice ofreplicon and minimal region ofreplicon 
Initial studies on the genetic manipulation of clostridia for use in CDEPT involved 
C. acetobutylicum (Theys et aI., 1999) and the closely related C. beijerinckii (Minton et al., 
1995). Expression vectors utilised in these preliminary CDEPT studies were based on the 
replicon from the B. subtilis plasmid pIM13 (Monod et al., 1986), and on the E. faecalis 
plasmid pAM/31 (Clewell et at., 1974; LeBlanc and Lee, 1984), respectively. 
C. acetobutylicum NI-4082 was the initial CDEPT host of choice. Therefore, vectors based 
on the pIM 13 replicon were generated due to their high segregational stability in this strain 
(Azeddoug et al., 1992). 
pIM13 is a 2.2 kb multicopy plasmid from B. subtilis that contains two ORFs over 100 
amino acids in length. The first ORF (ermC) confers resistance to the macrolide-
lincosomide-streptogramin B (MLS) antibiotics (Mahler and Halvorson, 1980). The second 
ORF constitutes a 16 kDa replication protein that has high homology to the replication 
protein of the cryptic Staphylococcus aureus plasmid pSN2. It is thought that the pSN2 
family of plasm ids, including pIMI3, replicate via asymmetric rolling-circle replication 
(Dempsey et al., 1995). 
The approximate minimal regIon of pIM13 required for replication was determined by 
performing a variety of deletions on pIM13 (Monod et al., 1986). The ermC determinant 
was not essential as deletion of the minor segment from the MboI site at position 1369 to the 
CfoI site at position 17 still yielded a stable high copy number plasmid. The smaller HindIII 
fragment from positions 882 to 1098 could also be deleted. The resultant plasmid was fully 
capable of stable replication with a high copy number. A Hinfl digest followed by Klenow 
DNA polymerase blunt-ending failed to give a functional plasmid. Finally a Bal31 digest 
from the CfoI site at position 17 showed that removal of approximately 100 bp in the 
clockwise direction still yielded a viable plasmid. Therefore, the minimal region of pIM 13 
required for replication encompasses the region from the CfoI site at position 17 to the 
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HindIII site at position 882 (Monod et al. , 1986) (see Figure 3.2). 
Klenow blunt and 
deletion fails to yield 
a functional plasmid 
D 
Hinfl Hinfl 
1 
RepL - replication 
protein 
Cfa! (17) - Bal31 
digestion for ",100 bp still 
yields a functional plasmid 
< 
Deletion stil l yields a 
stable high copy number 
vector in Bacillus subtilis. 
D 
HmdIII Hind III 
~ ~
palB Macrolide res istance 
gene (ermC) 
Mba! (1369) 
Minimal reg ion of replication contained 
within the Cra! to HindIII restriction 
sites. Cra! site is dispensible 
) 
2246 bp 
Figure 3.2: Derivation of minimal region required for replication in pIMl 3. Converging arrows 
represent repeat regions. To generate the clostridial shuttle plasmid pIMPl , pUC9 digested with 
HindIII was cloned in place of the small HindIII fragment ofpIM13 (Mermelstein et aI. , 1992). 
Practically, this CfoUHindIII regIOn has been fused to the chloramphenicol resistance 
detenninant (cat) ofpC194 to yield a fully functional replicating plasmid, pBD347 (Projan et 
aI. , 1987). Additionally, the small HindIII region (bases 882 to 1098) has been deleted and 
replaced with pUC9 to yield pIMP1 (Mennelstein et aI. , 1992), a vector widely used in 
C. acetobutylicum. It has also been found that pIM13-based vectors expressing the cytokine 
mouse tumour necrosis factor alpha (mTNFa) and the prodrug converting enzyme cytosine 
deaminase (codA ) are structurally and segregationally stable in C. acetobutylicum DSM 792 
(lbeys et al. , 1999; Tbeys et al. , 2001b). 
To generate the clostridial shuttle vector, the Gram-positive replicon from pIMP 1 
(Mennelstein et aI., 1992) containing the minimal region of replication was excised by 
digestion with SmaI and FspJ and cloned into BspHI (blunt-ended) digested pMTL4-Em 
givi ng plasmid pMTL51 00 (see Figure 3.3). 
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rig ure 3.3: Schematic representation of the cloning strategy for the construction ofpMTL5100. The Gram-positive pIM13 replicon (repL) from pIMPlwas 
cloned on (1 Sma I and F<;pI fragment and cloned into pMTL4-Em in place of bla which was previously deleted on a BspHI fragment, Ole result being pMTL5 J 00. 
3.2.1.3 Shuttle expression vector construction. 
An IPTG inducible ferredoxin promoter expression cartridge has been previously 
constructed (Carter et at., 2005). The cloning of a lac operator into the ferredoxin promoter 
(Graves and Rabinowitz, 1986) generated the fac promoter. The fac promoter is flanked by 
the ferredoxin and cellulase (ceIA) transcriptional terminators. 
The ferredoxin expression cartridge was obtained from pMTL9341aLS2 (Carter et aI., 2005) 
and cloned as an NheIlSphI into the XbaI site in the multiple cloning site of pMTL20 
(Chambers et al., 1988a) to yield pMTL20:fdxTfacaLS2:ceIAT (see Figure 3.4). The 
ferredoxin promoter (jac) and antisense LuxS fragment (aLS2) was replaced with a synthetic 
optimised ferredoxin promoter (jac2) (synthesised and supplied by Entelechon GmbH on 
plasmid pCR4:fac2). XbaI and NotI digests on both plasm ids yielded 
pMTL20::ceIATfac2fdxT (see Figure 3.4). The sequence of fac2 is identical to that 
published for fac (Minton et al., 1990) apart from a two nucleotide reduction in the spacing 
between the ribosome binding site (RBS) and the A TG start codon, such that the sequence 
changed from AGGAGGTGTATTTCATATG to AGGAGGTTAGTCATATG. An NdeI 
restriction site was included 'over' the ATG start to enable optimal positioning of the gene 
encoding the prodrug converting enzymes to the promoter. Additionally, a lac operator 
sequence was included infac2 to enable IPTG induction. The orientation of the lac operator 
sequence was reversed infac2 in relation tofac. 
The entire expression cartridge was then cloned as an AatIIIBamHI (both sites blunt-ended) 
fragment into pMTL51 00 I inearised with EcoRV to give pMTL51 02 (see Figure 3.4). 
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n gure 3. 4: Schematic representation of the cloning strategy for the construction of the/ae2 expression cartridge (1) and the consequent cloning ofthe/ae2 
expression ca rtridge into pMTL5100. For ease of cloning, tlle/dxTjaeASluxS:eefAT expression cartridge (2) was digested witll NheI and Spef and cloned into 
pMTL20 di gested with X ba l. /ae2 was digested WitJl No ff and .YbaI and cloned into pMTL20 :jdxTjaeASluxS:eefA T digested with No ll and Xba [ which excises (he 
ac AS/uxS fra gment, the result being pMTL20 :: eefA Tjae2JdxT (3) . The/ae2 express ion cartridge was then digested with BamHI and AatlI and cloned into 
pMTL5100 lincariscd with /?,eoRV (4) generating pMTL5102 (5) . Blue bars represent transcriptiona l tenninators. 
For conjugative mobilisation of the plasmid, oriT was first PCR amplified from pMTL30 
(Williams et aI., 1990) using ORITF and ORITR primers, and cloned into pCR-Blunt II-
TOPO (Invitrogen Ltd, Paisley, U.K.) to yield pEOriT. oriT was then excised on a 
SmaIlEcoRV fragment and cloned into the Pvull site ofpMTLSI02 yielding pMTLSl12 (see 
Figure 3.S). Finally to enable blue/white selection for cloning purposes lacZa was PCR 
amplified from pMTL20 using LACZALPHAF and LACZALPHAR primers to yield 
pCR2.1: :lacZalpha. lacZa was then digested with NdeIlNheI (blunt-ended) and cloned into 
pMTLS112 digested with NdeIlSmaI to give pMTLS122 (see Figure 3.6). 
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j l'ig ure 3. 5: Schematic representation of U1e clOlling strategy for the construction of pMTL5112. GriT was cloned from pEOriT as a EcoRV/Smal fragment and 
cloned into pMTL5102 digested with PvuII (1), resulting in pMTL5112 (2). 
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j,'iKure 3.6: Schematic representation of the cloning strategy for the construction ofpMTL5122. LacZ alpha was PCR amplified from pMTL20 and di gested with Nele l 
and Nhe l (b lunt-ended) and cloned into pMTL5 112 digested with NdeI and SmaT (1 ) to generate pMTL5122 (2). MCS = mulliple cloning si te. 
3.2.2 Conjugal transfer of shuttle vectors into C. sporogenes 
Preliminary studies were performed by J. Theys (University of Maastricht, The Netherlands) 
at the onset of the study on the differing in vitro sporulation capabilities and in vivo tumour 
colonisation potential of C. acetobutyticum NI-4082, C. acetobutylicum DSM 792, 
C. sporogenes M55, and C. sporogenes NClMB 10696. The C. acetobutyticum strains 
reached spore titres of 105_106 spores mrl. Much higher spore titres, in the region of 109_ 
1010 spores mrl, were obtained with the C. sporogenes strains. 108 spores of each clostridial 
strain were administered to tumour bearing mice. Following colonisation of the tumours, 
homogenisation of the tumour mass resulted in colony counts of up to 109 vegetative cells 
per gram tumour tissue for the C. sporogenes strains. Colonisation by the C. acetobutylicum 
strains was several-fold lower than that obtained for C. sporogenes. Utilising C. sporogenes 
M55, however, resulted in severe tumour oncolysis that compromised the reliable recording 
of tumour measurements. This made quantification of a prodrug conversion-related effect 
difficult to attain. Also, occasionally, toxicity and weight loss was observed in some 
animals. It was therefore decided to change the clostridial delivery strain to C. sporogenes 
NCIMB 10696 as the non-desirable side-effects were not observed with this strain. 
DNA transfer into C. sporogenes NCIMB 10696 has only recently been reported (Liu et at., 
2002). The electroporation method that was developed proved unreliable and irreproducible; 
no one outside of the author's laboratory could repeat the procedure (Minton, N.P. personal 
communication). One hypothesised reason for the low transformation frequency was the 
presence of extracellular endonucleases secreted by C. sporogenes (Liu et at., 2002). 
Supplementation of the electroporation buffer with a DNase inhibitor, aurintricarboxylic 
acid, did improve electroporation efficiencies up to - 1.5 x 102 transform ants per microgram 
plasmid DNA. Several attempts were made in this laboratory to reproduce the protocol with 
a variety of vectors harbouring different replicons, however all attempts failed to yield any 
transformants. A new DNA transfer procedure was therefore required. 
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Conjugal transfer of plasmids may be a way of negating the action of extracellular 
endonucleases due to the direct contact of the donor and recipient mating pair via the pilus 
during the conjugation process. Conjugative transfer has proven to be a reliable method for 
the introduction of plasmid DNA from an E. coli S 17-1 donor to a variety of clostridial 
recipients, including C. acetobutylicum (Williams et al., 1990), C. botulinum type A strains 
(Bradshaw et al., 1998), and C. perfringens (Lyras and Rood, 1998). A conjugation protocol 
has previously been developed for transfer of plasm ids from an E. coli CA434 (E. coli 
HB 101 harbouring plasmid R 702) donor to a C. difficile recipient (Purdy et aI., 2002). 
Currently, there are no reports of conjugative transfer of plasmid DNA into C. sporogenes. 
Initially, pMTL5112 was introduced into E. coli CA434 via electroporation and then mated 
with C. sporogenes NCIMB 10696 following the method described by Purdy et al (2002). 
pMTL5112 was found to transfer into C. sporogenes at a frequency of approximately 
1.0 x 10-7 transconjugants per donor cell. At the time, the only alternative mobilisable 
shuttle vector available was pMTL93 0 1 (based on the replicon from the 
C. difficile plasmid pCD6) (Purdy et aI., 2002). Conjugal transfer of pMTL9301 into 
C. sporogenes occurred at a frequency of approximately 1.0 x 10-5 transconjugants per donor 
cell. 
These initial findings indicate that conjugation is an improved method for the generation of 
recombinant strains of C. sporogenes. It has also highlighted a difference in the transfer 
frequency for two different plasmid replicons. 
3.3 DISCUSSION 
At the onset of this study there were pre-existing expression shuttle vectors available for 
transfer of plasmid DNA from E. coli to clostridia. However, these vectors \\ere the 
property of CAMR, Porton Down. With the early project move from CAMR to the 
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University of Nottingham, these vectors could not be employed without becoming signatory 
to a restrictive materials transfer agreement. This imposed limitations on the consortium's 
freedom to exploit any process developed. Therefore, a new vector was constructed , 
incorporating some improved features over pre-existing plasmids. 
The Gram-negative component of the vector generated was based on the pMTL4 backbone, 
a derivative of pBR322 (Chambers et al., 1988a). This vector was chosen as in relation to 
the pUC series of p\asmids, also based on pBR322, pMTL4 is some 293 bp smaller. The 
pMTL series of plasm ids contain deletions relative to the pUC plasm ids, thus allowing more 
unique restriction sites to be generated in the multiple cloning site of lacZa. The copy 
number of pMTL4-based vectors is high as the pBR322 RNAIIRNAII region was replaced 
with the pUC equivalent. A single base change, a G to A substitution, immediately 
preceding the 5' end of the RNAI coding region in pUC is hypothesised to cause the increase 
in copy number (Chambers et al., 1988a). 
As the CDEPT host was originally planned to be C. acetobutylicum NI-4082, the plasmid 
replicon from the B. subtilis plasmid pIM13 was utilised to supply the Gram-positive 
replication functions. The minimal Gram-positive replicon from pIMPl, a derivative of 
pIM13, was fused to the E. coli vector to yield the shuttle vector pMTL51 00. 
Concurrent with this study, work was initiated on the identification of the most suitable 
CDEPT host (1. Theys, MAASTRO, University of Maastricht, The Netherlands). This 
resulted in a change of host from C. acetobutylicum NI-4082 to C. sporogenes NCIMS 
10696. As a shuttle vector had been constructed based on the pIMl3 replicon, it was opted 
to generate a conjugative shuttle vector due to the difficulties in reproducing the published 
C. sporogenes electroporation protocol. There has been a considerable amount of success in 
introducing plasmid DNA into a variety of clostridia at a high frequency by conjugation. 
The use of an E. coli donor and cloning intermediate also greatly simplified the cloning and 
conjugation processes. The pseudomonad IncP, RP4/RK2 type mobilisation/conjugation 
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system was chosen for transfer of the vectors to clostridia. This system was preferable, as it 
has been successfully used in the past to facilitate transfer of plasmid vectors into clostridia. 
Also, the availability of a RP4/RK2 compatible E. coli donor strain meant that the system 
could be utilised immediately upon construction of a suitable shuttle vector. 
Prior to transfer, the ferredoxin inducible promoter expression cartridge was cloned into the 
vector. This then enabled conjugative transfer of the vector to be used for prodrug 
converting enzyme expression to be assessed for transfer into C. sporogenes. Conjugal 
transfer of pMTL5112 could be performed reproducibly. However, in comparison to the 
pCD6-based conjugative shuttle vector pMTL930 1, transfer frequencies of pMTL5112 were 
100-fold lower. This equated to tens of colonies obtained per conjugation compared to 
approximately 1,000 colonies obtained per conjugation with pMTL9301. This difference in 
transfer frequency could be attributed to the mode of replication of the two plasmids. pIM13 
is known to replicate via a rolling circle mechanism (Projan et al., 1987), where as it is 
thought that pCD6 replicates via a theta mechanism due to the homology to the theta 
replicating plasmid pIP404 (Purdy et at., 2002). Rolling circle plasmids are in general much 
less segregationally stable than theta replicating plasm ids, and it is this reduced segregational 
stability that could be affecting transfer frequency. This can be attributed to the lack of 
antibiotic selective pressure during the seven-hour conjugative mating process. During this 
time, a significant proportion of the cells will loose the plasmid dependant on the 
segregational stability of the replicon. The plasmid copy number of the different plasmids is 
not known, yet cannot be discounted as another factor influencing conjugative transfer 
frequencies. 
Even though the transfer frequency of the pIM 13 based conjugative shuttle vector is not as 
high as the other replicon studied, pMTL5112 appeared to be structurally stable. For this 
reason the pIM 13-based plasmid replication functions were not changed. The segregational 
stability of alternative replicons could be studied at a later date, and if necessary a more 
stable replicon cloned. 
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CHAPTER 4 
OVER-EXPRESSION OF PRODRUG 
CONVERTING ENZYMES 
89 
4.1 INTRODUCTION 
In the preVIOUS chapter, a shuttle vector based on the B. subtilis plasmid pIM 13 \\ as 
constructed. An expression shuttle vector was then generated by insertion of an expression 
'cartridge' based on the ferredoxin promoter from C. pasteurianum. Once the plasmid was 
generated, a conjugal transfer method was developed and transfer of two different vectors, 
based on different Gram-positive replicons, into C. sporogenes was demonstrated. 
In this chapter the isolation, cloning, and expression of two prodrug converting enzymes will 
be described. These are carboxypeptidase G2 from Variovorax paradoxus ATCC 25301 and 
nitroreductase from Haemophilus injluenzae Rd. Carboxypeptidase 02 from V paradoxus is 
currently utilised in other DEPT strategies. The H injluenzae Rd nitroreductase is one of 
several novel nitroreductases isolated and characterised previously (Anlezark, O. personal 
communication). Kinetic and cell cytotoxicity studies of the novel enzymes, identified H 
injluenzae NTR (HinNTR) to be the most effective in cell cytotoxicity assays. Kinetic 
studies on the conversion of CB 1954 identified that HinNTR only produces the toxic 4-
hydroxylamine form of the drug. HinNTR has a comparable Km (690 )lM) compared to 
NfnB (682 )lM), but a significantly higher Kcat of 56.2 S-l compared to a Kcat of 6 S-l for 
NfnB. It was therefore of interest to over-express this novel nitroreductase to see if it results 
in a significant anti-tumour effect. 
4.2 RESULTS 
4.2.1 Initial cloning of prodrug converting enzymes 
4.2.1.1 Carboxypeptidase G2 (CPG2) 
Gram-negative signal peptides are generally shorter compared to Oram-positi\'e signal 
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peptides (Van Wely et al., 2001). Thus, proteins from Gram-negative bacteria will not be 
easily secreted in Gram-positive bacteria. For efficient secretion of Gram-negati\e proteins 
in a Gram-positive host, a Gram-positive secretion signal needs to be fused to the protein. 
As such, the first stage in cloning and over-expressing CPG2 was to change the CPG2 signal 
peptide for one known to function in clostridia. 
The entire CPG2 gene, including the native signal sequence, from V paradox us ATCC 
25301 was initially PCR amplified from chromosomal DNA using primers CPG2F and 
CPG2R and cloned into pCR2.1 TOPO to yield pCR2.1 ::CPG2. The 5' region corresponding 
to the mature peptide was then amplified from pCR2.1: :CPG2 in order to be fused to the 
endoglucanase A (EglA) signal peptide from Clostridium saccharobutylicum P262. For ease 
of cloning, the unique XmaI restriction site in CPG2 was utilised, thus minimising the region 
that would need to be re-sequenced. Primer pairs EGLASOEF/EGLASOER were used to 
amplify up the eglA signal sequence from plasmid pHZ117, creating an NdeI restriction site 
over the ATG start codon of eglA signal sequence. The 5' end of EGLASOER is 
homologous to the 5' end of cleaved CPG2 sequence to enable a SOEing PCR fusion of the 
two components. PCR primers CPG2S0EFICPG2S0ER were used to amplify the 5' portion 
of CPG2, up to and including the unique XmaI restriction site. The amplified products were 
combined and a second round of SOEing PCR amplification was performed with the 
flanking primers. The resulting PCR amplicon was cloned into pCR2.1 TOPO to yield 
pCR2.1::egIASSCPG2S0E (see Figure 4.1). To fuse the two ends ofCPG2 together, a three 
way ligation was performed between pMTL21 digested with EcoRI, the 5' end of CPG2 
fused to the eglA signal peptide digested with EcoRI and XmaI, and the 3' end of CPG2 
digested out of pCR2.1 ::CPG2 on an XmaIlEcoRI fragment. The resultant plasmid, 
pMTL21: :egIASSCPG2, contained a fully functional copy of CPG2 transcribed by the lac 
promoter. CPG2 activity can be screened for by plating on media containing folate. CPG2 
converts folate to glutamate and the insoluble pteroate. CPG2 production is \isualised as a 
precipitated yellow halo of pteroate surrounding colonies on solid media due t\) the 
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extracellular secretion of CPG2 (Minton et al., 1983). The secretion of functional CPG2 
from pMTL21 ::egIASSCPG2 was confirmed on folate containing media (see Appendix II for 
DNA and protein sequence of CPG2). 
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Figure 4.1: Schematic representation of SOEing PCR fusion of the eglA signal sequence to the 5' end 
of cleaved CPG2 to generate egIASSCPG2S0E. A first round of PCR was performed with primers 
1 +2 and 3+4, (primer 2 has a tail complementary to the 5' end of cleaved CPG2). A second round of 
PCR with primers 1 and 4 was performed to generate the fusion product. S.S. = signal sequence. 
For potentially improved expressIOn, a synthetic verSIon of CPG2 (CPG2-synth) was 
synthesised by Entelechon GmBH based on the amino acid sequence of GenBank entry 
A06774 (see Appendix II for DNA and protein sequence of CPG2-synth). The codon usage 
of CPGi was optimised to the C. acetobutylicum codon usage table, the organism of choice 
for the delivery of prodrug converting enzymes at the time of the design of the gene. 
Unexpectedly, E. coli harbouring the plasmid supplied, pCR4-TOPO::CPG2-synth, did not 
produce the typical yellow halo seen on folate containing media. The presence of p-
lactamase from the vector encoded bla gene is known to dramatically effect the secretion (lj' 
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CPG2, possible due to the f3-lactamase competing with CPG2 for translocation across the 
cell membrane (Chambers et al., 1988b). CPG2-synth was therefore cloned into pMTL 1010 
(a tetracycline resistance encoding plasmid, with expression of the gene of interest driven by 
the lac promoter). However, E. coli recombinants harbouring pMTL1010::CPG2-synth still 
failed to show the expected yellow halo on folate containing media. BLAST searching the 
protein sequence used to generate CPG2-synth highlighted the presence of two GenBank 
entries for CPG2, accession numbers A06774 and M12599. Alignment of the two GenBank 
entries with CPG2-synth showed a single amino acid difference at position 418 where an 
arginine was present in CPG2-synth and A06774 and an alanine present in M12599. As the 
synthetic CPG2 sequence encodes a non-functional protein it was assumed that the M 12599 
submission was in fact the correct sequence. To ascertain if the difference at position 418 
caused the observed lack of activity of CPG2-synth, the region containing the difference was 
changed to the alternative sequence. 
In order to correct the amino acid difference, two oligonucleotides, CPG2correction 1 and 
CPG2correction2, were synthesised with the correct DNA sequence such that when ligated 
together left overhangs at the 5' and 3' ends which are complementary to the AvrIl and Pst! 
restriction sites (see Figure 4.2). The oligos were ligated and cloned into the AvrIl/Pst! sites 
of pMTLIOIO::CPG2-synth to yield pMTL1010::CPG2-synthv2. The sequence of the 
resultant clones was confirmed by sequencing. Screening for the production of CPG2 on 
folate containing media gave the characteristic yellow coloration expected. 
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Original synthetic CPG2 sequence - 3' end of GenBank entry A06774 
ATI !} 
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Corrected synthetic CPG2 sequence - 3' end correct sequence based on GenBank 
submission (M12S99) 
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Figure 4. 2: Correction of CPG2 synthetic by cloning an oligo in between the AvrIl and PstI restriction 
enzyme sites. Incorrect region excised on an AvrIVPstI fragment and the ligated oligo cloned in its 
place. DNA sequence of the top strand primer (CPG2correctionl) is highlighted in green, DNA 
sequence of the bottom strand primer (CPG2correction2) is shown in orange. 
4.2.1. 2 Nitroreductase - HinNTR 
The nitroreductase gene from H. injluenzae KW20 (Rd) (HinNTR) (GenBank Access ion 
number YP _ 249310) was PCR amplified from H injluenzae KW20 (Rd) chromosomal DN A 
(supplied by P . Langford, Imperial College London, London. U.K.). PCR primers 
HlNNTRF and HINNTRR were used to introduce an NdeI restriction site over the A TG start 
codon and StuVPsII sites at the 3' end of the gene after the stop codon. Once amplified. the , 
PCR product was cloned into pCR2 . ITOPO. A sequence perfect clone \\as generated 
designated pCR2.1 ::HinNTR (see Appendix II for DNA and protein sequence of HinNTR). 
A synthetic verSIOn of the gene (HinNTR-synth) was also generated (synthesised by 
Entelechon GmbH) in which the triplet codons were altered such that they were optimised to 
the C. acetobutylicum A TCC 824 codon usage table. Restriction sites were added to the 
5' and 3' end of the gene to aid cloning, namely, an NdeI site over the ATG start codon and a 
PstI site after the stop codon, the plasmid containing the synthetic gene was designated 
pCR4::HinNTR-synth (see Appendix II for DNA and protein sequence of HinNTR-synth). 
4.2.2 Cloning prodrug converting enzymes into the expression vector 
4.2.2.1 Carboxypeptidase G2 (CPG2) 
The wild type sequence CPG2 was excised from pMTL21: :egIASSCPG2 on an NdeIlEcoRI 
(blunt-ended) fragment. The synthetic sequence CPG2 was excised on an NdeIlPstI (blunt-
ended) fragment from pMTLI010::CPG2-synthv2. Due to the phenotypic indicator ofCPG2 
expression, the expression vector pMTL5112 was used as there is no need for blue/white 
selection of recombinant E. coli. pMTL5112 was digested with NdeI and SmaI and the 
CPG2 wild type and synthetic genes directionally ligated to pMTL5112 to generate 
pMTL5112::CPG2 and pMTL5122::CPG2-synth. 
4.2.2.2 Nitroreductase - HinNTR 
For cloning of the HinNTR wild type and synthetic genes, the over-expressIOn vector 
pMTL5122 was used due to the presence of LacZa enabling blue/white selection of putative 
ligation transformants. The wild-type HinNTR was excised from pCR2.1 ::HinNTR on an 
NdeIlStuI fragment. The synthetic HinNTR was isolated from pCR4::HinNTR-synth as an 
NdeIlPstI (blunt-ended) fragment. Several attempts were made to clone the genes directly. 
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However, any clones resulting from the ligation contained severe rearrangements or 
insertions as seen by the restriction enzyme profile compared to the expected profile. 
An alternative cloning strategy was therefore tested. The nitroreductases were digested from 
the same vectors as before as EcoRl blunt-ended fragments. These were then cloned into 
pMTL5122 digested with SmaI, the transformations being performed in the lacfl strain of 
E. coli, E. coli TopiO F'. The Top 10 F' strain over-expresses Lad, which binds to the lac 
operator present withinfac2, the result being tighter repression of transcription from thefac2 
promoter. Correct clones were then obtained with the nitroreductases in the correct 
orientation relative to the fac2 promoter. An NdeI deletion was then performed to delete the 
extraneous DNA between the NdeI restriction site of fac2 and that of the nitroreductase, 
again using E. coli Top 10 F' cells. Using this strategy, correct clones were obtained for both 
HinNTR genes, the plasm ids designated pMTL5122::HinNTR and pMTL5122::HinNTR-
synth. 
4.2.3 Over-expression of prodrug converting enzymes in E. coli 
4.2.3.1 Carboxypeptidase G2 
When plasmids pMTL5112::CPG2 and pMTL5112::CPG2-synth were transformed into both 
E. coli TOP 1 0 and the conjugation donor E. coli CA434, the expression of carboxypeptidase 
G2 was visualised by the phenotypic yeIlow halo surrounding colonies on folate containing 
media. Analysis of culture supernatants and the soluble and insoluble fraction of ceIl lysates 
by SDS-PAGE indicated no major over-expression of a 41.4 kDa protein corresponding to 
the size of mature CPG2, or of the 45.8 kDa preprotein (data not shown). However, CPG2 
enzyme assays on the soluble and insoluble fraction of lysates, and on supernatants from 8 
hour cultures showed expression of CPG2 in the soluble fraction of the Iysates. The 
synthetic CPG2 was produced to a much higher level compared to the wild-type gene (see 
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Figure 4.3). It has previously been found that the wild type CPG2 does not express well in 
E. coli, possibly due to the high G+C content of the V paradoxus derived gene (Minton. 
N.P. personal communication). One potential reason for the lack of expression in the E. coli 
culture supernatant is due to the generally lower secretion of peptides in Gram-negative 
bacteria compared to Gram-positive bacteria. Secondly, the EglA signal peptide employed 
for secretion is from a clostridial species and may well not be recognised efficientlv ill 
E. coli. 
CPG2 methotrexate assay on recombinant E. coli CA434 
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Figure 4.3: CPG2 methotrexate assay on E. coli CA434 donors used for conjugation into 
C. sporogenes NCIMB 10696. CPG2 activity shown in Units per mg protein of lysate (soluble 
fraction), supernatant, or precipitated proteins (i.e. insoluble fraction). 
4.2.3.2 Nitroreductase - HinNTR 
The wild type and synthetic sequence HinNTR bearing shuttle plasmids were transformed 
. t th . t ' donor E coli CA434 and the levels of nitroreduetase overproduced in In 0 e conJuga Ion . 
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the lysate of the soluble fraction assessed by SDS-PAGE and menadione reductase assay . 
Cultures were harvested 24 hours after inoculation at an OD600 of approximately 2.0 and the 
cells lysed. The lysates of the soluble fraction were nonnalised to the same OD600 prior to 
analysis. SDS-PAGE of the lysates showed that there was over-expression of a protein of 
25 .2 kDa when the lysates of the HinNTR over-expressing E coli were compared to a vector 
only negative control lysate (see Figure 4.4) . Menadione reductase assay on the same lysates 
indicated that a nitroreductase, presumably HinNTR, was over-expressed to a level 
corresponding to 3-fold over background for the wild type HinNTR and 4.5-fold for the 
synthetic HinNTR (see Figure 4.4). Background levels of nitroreductase are particularly 
high in E coli presumably due to the endogenous nitroreductase, NfuB. 
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Figure 4. 4: SDS-PAGE and menadione reductase assay of overnight culture soluble fraction Iysates of 
E coli CA434 harbouring pMTL5122 ::HinNTR pMTL5 122::HinNfR-synth or pMTL5122 (negative 
control). SDS-PAGE gel: M = BioRad Broad range protein markers, 1 pMTL5122 ::HinNTR (2 5.2 
kDa), 2 = pMfL5122: :HinNTR-synth (25.2 kDa). 3 = pMTL5122 (negative control). Arrow indicates 
presumptive HinNfR over-expressed protein. 
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Based on these findings that the vectors utilised for over-expression of CPG2 and HinNTR 
are functional in E. coli, studies on the over-expression in C. sporogenes were initiated. 
4.2.4 Over-expression of prodrug converting enzymes in C. sporogenes 
4.2.4.1 Carboxypeptidase G2 
Conjugation ofpMTL5112::CPG2 and pMTLSI22::CPG2-synth into C. sporogenes NCIMB 
10696 yielded transconjugants that secreted what appeared to be CPG2 due to a yellow 
coloration on folate containing media. The colouration was only present on the 10° dilution 
of the mating mix and was not observed on a 10-1 dilution of the conjugation mix. Passage 
of recombinants on selective media supplemented with folate resulted in the loss of yellow 
colouration. It was therefore assumed that the yellow coloration was possibly due to the 
E. coli donor expressed copy of CPG2 being present on the conjugation 'slurry' when the 
transconjugants were first plated out. The lack of expression was further confirmed by a 
lack of over-expressed protein in both the lysates of the soluble fraction and supernatants of 
4 hand 8 h culture samples by SDS-PAGE, and by enzyme assay of lysates of the soluble 
fraction and supernatants (data not shown). Plasm ids were checked for functionality, 
deletions/insertions, and/or rearrangements by isolation of the plasm ids from the 
C. sporogenes recombinants. Purified clostridial derived plasm ids were retransformed into 
E. coli TOP 10. Restriction enzyme profiles of the plasm ids had not altered compared to the 
parent plasm ids and plating of E. coli TOP 1 0 harbouring the clostridial derived plasm ids 
gave the characteristic yellow halo on folate containing selective media. 
4.2.4.2 Nitroreductase - HinNTR 
The nitroreductase over-expression vectors pMTLSI22::HinNTR and pMTLSI22::HinNTR-
synth were conjugated into C. sporogenes NClMB 10696. Clones were \erified hy 
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retransforming plasmids derived from C sporogenes recombinants back into E. coli . Clones 
of E. coli that were correct by restriction digest were then grown overnight and h,'sates of th 
_ e 
soluble fraction screened by SDS-PAGE. A band of the expected size (25.2 kDa) was noted 
indicting that the vector was still functional and expressed HinNTR to a high level in E. coli 
(see Figure 4.5). 
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Figure 4.5: SDS-PAGE analysis of HinNTR recombinants in E. coli CA434. M = BioRad Broad 
range protein markers, lane 1 = pMTL5122 (negative control), lane 2 = pMTL5122::HinNTR, lane 3 
= pMTL5122: :HinNTR-synth. Arrow represents location of HinNTR. 
Fol1owing successful identification of suitable erythromycin resistant recombinant clones of 
C sporogenes, expression of HinNTR was monitored by menadione assay relative to a 
negative control background (see Figure 4.6) . Maximal expression was observed at the 
shoulder of exponential and stationary phase. corresponding to 6 hours post inoculation. \\;th 
levels equivalent to 3-fold over background levels of endogenous nitroreductase acti it\·. 
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Analysis of the lysates of the soluble fraction that gave the highest expression by assay did 
not give the expected over-expressed band when visualised by SDS-PAGE (data not sho\-\l1). 
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Figure 4.6: Menadione reductase assay (results represented by the bars on the graph) on 
C. sporogenes lysates collected at 4 h, 6 h, 8 h, and 24 h. A growth curve (represented by the lines on 
the graph) was also perfonned to verify that the presence of the over-expression plasmid in the host 
was not affecting growth. 
RT-PCR was used to detennine whether the relatively low-level expression of HinNTR over 
background levels in C sp orogenes was due to a transcriptional or translational problem . 
RNA was harvested and purified from a 6 hour culture (OD600 = -1.5) . Following 
quantification of the RNA, RT-PCR was perfonned using primers HINWTRTF and 
HINWTRTR for the wild type HinNTR and primers HINSYNTHRTF and HINSYNTHRTR 
for the synthetic H inNTR. Agarose gel electrophoresis of the RT -PCR products showed a 
product of the expected size (663 bp) for the RNA samples and the DNA positive control 
(see Figure 4.7). The negative controls, RNA with no RT and water with no RT pro cd 
there was no DNA contamination of the RNA. The band intensities were of similar strength 
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indicating that the HinNTR RNA was of sufficient proportion of the total RNA isolated. 
Figure 4. 7: RT-PCR on HinNTR expressing C. sporogenes NCTh1B 10696. M = NEB 2 log DNA 
ladder, 1 = HinNTR RNA + RT-PCR, 2 = HinNTR-synth RNA + RT-PCR, 3 = HinNTR DNA + Taq. 
4 = HinNTR-synth DNA + Taq, 5 = HinNTR RNA + Taq (negative control), 6 = HinNTR-synth RNA 
+ Taq (negative control), 7 = negative control (H20 + HINWTRTF+lllNWTRTR primers), 8 = 
negative control (H20 + HINSYNTIIRTF+HINSYNTHRTR primers). 
4.2.5 In VIVO anti-tumour testing of C sporogenes NCIMB 10696 expressmg 
HinNTR-synth 
Having identified a level of expression from HinNTR-synth 3-fold above the background 
level provided by genome encoded nitroreductase expression, it was of interest to test this 
first generation strain in an in vivo model. All of the work described in this section (4.2.5) 
was performed by 1. Theys, MAASTRO, University of Maastricht, The Netherlands . It is 
included here for completeness. 
4.2.5.1 Development of an in vivo model 
Previous in vivo work at MAASTRO focused on the use of the rat rhabdomyosarcoma 
model. However, it was decided early on in the project to change to a mouse animal model. 
in particular the immunodeficient nuJnu mouse, due to more celJ lines and cell li nes of 
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human origin being available for the model. This would make it more suitable to study anti-
tumoural effects on a variety of cancer cells in a later stage. 
Initially, toxicity of C. sporogenes NCIMB 10696 spores was assessed in vivo by 
intravenous injection of 108 spores (in a total volume of 100 /11 PBS in the tail vein of nu/nu 
mice) in a series of non-tumour bearing nu/nu mice. The animals showed no signs of toxicity 
and were normally active throughout the entire follow-up period. 
To test the tumour colonisation capability of C. sporogenes, HCTl16 colon carcinoma cells 
were xenografted into nu/nu mice. Growth of the tumours was followed and three weeks 
post injection, when the tumours had grown to approximately 400 mm3, animals were 
injected via the tail vein with either 5 x 107 or 5 x 108 spores of C. sporogenes NelMB 
10696. After 8 days, the tumours were excised from euthanized animals and the bacterial 
cells quantified. Examination of the tumours revealed that up to 109 cfu of C. sporogenes 
were obtained per gram of tumour tissue. Ample tumour colonisation occurred using the 
lower spore titre, therefore the following experiments were performed using 107 spores. 
4.2.5.2 In vivo anti-tumour assessment of HinNTR-synth expressing C. sporogenes 
- single cycle treatment 
Having identified the supenor colonisation capability of C. sporogenes, the ability of 
HinNTR-synth recombinant C. sporogenes NCIMB 10696 to elicit an anti-tumour activity 
was assessed. 
Spores of recombinant C. sporogenes NCIMB 10696 were systemically injected into nu/nu 
mice, once the xenografted HCTl16 colorectal carcinoma cells had developed to an average 
tumour volume of 400 mm3. Colonisation of the tumours was allowed to occur for 5 days 
prior to CB 1954 prodrug administration. As controls, animals were either left untreated 
receiving no spores or prodrug, received CB 1954 prodrug alone from day 5 (at a 
concentration of 15 mg kg-I, intraperitonially for 5 days). or recombinant spores (at a 
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concentration of 5 x 107 spores in a volume of 1 0 0 ~ 1 1 PBS via the tail vein) followed by 
prodrug vehicle only on day 5 (sham treatment). Treatment and growth of the tumours were 
measured by recording tumour size using callipers and recording the body weight of the 
mice. A level of control was also added to the experiment to quantitatively evaluate the 
approach and distinguish between effects due to administration of the spores and the effects 
resulting from Clostridium-mediated prodrug conversion, by utilising an antibiotic controlled 
experiment. The daily prodrug injections were followed by a treatment with the antibiotic 
Flagyl® (200 mg kg-I, two times a day for nine days), which has been previously shown to 
eradicate clostridial spores from tumours (Theys et al., 2001 b). 
Tumour colonization following recombinant spore administration, but prior to the onset of 
antibiotic treatment, was quantified by performing dilution series of randomly selected 
tumours from spore-treated animals. All tumours screened showed colonization levels of 
108 _109 cfu g-l tumour tissue. To confirm the specificity of the system, normal tissues were 
also screened for spores, and as expected no spores could be detected. CB 1954 
administration alone was found to have no effect on tumour volumes. Administration of 
spores alone caused a tumour growth delay (p=0.09, Student's t-test) (see Figure 4.8 (A)), 
which is presumed to be a consequence of moderate oncolysis and the appearance of 
hemorrhagic necrosis. 
The most apparent effect in vivo was found when recombinant spores were combined with 
CB 1954 administration. Following prodrug injection, the tumour growth rate reduced to a 
near static level with no significant tumour growth occurring over the 25 day study. 
Statistical analysis of the anti-tumour effect highlighted that the increase was significant 
when compared to the sham control (p=0.016, Student's t-test) (see Figure 4.8 (A)). 
During the course of this pilot study, the evolution of the animals' body weight was followed 
as an indicator of the toxicity of the treatment. The data obtained indicated that the initial 
reduction in weight was only transient, and this weight loss was reversible with reversion to 
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normal body weight after 25 days (see Figure 4.8 (B)). 
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Figure 4.8: Tumour volume reduction following systemic administration of HinNTR-syntJl 
recombinant C. sporogenes spores to nu/nu mice bearing HCTl16 colon carcinoma cell line tumolUS. 
(A) Tumour growth as monitored after one cycle of recombinant C. sporogenes spore trcaancnt with 
CBl954 prodrug (_) or drug vehicle only (sham) (A ) treatment. Control aninlaJs received no 
treaanent (. ). (B) Representative body weight evolution dtuing a treatment cycle of prodrug (. ) and 
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sham treated ( .. ) mice. Data was obtained from at least 5 mice per group. Figures kindly provided 
by 1. Theys, MAASTRO, University of Maastricht, The Netherlands. 
4.2.5.3 In vivo anti-tumour assessment of HinNTR-synth expressing C. sporogenes 
- repeated cycle treatment 
Subsequently, it was of interest to see if repeated treatment cycles could be perfonned as this 
more closely reflects the actual clinical setting where chemotherapy is given in mUltiple 
cycles to allow recovery of the patient. To evaluate this, the basic treatment cycle as 
outlined above was followed by a week long recovery period, which was then followed by a 
second and third cycle of treatment identical to the first cycle. Sham treated animals only 
received two cycles as the tumours grew to a size that necessitated killing of the animals 
prior to a third cycle of treatment. 
The tumour volume data obtained shows a reduction in tumour growth with the sham 
treatment (see Figure 4.9). This highlights that not only can the spores genninate and 
effectively re-colonise the tumour to give an anti-tumour effect, but also means that the 
tumour microenvironment did not change dramatically following the first treatment cycle 
such that re-colonisation could not occur. 
Repeated treatment with the recombinant spores and CB 1954 prodrug resulted in a more 
significant anti-tumour effect with the tumour only doubling in size over the 70 day 
treatment, compared to the HCT116 control which doubled every 7 days and the sham 
treatment which doubled every 20 days (see Figure 4.9). This reduction in tumour growth 
for the recombinant spore treatment allowed application of an additional third treatment 
cycle. Throughout the three cycles, the treatment resulted in sustained growth delay effects. 
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Figure 4.9: Anti-tumour effect following repeated treatment cycles of HinNTR-syntll recombinant 
C. sporogenes in combination with CB1954 administration (_) or drug vehicle only (sham) (A) 
treatment. Control animals received no treatment (. ). Figure kindly provided by J. Theys, 
MAASTRO, University of Maastricht, The Netherlands. 
4.3 DISCUSSION 
The experiments presented in this chapter demonstrate that C sporogenes NCIMB 10696 
can be utilised for the expression of prodrug converting enzymes, in particular the 
nitroreductase from H. injluenzae. E ~ ' P r e s s i o n n of CPG2 was, however, not as promising. 
CPG2 enzyme activity was detectable in the soluble fraction of E. coli Iysates but not in th e 
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culture supernatant probably due to the general difficulties associated with secreting proteins 
III Gram-negative bacteria. Expression of CPG2 was not obtained in C. sporogenes. 
C. sporogenes is classified as a proteolytic member of the genus Clostridium, with high 
levels of extracellular proteases detectable after exponential growth (Allison and 
MacFarlane, 1990). Proteolysis of CPG2 by C. sporogenes cannot be excluded as a factor 
contributing to the lack of expression. Indeed, crude experiments in which late exponential 
C. sporogenes culture supernatant was incubated with purified CPG2 resulted in a marked 
decrease in enzyme activity (data not shown). Due to time constraints and the potential for 
proteolysis of secreted CPG2, efforts were focused on nitroreductase which being both 
intracellular and smaller than CPG2 may be more easily over produced. 
Cloning of both the native sequence and synthetic HinNTR into pMTL5122 resulted in over-
expression in E. coli, which could be visualised by SDS-P AGE. However, once conjugated 
into C. sporogenes, increased expression levels could only be detected by enzyme assay. No 
over-expressed band was visible by SDS-PAGE of recombinant cell soluble fraction Iysates. 
RT-PCR confirmed that HinNTR mRNA was being produced. Therefore, the low level of 
expression as visualised by SDS-PAGE could be due to translational problems such as sub 
optimal codon usage. 
Nitroreductase recombinant spores were delivered systemically to immunodeficient nu/nu 
mice harbouring xenografted HCT116 colorectal carcinoma cells. Delivery of the 
recombinant spores resulted in a clear sustained growth delay when combined with CB 1954 
prodrug. Administration of spores alone caused a significant tumour growth delay that can 
be attributed to moderate oncolysis and appearance of haemorrhagic necrosis. This 
observation foHowing spore administration is seen when using other proteolytic clostridial 
species such as C. novyii-NT and C. sporogenes M55. However, when combined with 
CB 1954 prodrug administration, the anti-tumour effect significantly increases, 
demonstrating the feasibility of using this process. Interestingly, the clostridial spores could 
also be delivered in multiple cycles, a scenario which more closely relates to clinical 
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chemotherapy regimes. As immunodeficient mice were used in the study, no conclusions 
can be drawn as to the immune response following multiple spore doses. 
Since such an outstanding anti-tumour response is seen with both single and repeated cycles, 
it must mean that not only the hypoxic but also aerobic cells are being killed as a result of a 
bystander effect that is contributing to the effect seen. 
Recently, an endogenous nitroreductase activity has been detected in several clostridial 
species (Theys, J. personal communication). Incubation of clostridial lysates with CB 1954 
results in conversion of CB 1954 to the toxic drug as visualised by TLC. Also, incubation of 
CB 1954 with non-toxic concentrations of clostridial lysate decreased the CB 1954 LDso 
concentration required to kill HCTl16 colorectal carcinoma cells 20 to 40-fold depending on 
the concentration of clostridial lysate. Therefore the effect of endogenous nitroreductase 
activity cannot be discounted for the effect seen in vivo. 
The only other published significant anti-tumour effect observed with recombinant 
C. sporogenes was utilising the prodrug converting enzyme cytosine deaminase (CodA) in 
combination with the prodrug 5-FC (Liu et at., 2002). These studies followed tumour 
growth for 11 days following a single intravenous injection of recombinant C. sporogenes 
spores into syngenic C3H1Km mice harbouring transplanted SCCVII tumours. A tumour 
growth delay was observed, but resistance to the toxic drug 5-FU was observed after 7 days 
of daily injections of 5-FC, after which time tumour growth paralleled normal non-treated 
control tumour growth. In comparison to the data presented in this chapter where a 
significant growth delay is seen, the growth delay effect reported by Liu et a!. was transient. 
This is attributed to the cancer cells developing resistance to the drug, a scenario not seen 
with the nitroreductase system developed here. 
The potential of combining vascular targeting agents with enzyme prodrllg therapy lIsmg 
engineered C. sporogenes has now been demonstrated (Liu ef a!., 2003). For these studies 
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the recombinant plasmids carrying nfnB or codA that had previously been introduced into 
saccharolytic clostridia (Fox et al., 1996; Lemmon et al., 1997) were transformed into 
C. sporogenes NClMB 10696. The resultant clones were then used in a therapy experiment 
in which the vascular targeting agent DMXAA (5,6 dimethylxantheone-4-acetic acid) was 
administered some 4 hours after spore injection. DMXAA was found to elicit a 4-fold 
increase in the extent of tumour colonisation. Complete tumour regression was achieved 
with both subcutaneously transplanted murine SCCVII and human HT29 carcinomas in C3H 
and nude mice, respectively. These experiments also evaluated the benefit of using more 
soluble derivatives of the prodrug CB 1954. One of the prodrugs tested (SN24927) was 
shown to cause more effective tumour regression in combination with clostridial cells 
overproducing nitroreductase. This result further supports the findings of Wilson et al 
(2002) where SN24927 was found to provide curative activity against WiDr tumours using a 
multilayer tissue culture model. However, since the presentation of this data three years ago, 
no further data has been presented by this group on nitroreductase expressing recombinant 
C. sporogenes. 
Despite the encouraging results, at this stage it is not entirely clear as to the contribution of 
HinNTR to the observed in vivo effect due to the relatively low level of expression. This 
could be clarified by bringing about a significant improvement to expression levels. 
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CHAPTERS 
CHARACTERISATION OF THE SHUTTLE 
VECTOR AND IMPROVING EXPRESSION 
OF NITROREDUCTASE ENZYMES 
1 1 1 
5.1 INTRODUCTION 
At this stage of the study, the level of HinNTR production observed was disappointing. 
When it is considered that the ultimate aim of CDEPT is to have the prodrug converting 
enzyme integrated into the genome as a single copy this would further reduce expression 
levels. It became apparent that expression would need to be improved. 
One factor that could affect expression levels is the segregational stability of the plasmid 
system utilised. An analysis of the segregational stability of the over-expression vector was 
therefore undertaken. The relative strength of the promoter used to drive expression of the 
prodrug converting enzyme is also a factor that may be effecting expression. Therefore, in 
parallel with the plasmid segregational stability study, the possibility of utilising an 
alternative promoter to fac2 was investigated. 
It is possible that there are specific gene related effects hampering expression. To study this, 
it was of interest to see if NfnB which has previously been expressed to high levels in 
C. beijerinckii (Minton et al., 1995) and C. sporogenes (Liu et al., 2003), could be expressed 
utilising the original expression vector pMTL5122. 
Finally, codon usage is also known to influence expression of genes especially in bacteria 
with genomes of extreme high or low G+C content. Therefore, the currently available 
nitroreductases were analysed for codon usage. Based on this, new synthetic genes were 
generated with the codon usage optimised to the C. tetani codon usage table. A study of the 
completed clostridial genome codon usage tables with the preliminary data available for 
C. botulinum and C. sporogenes identified that the C. tetani codon usage table proved to be 
the closest match. Once synthesised, the expression of these genes was assessed. 
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5.2 RESULTS 
5.2.1 Segregational stability of pMTLS122 
To assess the segregational stability of pMTLS122 cells of C. sporogenes NCIMB 10696 
harbouring the plasmid were grown non-selectively for 48 hours, passaging into fresh non-
selective media every 12 hours. At the end of the passaging regime the cells had undergone 
the equivalent of 48 generations. The cells were then serially diluted and plated out onto 
non-selective media. Following overnight growth, 50 colonies were then picked and 
streaked out onto both non-selective and selective media. No growth was obtained on the 
antibiotic-containing selective media, relative to a positive control streak. Therefore, it can 
be assumed that less than 2% of the cell population are retaining pMTLS122. This indicted 
the segregational instability of pMTLS122 and prompted a further study of alternative 
clostridial replicons. 
5.2.2 Segregational stability of alternative clostridial replicons 
5.2.2.1 A novel clostridial plasmid 
Indigenous plasmids are inherently segregationally stable in their native host. Recently, a 
cryptic indigenous plasmid designated pBP 1 has been identified in C. botulinum NCTC 2916 
(Davis, 1998). Due to the close phylogenetic relation of C. botulinum to C. sporogenes 
(Collins et ai., 1994) the potential of utilising this plasmid was studied. 
Analysis of pBPl translated DNA sequences and comparison to the available SwissProt 
database identified 8 ORF's of which a role in plasmid replication could be attributed to 
ORF 1 (see Figure S.l). ORF 1 was found to bear a high degree of similarity with a group of 
topoisomerases with replicative origin-specific activities. This class of proteins are 
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implicated in initiating the replication of plasmids whose members are broadly represented 
by pC 194, a plasmid which replicates via a rolling circle mechanism (Novick, 1989) . An 
alignment of several replication proteins most similar to ORF 1 demonstrated that the 
primary sequence of ORF 1 essentially confirms to the five conserved regions described fo r 
this class of replication protein (N oirot -Gros et al. , 1994). 
ORF 2 
Replication 
protein 
ORF 3 
Xbal 
ori 
Hind II I 
pBP1 
5927 bp 
Hind II I 
ORF4 
ORF 8 
ORF 5 
c...--ORF 6 
'r---ORF 7 
Figure 5. J: Schematic representation of pBPI . The location of all identified ORF's are highlighted as 
well as the replication protein and HindIIIlXbaI restriction sites used for cloning. 
Plasmid origins of replication had also been identified and two inverted repeats are found 5' 
to the putative replication protein . One of these occurs 28 bp before a heptameric moti f 
described as a double - stranded origin nick site (dso) , characteristic of the pC 194 group of 
plasmids (Seery et of. , 1993). Indeed, the occurrence of the combinati on of an inverted 
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repeat, dso, and pC 194 type replication protein are suggestive features that this type of 
extrachromosomal element is a plasmid which replicates via a rolling circle mechanism. A 
second region of dyad symmetry is found between the dso and replication protein. Such 
features are found in other examples of this class of plasmid (Devine et aI., 1989; Josson et 
al., 1990) and may also serve some function in plasmid maintenance/replication. The 
evidence found so far thus indicates that pBPl replicates via a rolling circle mechanism. 
5.2.2.2 Cloning of pBP 1 plasmid replication protein fragment and segregational 
stability 
Previous work was performed by T. Davis on the identification of a minimal regIon 
containing plasmid replication functions (Davis, 1998). pBP 1 was first digested with 
HindIII into two fragments of2.711 kb and 3.216 kb (see Figure 5.1). Cloning of these two 
fragments into pMTL20E yielded pMTL20EBP2 and pMTL20EBP19 respectively. The 
plasm ids were then electroporated into C. beijerinckii NCIMB 8052 and transform ants were 
only obtained with pMTL20EBP 19. Thus, it was concluded that the replication functions 
were present on the 3.216 kb HindIII fragment of pBPl. The replicon was then further 
reduced by restriction digestion with HindIII and Xbal (see Figure 5.1). The 2.633 kb 
HindlII/XbaI fragment was cloned into pMTL20E to generate pMTL5200. The resulting 
plasmid could also transform C. beijerinckii NCIMB 8052. (Minton, N.P. personal 
communication). The vectors were also assessed in C. botulinum ATCC 3502 Hall A 
(Bennik, M. personal communication). Electroporation of pMTL5200 resulted in a 
frequency of approximately 2.0 x 103 cfu f.1g- 1 plasmid DNA. The plasmid was also assessed 
for segregational stability and was found to be 100% stable in C. botulinum ATCC 3502 
after four 8 hour passes in non-selective media (Bennik, M. personal communication). 
Based on the high segregational stability obtained in C. botulinum it was therefore of interest 
to determine if the replicon from pBPl was functional and 100% segregationally stable in C. 
sporogenes NCIMB 10696. For conjugative mobilisation of pMTL5200 into C. sporogenes 
I J ~ ~
NCIMB 10696, oriTwas cloned in as an EcoRV/Smal fragment from pEOriT into the SmaI 
site of pMTL5200 to give pMTL5210. Conjugal transfer of pMTL521 0 into C. botulinum 
Hall A still resulted in a 100% segregationally stable plasmid, indicating that oriT was not 
effecting the segregational stability. 
5.2.2.3 Segregational stability of clostridial replicons 
During the course of these studies the following vectors based on a variety of plasmid 
replicons became available: 
l. pMTL9301 (pMTL28 + pCD6 replicon [4133 bp PvuII region] from pCD3SEC + 
OriT from pMTL30) (Purdy et aI., 2002) 
2. pMTL9401 (pMTL28 + pCB102 replicon [1628 bp Csp45I1HindlII region] from 
pCB102 + OriT from pMTL30) (Purdy et al., 2002) 
3. pMTL961l (pMTL29 + plP404 replicon [2544 bp NspIlNheI region] from pJIR418 
+ OriT from pMTL30) (Purdy et al., 2002) 
4. pMTL9511 ( p A M ~ ~ 1 based shuttle vector, M. Herbert, HPA, Porton Down, 
Salisbury) 
Also available for segregational stability screenmg are pMTLS112, pMTLS210, and a 
conjugal version of the plMP1 plasmid, pIMPl ::OriT. plMP1 ::OriT was constructed by 
cloning OriT as a SmaIlEcoRV fragment into SmaI digested pIMP1. 
All the vectors were conjugated into C. sporogenes NCIMB 10696. Once the various 
recombinant strains were verified correct by PCR screening and retransforming the plasm ids 
back into E. coli, the rate of plasmid loss and loss per generation was determined (see Table 
S.l). Recombinant C. sporogenes was grown non-selectively for 48 hours passaging into 
fresh non-selective media every 12 hours, an equivalent of 48 generations. Once cultures 
had been grown for 48 generations a serial dilution of the culture was plated onto non-
selective media. To calculate plasmid stability, 100 randomly picked colonies were streaked 
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onto media with or without antibiotic selection, the proportion of cells that grew on the plate 
containing antibiotic selection being taken as the representation of plasmid segregational 
stability. Due to the low segregational stability of pIM I3-based vectors, segregational 
stability was calculated based on cell counts on selective and non-selective media following 
48 generations of growth in non-selective media. 
Plasmid Replicon 
p1MP1:0riT plM13 
pMTL5112 plM13 
pMTL9301 pCD6 
pMTL5210 pBP1 
pMTL9401 pCB102 
pMTL9511 pAMP1 
pMTL9611 plP404 
Stability (% of cells 
maintaining plasmid) 
0.00835 * 
0.01087 * 
58 
73 
84 
96 
98 
Loss per 
generation 
1.78x10-i 
1.73 x 10-1 
1.13 x 10-2 
6.54 x 10-3 
3.63 x 10-3 
8.50 x 10-4 
4.21 x 10-4 
Method of 
replication 
rc 
rc 
Theta? 
rc? 
? 
Theta 
Theta 
Table 5.1: Plasmid segregational stability of the available clostridial replicons. * = due to low 
stability, data was collected from colony counts of cultures plated onto selective and non-selective 
media (approximately 10,000 cfu would need to be screened to isolate a single plasmid-bearing 
clone). rc = rolling circle, ? = not known. 
Unexpectedly, the pIM 13 based plasm ids pMTL5112 and pIMP 1: :OriT were severely 
unstable with a plasmid loss per cell generation equating to 17%. Also, it was disappointing 
to find that the pBPI replicon was not 100% segregationally stable as determined for 
C. botulinum. The most stable plasmid was pMTL9611, based on the C. perfringens plasmid 
pIP404, with 98% of the population retaining the plasmid after 48 generations, a figure that 
equates to a 4.21 x 10-4 loss of the plasmid per generation. 
pIP404 is a small (10.207 kb), low-copy. mobilisable plasmid which encodes a UV inducible 
bacteriocin. Unlike other plasm ids from Gram-positive bacteria, pIP404 does not appear to 
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replicate via a ssDNA intermediate as evidenced by a lack of signal in DNA hybridisation of 
crude Iysates of both C. perfringens and B. subtilis harbouring either pIP404 or derivatives 
of pIP404 respectively (Gamier and Cole, 1988). The exact method of replication utilised by 
plP404 is not yet known. It is possible that pIP404 replicates via a theta mechanism due to 
the lack of ssDNA intermediate and the presence of an extensive repeat region downstream 
of the replication protein. The increased stability of pMTL9611 could therefore be partly 
attributed to this alternative method of replication, as ssDNA is known to be highly 
recombinagenic and unstable. This is further supported by the fact that the p A M ~ ~ I-based 
plasmid pMTL9511, which is known to replicate via a theta mechanism, is also highly stable 
in C. sporogenes. 
The minimal region of pIP404 which has been identified to confer replication proficiency is 
the 2.792 kb EcoRIIEcoRV fragment (Gamier and Cole, 1988). Furthermore, Sal3I 
digestion from the EcoRI site into ORF 4 (the putative copy number control ORF) increases 
copy number by approximately 5-fold. The region of pIP404 used in pJIR418 to provide 
Gram-positive plasmid replication was the 2.629 kb HindIIIIEcoRV fragment, the restriction 
sites being deleted during the cloning of pJIR418 in order to free them up for introduction 
into the multiple cloning site. This region was further reduced during the cloning of 
pMTL9611 by taking a 2.544 kb NheIlNspl fragment (Purdy et aI., 2002). 
5.2.3 Development of a segregation ally stable mutant strain of C. sporogenes 
NelMB 10696 
The curmg of strains harbouring pIM13-based plasmids can increase the segregational 
stability of these plasm ids when they are reintroduced into the cured mutant (Azeddoug et 
a/.
J 
1992). Based on the poor segregational stability of pMTL5122, it was decided to create 
a cured strain of C. sporogenes NCIMB 10696. 
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The C. sporogenes NCIMB 10696 strain harbouring pMTLSI22::nfoB (discussed in Section 
5.2.5) was cured of the vector by growing recombinant cells non selectively for 98 hours 
passaging every 24 hours, a more severe process compared to the stability study as loss of 
the plasmid was desired. Cultures were then plated out onto media with or without antibiotic 
selection in order to determine plasmid segregational stability. In total, 0.011 % of the wild 
type C. sporogenes NCIMB 10696 cells harbouring pMTLS122: :nfoB remained resistant to 
erythromycin, a level comparable to that obtained during the segregational stability study. 
Of the colonies that grew on the non-selective media, 100 were then screened for loss of the 
plasmid by picking onto plates with or without antibiotic selection. Two clones that were 
erythromycin sensitive, designated 10696-1 and 10696-3, were screened for loss of the 
plasmid by colony PCR using plasmid replicon specific primers. A faint signal was present 
when the PCR products were visualised on a 1 % agarose gel, indicating a proportion of the 
population of the colony still harboured the plasmid. This was resolved by passaging the 
strains a further two times on non-selective media and re-screening the resulting individual 
colonies for loss of the plasmid. 
Following the generation of a cured strain the next stage was to assess any effects on the 
maintenance of introduced plasmids. Accordingly, pMTLS122 and pMTLSI22::HinNTR-
synth were transferred into the cured strain 10696-1. Conjugations into the wild type strain 
were repeated as a control using the same donor culture for both recipients. Conjugation 
transfer frequencies were calculated, and an increase in transfer frequency was observed in 
the cured strain equivalent to an increase of 1 x 10-7 transconjugants per donor cell for the 
wild type bacterium to 1 x 10-5 transconjugants per donor for the cured strain. The transfer 
frequency of pMTLS122 in the cured strain is now comparable to the transfer frequencies 
observed with other clostridial replicons in the wild type C. sporogenes NCIMS 10696 
strain. 
Both the wild type and cured recombinants were cultured non-selectively for 48 hours with 
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passage every 12 hours, an equivalent to 48 generations. Cells were then plated out onto 
selective or non-selective media and the rate of plasmid loss calculated based on the number 
of colony forming units derived (see Table 5.2). 
Plasmid cfu mr' TYG cfu mr' % loss- cfu mr' TYG cfu mr' % loss-
TYG+Erm wIt TYG+Er cured 
m 
pMTL5122 3.75x 108 4.07 x 104 99.9891 6.30 x 108 2.12*108 66.3492 
pMTL5122:: 5.20 x 107 1.84 X 106 96.4615 6.30 x 108 2.37*108 HinNTR-synth 62.3810 
Table 5.2: Segregational stability of two pIM13 based shuttle vectors in the wild type and plasmid-
cured derivative ofC. sporogenes NCIMB 10696. 
The plasmid losses calculated equate to a loss per generation of 1.73 x 10-1 for pMTL5122 in 
the wild-type bacterium and 2.24 x 10-2 for pMTL5122 in the cured strain. For 
pMTL5122::HinNTR-synth, the loss per generation in the wild type C. sporogenes NCIMB 
10696 was 6.72 X 10-2 , whereas in the cured strain th is decreased to 2.02 X 10-2. A 
significant improvement in plasmid stability was therefore seen in the cured strain of 
C. sporogenes. 
5.2.4 Improving expression - assessment of available promoters using a GusA 
reporter vector 
Reporter gene systems are an indispensable technology for characterization of promoter 
strength and regulation. Two reporter gene vectors have been developed in our laboratory 
based on either the chloramphenicol acetyltransferase gene (caIP) of C. perfringens (Steffen 
and Matzura, 1989) or the ~ - g l u c u r o n i d a s e e (gusA) gene from E. coli. CatP has been 
previously used to study expression at the transcriptional level of the C. pe,/ringens pIce 
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gene (Bullifent et ai., 1995; Matsushita et al., 1994). GusA has been used previously to 
measure expression from the promoters of both the cpe gene (encoding C. perfringens 
enterotoxin) and the nanEA operon (encoding N-acetylmannosamine-6-phosphate epimerase 
and sialic acid lyase also in C. perfringens (Melville et al., 1994; Walters et al., 1999; Zhao 
and Melville, 1998). In C. difficile, GusA has also been used to study the expression of the 
toxin genes toxA and toxE in utilising C. perfringens as the host for the reporter assay 
(Dupuy and Sonenshein, 1998). In C. beijerinckii NCIMB 8052, GusA has been used as a 
reporter to study the solventogenesis/acidogenesis associated genes acetoacetate 
decarboxylase (adc) from C. acetobutylicum and phosphotransbutyrylase (ptb) from 
C. beijerinkcii (Ravagnani et al., 2000). Finally, in C. acetobutylicum the thiolase (thf), 
acetoacetate decarboxylase (adc), phosphotransbutyrylase (ptb), hydrogenase (hydA) and 
xylose isomerase (xyiA) promoter activities were screened using GusA as the reporter 
(Girbal et al., 2003). 
For maximal expression of the prodrug converting enzymes, the optimal promoter from a 
range of available promoters was sought and compared to the modified ferredoxin promoter 
(fac2) using the GusA reporter vector pMTL9361gusA (see Figure 5.2). The promoters 
available are all derived from clostridial genes and are listed in Table 5.3. The clostripain 
(closl) promoter GusA reporter vector was constructed by cloning the closI promoter from 
pKNT19closlpcodA on a HindIIIINcol blunt-ended fragment and ligating to pMTL9361gusA 
digested with EcoRICRIIXbal blunt-ended fragment (see Figure 5.2). The alternative 
promoter reporter vectors were constructed by G. Carter, University of Nottingham. 
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Xbal 
fdx 
fac2 
EcolCRI 
gusA 
celA 
ermB 
ColEI 
RNA" 
oriV 
pMTL9361 gusA 
10846 bp 
traJ PpuMI 
repA 
ull 
Pvull 
lacl 
Figure 5.2: Schematic representation of the reporter vector pMTL936JgusA. Promoters were cloned 
as blunt fragments into the XbaIlEcoICRI blunt sites of pMTL9361gusA. If required, the 1656 bp 
Ppu1vfl/Pvull region encompassing the ptb promoter and lacI was deleted such that promoters 
containing lac operator sites became constitutive. 
Promoter Source SourcefReference 
eglA p-l ,4-endoglucanase from S. Barbe, K.U. Leuven 
C. acetobutylicum P262 (Zappe et aI. , 1988) 
hydA Hydrogenase from (Santangelo et al.. 1995) 
C. acetobutylicum P262 
gInA Glutamine synthetase from S. Barbe, K.U Leuven 
C. beijerinckii NCIMB 8052 (Quixley and Reid, 2000) 
closl Clostripain from S. Barbe, K.U Leuven 
C. histolyticum DSM 1126 (Dargatz et aI. , 1993) 
Table 5.3: Promoters available for assessment of activity in C .sporogenes utilising p M T T 9 3 6 1 g u ~ . . t t
reporter vector. 
GusA reporter assays indicated that all the promoters are relatively similar in strength. 
although the clostripain promoter from C. histolyticum was the strongest at just over a 2.8-
fold ' stronger' compared to fac2 (see Figure 5.3) . 
GusA assa y data on clostridia l promote rs 
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Figure 5.3: GusA reporter vector data fo r the clostridial promoters. 
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5.2.4.1 Cloning of a novelferredoxin promoter from c. sporogenes 
During the course of this study, work was published on the characterisation of a novel 
ferredoxin (jdx) promoter from C. perfringens strain13 and its use in the over-expression of a 
clostridial sialidase in C. perfingens strain 13 (Kaji et aI., 2003; Takamizawa et aI., 2004). 
The group headed by Okabe identified a homolog to the C. pasteurianum ferredoxin protein 
(Fdx) in C. perfringens. A region 70 bp upstream of the +1 site of the promoter was cloned 
and compared to the C. pasteurianum fdx promoter using a CatP reporter vector. Reporter 
assays indicated that the C. perfringens ferredoxin promoter is 10-fold more active compared 
to the C. pasteurianunifdx promoter (Kaji et al., 2003). 
Based on this result, an in silico analysis of the partially annotated C. botulinum genome (at 
the current time the genome sequence was only available at the private C. botulinum Sanger 
web site - http://www.sanger.ac.uklProjects/C_botulinum/private) was performed utilising 
the Artemis package (Sanger Institute, Cambridge, U.K.). Screening of the genome for 
ferredoxin orthologues revealed three putative orthologues: 
1) CB00039 (262 amino acids, 29.8 kDa) - homology to two ferredoxins: 
a) Clostridium tetani putative polyferredoxin (258 amino acids) - fasta scores: EO: 
2.3e-44, 50.95% homology over 263 amino acids. 
b) Clostridium acetobutylicum polyferredoxin (249 amino acids) fasta scores: EO: 
4.7e-20, 35.65% homology over 258 amino acids. 
2) CB00059 (56 amino acids, 5.6 kDa) - homology to Clostridium pasteurianum 
ferredoxin (55 amino acids) - fasta scores: EO: 1.6e-18, 90.9% homology over 55 
amino acids. 
3) CB00089 (63 amino acids, 7.0 kDa) - homology to two ferredoxins: 
a) Thermatoga maritima ferredoxin (60 amino acids) - fasta scores: EO: 0.00016, 
38.98% homology over 59 amino acids. 
b) Clostridium perfringens ferredoxin (62 amino acids) - fasta scores: EO: 3.4C-07, 
124 
45.76% homology over 59 amino acids 
Alignment of the three ferredoxins identified in the C. botulinum genome with the 
C. perfringens and C. pasteurianum ferredoxins highlighted that CB00059 was the correct 
homologous ferredoxin from which to amplify the promoter from (see Figure 5.4). The 220 
bp fragment extending from nucleotide positions -178 to +42 relative to the transcription 
initiation start site ofbot1'dx was PCR amplified using primers BOTFDXF and BOTFDXR 
and chromosomal DNA from C. botulinum Hall A ATCC 3502 and C. botulinum ATCC 
2916, plus C. sporogenes NCIMB 10696. The C. sporogenes fdx promoter was PCR 
amplified using three independent PCR's to avoid the introduction of PCR errors into the 
sequence. The 177 bp fragment extending from nucleotide positions -137 to +40 relative to 
the transcription start site of per1'dx was PCR amplified using primers PERFDXF and 
PERFDXR and chromosomal DNA from C. perfringens strain 13 and C. perfringens NCTC 
8237 (supplied by J. Scott, Nottingham). Oligonucleotides complementary to the 5' and 3' 
ends of the promoters were used, with an NdeI restriction site created over the A TG start 
codon and a NotI restriction site added to the -178 end for the C. botulinum fdx promoter or -
137 end for the C. perfringens fdx promoter. 
CpastFdx MAYKIADSCVSCGACASECPVNAISQGDSIFVIDADTCIDCGNCANVCPVGAPVQE 56 
CB00059 MAYKITDACVSCGACAAECPVNAISQGDSIFDIDADTCIDCGNCANVCPVGAPVQD 56 
CperfFdx MAYKILDTCVSCGACAAECPVDAISQGDTQFVIDADTCIDCGNCANVCPVGAPVQE 56 
***** *.********.****.******.  .  * ***********************: 
Figure 5.4: Protein alignment of clostridial Fdx homologues. "*,, indicates residues or nucleotides in 
that column which are identical in all sequences in the alignment. ":" indicates that c o n s e r \ ' ~ d d
substitutions have been obseIVed (amino acids coloured red), no mark indicates no homology (amino 
acids coloured blue). 
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Once amplified, clones with the promoter in the correct orientation in pCR2.l TOPO (5' end 
of the promoter nearest the XbaI site in pCR2.1), were cloned into the GusA reporter vector 
pMTL9361gusA as Sad/XbaI fragments. Several attempts were made to clone the promoter 
fragments into pMTL9361gusA reporter vector but correct reporter vectors for all the 
promoters could not be obtained. To overcome the cloning difficulties, an alternative CatP 
reporter vector pMTL9361eatP was utilised (see Figure 5.5). Thefdx promoters were cloned 
in utilising the XbaI and Sad sites in pCR2.1-TOPO and the XbaI and Sad sites in the 
polylinker of pMTL9361eatP. Reporter assay data from an 8 hour time point indicated that 
both the C. perfringens fdx and C. sporogenes fdx showed improved promoter strength 
compared to the C. pasteurianum derivedfae2, with the C. perfringens fdx promoter giving 
2.5-fold improvement over fae2 and the C. sporogenes fdx promoter giving a 3.5-fold 
improvement overfae2 (see Figure 5.6). 
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Figure 5.5: Schematic representation of pMTL9361catP. For cloning of promoter fragments into 
pMTL936 1 MCScatP, promoters were cloned in as XbaUSacI fragments from pCR2.1-TOPO clones 
into tJle XbaUSacI sites in the MCS ofpMTL9361catP. If required. the 1656 bp PpuMIJPvuIJ region 
encompassing the ptb promoter and lacI was deleted such that promoters containing lac operator sites 
became constitutive. 
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Figure 5.6: CatP promoter reporter data for clostridial ferredoxin promoters. Data collected at 8 hour 
time point. Samples all normalised to an OD6OOmn of 1.0. fac = Jae2 , spo = C. sporogenes Jdx 
promoter, per = C. perfringens Jdx promoter. 
Combining all the collated promoter reporter data for the clostridial promoters highlighted 
the optimal promoter to be the fdx promoter from C sporogenes (spofdx) . This was based on 
the relative promoter strength at the 8 hour time point of the growth cycle (see Table 5.4) . 
Promoter Relative ratio· 
gInA 0.89 
fac2 1.00 
hydA 1.10 
perfdx 2.32 
eglA 2.37 
closl 2.80 
spofdx 3.18 
Table 5. -I : Combined promoter data from GusA and CatP reporters. * expressed as ratio to the 
actjvity of theJac2 promoter in either assay. 
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5.2.5 Cloning and expression of an alternative nitroreductase, NfnB 
The in vivo data obtained for HinNTR-synth was very promising. There was, however, no 
distinguishable reduction in tumour volume, just maintenance at a static level. Recently, Liu 
and colleagues published initial findings on the over-expression of the E. coli nitroreductase 
NfnB in C. sporogenes where a significant reduction in tumour volume was found (Liu et 
ai., 2003). 
In order to establish ifNfnB could be over-expressed, as has been previously reported (Liu et 
al., 2003; Minton et ai., 1995), it was decided to replace HinNTR with NfnB and repeat the 
expression studies using pMTL5122. This would verify if the reason for the lack of 
expression lies with the vector, as nfnB is known to be capable of being expressed in both 
C. beijerinckii and C. sporogenes, albeit using different expression vectors. 
Primer pair NFNBF and NFNBR were used to amplify nfnB from pF25 (nfnB cloned into 
pTrc99A) such that an NdeI site was created 'over' the ATG start codon and XbaIlStuI sites 
were at the 3' end for cloning into the expression vector (see Appendix II for DNA and 
protein sequences of nfnB). pMTL5122 was digested with NdeI and PvuII and nfnB was 
cloned in to the expression cartridge on a NdeIlStuI fragment to give pMTL5122::nfnB. 
Expression was first verified as before in E. coli CA434 using SDS-PAGE and menadione 
reductase assay on the soluble fraction of Iysates from an 8 hour culture (see Figure 5.7). 
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Figure 5.7: (A) SDS-PAGE of the soluble fraction of lysates from an 8 hour cuJture of E ali o\"C r-
expressing NfnB and HinNfR. M = BioRad Broad Range protein marker. lane I = negatiye control. 
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NfnB was proven to have been expressed as evidenced by the over-expression of a protein of 
23.9 kDa that was not evident in a vector only control. This over-expression corresponded to 
a value of 12.7% soluble protein by densitometric analysis of the SDS-PAGE gel. Analysis 
of the 8 hour soluble fraction lysates by menadione reductase assay showed that NfnB was 
over-expressed to a level lO-fold over background NfnB activity. This compared to a le\ el 
of3-fold over background for the HinNTR (see Figure S.7). 
pMTLSI22::nfoB was then conjugated into C. sporogenes NCIMB 10696 and erythromycin 
resistant transconjugants were verified to be correct by PCR screening for the plasmid and 
isolating the plasmid and retransforming back into E. coli. Further screening of the E. coli 
clones by SDS-PAGE proved that the plasmid had not undergone any major rearrangements 
whilst in C. sporogenes, such that expression was affected (data not shown). C. sporogenes 
soluble fraction lysates were prepared from 8 hour cultures of recombinants harbouring 
pMTLSI22::nfoB. All clones screened showed an abundance of a protein of between 20.6 
kDa and 28.9 kDa, which was not evident in a negative control lysate derived from cells 
harbouring an insert-free expression vector pMTLS122 or pMTLSI22: :HinNTR -synth (see 
Figure S .8). 
Analysis of the 8 hour soluble fraction lysates by menadione reductase assay indicated a 
major increase in over-expression compared to the HinNTR and negative control Iysates, 
corresponding to a level of IS-fold over background levels of nitroreductase activity 
recorded in the negative control (see Figure S.8). 
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Figure 5.8: Over-ex-pression of NfnB in C. sporogenes NCIMB 10696 as detennincd by SDS-PAGE 
(A) and menadione reductase assay (B). percentage soluble protein indicated in brackets. M = BioRad 
Broad Range protein marker; lane I = HinNTR-syntb lysate: lane 2 = NfnB lysatc (7 .2% solublc 
protein); lane 3 = negative control (pMTL5122). The arrow indicates the location of the O\cr-
ex-pressed protein. 
The data obtained for the over-expression of NfnB highlights that proteins can be over-
expressed in C. sporogenes NCIMB 10696 utilising the expression vector pMTL5122. 
However, in the context of nitroreductase, in particular NfnB, the products of the reduction 
of CB 1954 are important. As well as reducing the 4-nitro group to give the toxic 
4-hydroxylamine drug, NfnB also reduces the 2-nitro group to the less potent 
2-hydroxylamine derivative. Therefore either improved prodrugs or enzymes are sought for 
nitroreductase, a case that was thought to have been resolved using HinNTR. 
The first possible route to obtaining expression of HinNTR was through optimisation of the 
over-expression vector as plasmid stability and promoter strength are two factors that can 
influence expression of proteins. The effect of changing the replicon and promoter was first 
assessed on vectors containing nfnB as any improvement in expression can be compared to 
that already obtained. 
5.2.5.1 Alteration of promoter and/or rep/icon of the NfnB over-expressing plasmid -
effect on expression 
To determine the effects that the identified optimal plasmid would have on expression, 
variants of pMTL5122: :rifhB were constructed. First as a negative control for expression, a 
pIP404 RepA version of pMTL5112 was generated by deleting out repL on a blunted 
AatlII BamHI fragment, and cloning in the plP404 replicon on a blunted NheIINspI fragment, 
to yield plasmid pMTL5612. The over-expression plasmid pMTL5122::njnB was then 
altered to contain the plP404 replicon using the same digest to give pMTL5622::nfi1B. 
Secondly, the C. sporogenesfdx promoter was cloned into pMTL5122::njnB as an NdeIIYo[! 
fragment into an NdeIlNotI fac2 deleted version of pMTL51 :?:?::njnB to gl\e 
pMTL5123 ::nfnB. Finally, the pIP404 RepA was cloned pMTL5123 ::1if11B to \ ield 
pMTL5623: :nfnB. The final result was four different plasmids all expressing nfnB dri\ en by 
either the C. sporogenes fdx promoter or fac:?, and with either the unstable pIM 13 RepL or 
stable pIP404 RepA replicon. The combination of pIM 13RepL and C. sporogenes fiit was 
generated but not tested in C sporogenes due to stability problems associated with th 
pIM13 replicon in C sporogenes. 
The nfnB variant plasmids were first transfonned into E. coli CA434 and expression ofNfnB 
was checked by SDS-P AGE of the lysates of the soluble fraction from overnight cultures 
(see Figure 5.9) . All 3 plasmids expressed NfnB, indicated by over-expression of a protein 
of 23 .9 kDa. Densitometric analysis of the SDS-PAGE gel predicted that the fac2-based 
vectors over-expressed to a level equating to 4% soluble protein, where as the spofdx 
promoter based vector over-expressed to a level equating to 15% soluble protein, indicating 
that the spofdx promoter is better recognised by E. coli RNA polymerase thanfac2. This is 
most likely due to the spacing between the -10 and -35 sequence of the spofdx promoter 
being identical to the E. coli consensus of 17 bp (see Figure 5.10). 
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ACTTACACT TTTAAA AAGTTTAAAAACATGA TACAAT AAGTTA 
AAAAATTAC TTTAAA AATTAATAAAAACATGG TAAAAT ATAAAT 
TTGACA ( 1 7 bp ) TATAAT 
RBS start 
TTTA AGGAGG TTAGTCAT ATG 
TTTA AGGAGG TGTGTTACAT ATG 
AGGAGG (9 bp) ATG 
Figure 5.10: Location and sequence of/ac2 and the C sporogenes ferredoxin promoter. Consensus == 
E coli consensus sequence. 
The plasmids were then conjugated into C sporogenes NCIMB 10696. Screening of soluble 
fractions obtained after lysis of overnight cultures by SDS-PAGE indicated that all three 
vectors were capable of over-expressing NfnB, at broadly equivalent levels of 10-11 % 
soluble protein (see Figure 5.11). Unfortunately, the expected 3-fold improvement in 
expression from the C sporogenes fdx promoter predicted from the CatP reporter assay was 
not seen in the over-expression of NfnB. Based on the reporter data, an increase In 
expression from 10% to approximately 30% soluble protein would be anticipated. 
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5.2.6 Expression of nitroreductases in the cured strain of C sporogenes 
Having identified that the cured strain was approximately 10- to 1 DO-fo ld more effic ient at 
gene transfer an<L once introduced, plasmids were several fold more stable, it was of interest 
to determine the effects on expression of nitroreductase enzymes. 
The recombinant cured strain C sporogenes NCIMB 10696 harbouring the HinNTR and 
HinNTR-synth over-expression plasmids as well as the NfnB over-expression plasmid were 
studied for expression levels. Lysates of the soluble fraction from 8 hour cultures were 
analysed by SDS-PAGE (see Figure 5.12) . 
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SDS-PAGE analysis of the lysates of the soluble fraction indicated that the fnB expressing 
plasmids were still functional in the cured strain. Densitometric scanning of the gel 
predicted levels of between 5% and 10% soluble protein at 8 hours , with the pfP404 based 
vectors producing the larger amount of enzyme at this time point. Of particular interest. 
however was the expression obtained from the synthetic H. injluenzae nitroreductase. Over-
expression of HinNTR-synth could not be visualised in lysates of the soluble fraction from 
wi ld type C sporogenes NCIMB 10696, however, in lysates of the soluble fraction from the 
cured strain recombinant harbouring pMTL5122::HinNTR-synth over-expression could be 
detected. This was further confirmed to be the case when the soluble fraction lysates were 
examined using the menadione nitroreductase assay (see Figure 5.13). In comparison to 
NfnB expressed from pMTL5122, where a level of 22-fold over background nitroreductase 
activity was obtained, HinNTR-synth was expressed at a level of 14-fold over background. 
If the levels of soluble protein produced are also taken into consideration then the units of 
nitroreductase per mg of total protein are comparable for the two enzymes (see Table 5.5) . 
Menadione NTR assay - cured 10696 harbouring ove rexpression 
plasm ids 
Figure 5.13: Menadione assay on the cured strain of C sporogenes NCfMB 10696 o\·cr ... c"pr 
NfuB or HinNTR nitroreductases from the expression plasmid pMTL51 22 . 
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Enzyme % soluble Total soluble Units mg-i Units mg-' 
protein protein (mg mr1) total protein nitroreductase 
NfnB 5.41 1.83 2.34 43.3 
HinNTR-synth 4.01 1.37 1.57 39.1 
Table 5.5: NTR activity calculated on units mg- I protein based on densitometry scan of SDS-PAGE 
gel. 
Segregational stability of the clones revealed that, as before, the pIM 13-based clones were 
more stable in the cured strain compared to the wild-type strain. 
5.2.7 Cloning of HinNTR into a stable vector - expression in wild type and 
cured strains 
One plausible explanation for the over-expression of HinNTR-synth in the cured strain could 
be due to the increased segregational stability of pIM 13-based plasm ids in this host. To 
assess this, the stable pIP404 replicon was cloned into pMTL5122::HinNTR-synth to yield 
pMTL5622::HinNTR-synth. This was obtained by cloning the blunt-ended NheIlNspI 
pIP404 replicon from pJIR418 and cloning into pMTL5122::HinNTR-synth digested with 
BamHI and AatII and blunt-ended to delete repL. pMTL5622::HinNTR-synth was then 
conjugated into both strains of C. sporogenes NCIMB 10696 and Iysates of the soluble 
fraction from mid-exponential cultures analysed by SDS-PAGE (see Figure 5.14). 
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Figure 5.14: SDS-PAGE analysis of effect of plasmid stability on HinNTR over-exrpressing clones. 
Lanes 1-3 are lysates of the soluble fraction from recombinant C. sporogenes NCIMB 10696. Lanes 
4-6 are lysates of the soluble fraction from recombinant cured strain C. sporogenes NCIMB 10696. 
Percentage soluble protein determined by densitometry on over-expressed bands is shown in brackets. 
Lane 1+4 = pMTI..,5122 (negative control), lane 2+5 = pMTL5122: :HinNTR-synth (lane 2 = 0%., lane 
5 = 7.25% soluble protein), lane 3+6 = pMTI..,5622 ::HinNTR-syntb (lane 3 = 8.58%, lane 6 = 13.3% 
soluble protein). M = NEB Broad range protein markers. The arrow indicates the location of the 
over-expressed protein. 
Expression of HinNTR-synth was obtained in the wild-type strain of C. sporogenes Ne lMB 
10696 when the gene was cloned in a segregationally stable version of the expression vect or. 
This indicates a role for plasmid segregational stability in gene over-expression. 
5.2.8 Cloning of a 'final' optimal expression vector 
5.2.8.1 Characterisation of a novel improved nitroreductase 
During the course of these studies another project was initiated on the in silico identification 
of new and improved nitroreductase enzymes for use in DEPT strategies (1. Heap, School of 
Pharmacy, University of Nottingham). One such novel nitroreductase isolated, termed 
NTR-N had an approximately 1- to 2-fold improvement in CBl954 specific activity 
compared to HinNTR. An approximately 3.5- to IO-fold improvement was noted when 
NTR-N was compared to NfnB (Heap, J. personal communication). Additionally, NTR-N 
only produces the desired toxic 4-hydroxylamine drug from the CB 1954 reduction. All 
kinetic studies performed gave the following rank order of the enzymes: 
NTR-N > HinNTR > NfnB 
Based on this preliminary data it was of interest to obtain over-expression of this novel 
nitroreductase in C. sporogenes. 
5.2.8.2 Cloning of the novel nitroreductase into the optimised vector 
NTR-N was cloned from pMTL1015::NTR-N on a NdeIlPvuI fragment and cloned into 
pMTL5122::nfoB digested with the NdeI and PvuI to give pMTL5122::NTR-N (see 
Appendix II for DNA and protein sequence ofNTR-N). NTR-N could not be cloned directly 
into pMTL5623 directly due to the presence of an internal NdeI restriction site present in the 
replication protein of pIP404. The fac2 promoter was then switched for the C sporogenes 
ferredoxin promoter using NdeI and NotI to give pMTL5123: :NTR-N. Finally the pllvl13 
replicon was excised using BamHI and AatII and T4 blunted, the replacement stable replicon 
from pIP404 was cloned in as a blunt NheIlNspI fragment. The resulting plasmid was 
designated pMTL5623::NTR-N. 
Lysates of the soluble fraction from all the deri\'ati\es of the NTR-N over-e:\pressmg 
}40 
plasmid clones (pMTL5122::NTR-N, pMTL5123::NTR-N and pMTL5623::NTR-0J) in both 
the wild type and cured strains of C. sporogenes NCIMB 10696 were screened for over-
expression by SDS-PAGE, however none gave the expected 24.7 kDa size over-expressed 
band visible on the SDS-PAGE gel. Furthermore, no activity above background levels was 
detectable via menadione nitroreductase assay (data not shown). 
One potential cause of low level expression of genes can be poor codon usage. Therefore the 
next step in improving expression was to identify the codon usage of the novel 
nitroreductases in relation to NfnB. 
5.2.9 Codon usage as a determinant of expression 
Codon usage is considered to be an important contributor to setting the level of gene 
expression. In the two highly studied microbial species, E. coli and B. subtilis, highly 
expressed genes are transcribed from optimal codons that are recognised more efficiently by 
the most abundant tRNA (Karlin et aI., 1998; Kunst et al., 1997). In other bacterial species 
codon usage is shaped more by mutational bias and, therefore, is mainly determined by the 
G+C content of the genome. Of the clostridial genomes sequenced so far all possess G+C 
contents in the region of 29% - 31 % G+C (Bruggemann et aI., 2003; Nolling et aI., 2001; 
Shimizu et a!., 2002). Examination of the clostridial genomes identified a significant A+ T 
codon bias for highly expressed genes which possessed a GC content of between 13% and 
18% (Sharp et a!., 2005) with a significant predominance of A and T at the 'silent' third 
position of the triplet codon. Therefore it can be concluded that the main factor influencing 
codon usage is the strong mutational bias towards A and T. 
The four nitroreductase genes utilised (nfnE, HinNTR, HinNTR-synth. NTR-N) \\ere 
analysed for G+C content. As expected the synthetic HinNTR has the lowest G+C content at 
33.'+8%, in comparison to the wild-type HinNTR that has a G+C content of .+ 1.93%, 
1.+ 1 
indicating a potential reason as to expreSSIOn of the synthetic gene over the wild-type 
sequence gene. However, nfnB has a much higher G+C content at 51.53% G+C compared to 
the HinNTR. NTR-N has a nearly identical G+C content (51.65%) compared to nfnE yet is 
not expressed. Therefore some alternative factor(s) must be influencing expression of the 
genes. 
Codon usage of the various nitroreductases was analysed utilising the codon usage analyser 
GCUA (http://www.gcua.de). A partial codon usage table is currently available for 
C. sporogenes and the closely related C. botulinum Hall A. Codon bias may be exist when 
only a few coding sequences have been analysed. Therefore, a comparison of this partial 
data to the three full genome codon usage tables available for C. acetobutylicum, 
C. perfringens, and C. tetani was performed (see Table 5.6). This indicated that the codon 
usages of all clostridia are relatively similar. The C. tetani codon usage gave the closest 
match to C. sporogenes. (see Table 5.6). 
Clostridial species (no of CDS' ) s 
Complete genome codon usage Partial codon usaqe 
Amino Triplet C. C. C. tetani C. 
acid codon acetobutylicum perfringens (2373) C. 
(3945) botulinum sporogenes (2723) (146) (7) 
Ala GCA 45 45 47 44 
Ala GCU 54 49 
Arg AGA 70 86 77 73 80 
Asn AAU 80 83 85 90 79 
Asp GAU 85 87 86 90 83 
Cys UGU 70 79 80 80 84 
End UAA 64 75 70 76 100 
Gin CAA 70 86 82 86 92 
Glu GAA 74 77 83 83 86 
Gly GGA 51 58 55 50 49 
His CAU 78 81 83 88 82 
lie AUA 58 62 65 53 59 
Leu UUA 42 66 58 65 59 
Lys AM 68 70 78 81 83 
Met AUG 100 100 100 100 100 
Phe UUU 85 81 88 89 83 
Pro CCA 53 45 48 
Pro CCU 45 45 47 
Ser AGU 28 29 29 31 25 
Ser UCA 27 32 
Ser UCU 30 29 32 
Thr ACA 44 
Thr ACU 50 44 47 55 
Trp UGG 100 100 100 100 100 
Tyr UAU 78 84 85 90 88 
Val GUA 51 47 56 
Val GUU 45 52 
Table 5.6: Codon usage table for the three sequenced clostridial genomes plus 4 clostridial genes 
(number in brackets represents number of codong sequences used to generate codon usage). Only 
frequent optimal codons (27 out of 64 codons) are shown. Figures in bold indicates codons used 
preferentially when two or more codons are available with similar frequency. 
5.2.9.1 Codon usage of currently available nitroreductase genes 
GCUA analysis of the available nitroreductases (nfnB. HinNTR, HinNTR-synth, NTR-,\) 
gave an indication as to the codon usage of each particular gene, (for the raw graphical 
representations see Appendix II). It was anticipated that this analysis \\ l ~ l l i d d highlight the 
correlation between the total number of low scoring codons (i e the tRNA 
.. , occurs at less 
than 10% of the tRNA pool, indicated as red bars in the GCUA graphl'c I . a representatIOn). 
and expression of the protein. The data is presented in Table 5.7. 
% of tRNA pool for a n ~ ~ ~ i v e n n codon 
Gene 1% 2% 3% 4% 5% 6% 7% 8% 9% 10% Total % of 
<10% total 
codons codons 
nfnB (218 
aa) 6 15 10 16 0 4 4 17 0 12 84 38.5 
HinNTR 
(221 aa) 12 2 3 10 0 4 1 11 3 9 55 24.9 
HinNTR-
synth 0 0 0 1 0 0 0 0 2 0 3 1.4 
NTR-N (222 
aa) 13 2 7 21 0 5 5 12 13 9 87 39.2 
Table 5.7: Tabulated data on the frequency of low scoring codons. 
As can be seen there is no correlation between the total number of low scoring codons and 
expression. NfnB, which is well expressed, has 84 codons that are in less than 10% of the 
tRNA pool, which represents a total of 38.5% of the total number of 218 triplet codons in the 
entire protein. NTR-N has a similar number compared to NfnB and HinNTR has nearly half 
the number of low scoring co dons yet both are not expressed. The presence of particular 
exceedingly rare codons (l % of tRNA pool) does, however, correlate with expression. 
HinNTR contains 12 rare codons and NTR-N contains 13 rare codons. The dependency on 
these particular rare codons (CUC [Leucine], CGC + CGG [Arginine], and UCG [Serine]) 
may be limiting expression even though they represent only 5% of the total number of 
codons. In particular, the codon CGC appears to be the most prevalent rare codon in 
HinNTR and NTR-N. This may be the limiting factor, especially if the tRNA for CGC is 
actually the least abundant in C. sporogenes. The exception to the rule is HinNTR-synth, 
which is not expressed, yet has only 3 low-scoring codons. none of which are rare. 
Clustering of rare codons has also been suggested to limit expression level (V s arenne and 
Lazdunski 1986). Analysis of the nitroreductases for the clustering of low sco . d . flng co ons IS 
shown in Table 5.8. 
Gene Singlet Doublet Triplet Quadruplet Quintuplet Sextuplet Total 
<10% 
codons 
NfnB 35 11 6 1 1 0 84 
HinNTR 26 13 1 0 0 0 55 
HinNTR- 3 0 0 
synth 0 0 0 3 
NTR-N 35 11 6 0 0 2 87 
Table 5.8: Tabulated data on the clustering of low scoring co dons from GCUA analysis. 
No correlation between the clustering of low scoring codons and lack of expression can be 
drawn. Rare codons are distributed through out the genes and clustered rare codons are 
present in all genes. In fact, NfnB which is expressed has up to 5 low scoring codons 
clustered together. 
Finally, it is thought that the occurrence of low scoring codons early on in the translation of 
mRNA can lead to early termination of translation (Makoff et at., 1989). This factor could 
be influencing expression of the nitroreductases. However, the GCUA analysis did not 
reveal any correlation as NfnB has 19 low scoring codons in the first 50 codons, the highest 
frequency of low scoring codons of all the nitroreductases screened. 
To summarise, the presence of several rare codons appears to be influencing expression. It 
was of interest to see if altering the codon usage could enhance expression of HinNTR and 
NTR-N. 
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5.2.9.2 Construction of second generation synthetic nitroreductase genes 
It was decided to redesign the DNA sequence and re-synthesise NTR-N and HinNTR such 
that the optimal most abundant tRNA was used at any given triplet position. This would 
give a definite indication of whether or not codon usage is important in obtaining over-
expression. The LETO codon optimisation programme (Entelechon GmbH) \vas employed 
for the initial optimisation of both genes. LETO uses a genetic algorithm to enable the 
simultaneous optimisation of a large set of competing parameters such as codon usage, 
codon tandem repeats, mRNA secondary structure, GC distribution, long range repeats, and 
AT/GC stretches. Initially both genes were optimised utilising the codon usage and 
secondary structure optimisation criteria only. The sequence obtained for NTR-N was left as 
determined using LETO, however, the sequence given for HinNTR was further manually 
optimised from the given sequence as in some cases a less than optimal codon was chosen. 
In addition, the sequence returned was relatively similar to HinNTR-synth as Entelechon 
GmbH probably used LETO for the design of the first generation synthetic HinNTR 
(HinNTR-synth vI). The manual optimisation was based on the criterion that if the same 
amino acid was repeated in HinNTR or spaced only one amino acid apart then the second 
most abundant tRNA was used for the second amino acid in the sequence. Both genes were 
synthesised by Entelechon GmbH with an Ndel restriction site 'over' the ATG start codon 
and an .xhol restriction site after the stop codon and supplied cloned into pCR-Script Amp 
SK(+) (Stratagene) (see Appendix II for DNA and protein sequences of HinNTR-synth \'2 
and NTR-N-synth). 
Both synthetic nitroreductase genes were cloned as NdeII.xhoI fragments from pCR-Script 
into pMTL5I22 digested with NdeI and .xhoI to yield pMTL5122::HinNTR-synth \'2 and 
pMTL5122::NTR-N-synth, the aim being to identify the sole effect of optimising codon 
usage without altering the initial plasmid. FolIO\\ing conjugation into C. sporogenes 
NCIMB 10696 and the cured derivative of C. sporogenes NCI\ lB 10696. Iysatc:-; of the 
soluble fraction from 8 hour cultures were visualised by SDS PAGE ( F ' --
- see 19ure ) . 1.)) . 
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Figure 5. J 5: SDS-PAGE gel of soluble fraction lysates from NTR-N-synth and HinNTR-synUl v.2 
over-expressing C sporogenes NCIMB 10696. Lane I = pMTLS122, lane 2 = pMTLSI 22::NTR- . 
lane 3 = pMTLSI22::NTR-N-syntb (9.9% soluble protein), lane 4 = pMTLS1 22 :: HinNTR-syntll v.2 
(11.0% soluble protein). M = NEB Broad range protein markers. The arrow indicates the location of 
the over-expressed protein. 
Both synthetic derivatives of NTR-N and HinNTR were over-expressed in C sporogene. 
NCIMB 10696 to relatively similar high levels . Expression was also obtained in the cured 
strain to a similar level (data not shown). The presence of a doublet for NTR-N \\35 
presumed to be due to the presence of truncated proteins caused by premature termjnation of 
translation . 
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5.2.10 Characterisation of the cured strain - sporulation efficiency and protease 
production 
As a precursor to future studies, some preliminary characterisation of the C. sporogenes 
cured strain was performed to ascertain if any phenotypic changes had occurred during the 
curing process. 
The cured strain 10696-1 was studied further for sporulation efficiency and protease 
production, two features of C. sporogenes that aid in its superior colonisation of the tumour. 
Spore assays were performed on 72 hour cultures grown in TYG media not supplemented 
with glucose. Approximately 10% of wild type C. sporogenes NCIMB 10696 cells \\ere 
spores, compared to only 1 % of the cured strain. The cured strain therefore has an 
approximate 10-fold reduction in sporulation efficiency compared to the wild-type 
bacterium. This is, however, still 100-fold higher than the sporulation efficiency of the 
original CDEPT host C. acetobutylicum (Theys, J. personal communication). Thus the 
reduction in spore forming capability of the cured strain still renders it a useful delivery tool 
compared to C. acetobutylicum. 
Analysis of protease production by both the wild-type and cured strains of C. sporogenes 
NelMB 10696 utilising collagen zymogram gel analysis of supernatants from overnight 
cultures showed that protease production, specifically collagenase secretion, was not 
markedly altered between the two strains for the time point studied (data not shown). 
5.3 DISCUSSION 
In Chapter 4, a low level of expression of HinNTR was obtained, although this appeared to 
be sufficient to exhibit a static anti-tumour effect in vivo. Therefore in this chapter the 
. d d .. d fI se in C sporogenes The potential 
expression vector was characterIse an optimise or u· . 
I'+S 
of affecting expression by altering the gene was also studied. 
The segregational stability of pMTL5122 was shown to be exceedingly low \'n C 
. sporogenes 
NCIMB 10696. Studies comparing pMTL5112 to pIMP1::0riT highlighted that the pIi\113 
replicon is highly unstable in C. sporogenes NCIMB 10696, both vectors being lost at a 
frequency of approximately 1.7 x 10-1 per generation. This confirms that no essential 
plasmid replication functions of pIMP 1 were deleted in the construction of pMTL5122. 
pIM13-based plasmids are generally segregationalIy unstable in other clostridial species with 
losses of 2.3 x 10-2 per generation in C. acetobutylicum NI-4081 (Azeddoug et al., 1 9 9 ~ ) ) and 
4.7 x 10-3 per generation in C. cellulolyticum (Jennert et al., 2000). The exceptions to this 
are C. acetobutylicum DSM 792 and C. acetobutylicum NI-4082 where pIM 13-based 
plasm ids are segregationally stable. The extreme low stability of pIM13-based plasm ids in 
C. sporogenes prompted a segregational study of the other clostridial plasmids as 
segregational stability may be influencing gene over-expression. 
Prior to the initiation of this study, work was performed on the isolation and characterisation 
of a novel cryptic plasmid, termed pBPl, from C. botulinum NCTC 2916. A shuttle vector 
was constructed based on a presumptive minimal replication region from pBP 1. This vector 
was 100% segregationally stable in C. botulinum Hall A A TCC 3502. It was thought that a 
pBPl rep licon-based vector was likely to be segregationally stable in C. sporogenes even 
though the plasmid is thought to replicate via a rolling circle method, due to the close 
phylogenetic relationship of C. sporogenes to C. botulinum. This would make the pBP 1 
replicon an ideal candidate for the construction of a vector for use in CDEPT. 
Unfortunately, this expected stability was not found to be the case in C. sporogenes. 
Segregational stability studies on a variety of clostridial replicons identified pBP I to be lost 
-1 . 
at frequency of 6.54 x 10- per generatIOn. The most stable plasmid, based on the 
C. perfringens plasmid pIP404, was nearly 100% segregationally stable O\er ..+8 generations 
with a loss of 4.21 x 10-4 per generation. Therefore the choice of plasmid replicc1Jls appears 
1-+9 
to be very species specific. Interestingly the most stable plasm ids in C spo 
. rogenes \\ere 
also the plasm ids that are known to replicate via the theta mechanism. This confirms to the 
general consensus that theta-replicating plasmids are more segregationally stable than 
plasmids that replicate via the rolling circle mechanism. There are situations \vhere this 
general rule is not confirmed. In C. cellulolyticum, both the p A M ~ ~1 (theta-replication) and 
plM 13 (rolling circle, ssDNA) replicons are moderately stable, with a loss per generation of 
approximately 7.8 x 10-3 and 4.8 x 10-3 respectively (Jennert et al., 2000). 
Having identified the exceedingly low segregational stability of plM 13-based shuttle vectors 
it was of interest to generate a cured strain of C. sporogenes. The aim being to see if a 
similar increase in segregational stability is seen as observed in C. acetobutylicum NI-4081 
and the cured strain NI-4082 (Azeddoug et al., 1992). Once generated, plasmid transfer into 
the cured C. sporogenes strain occurred at a 10- to 100-fold higher frequency. Also, the 
segregational stability increased from a loss per generation of 1. 73 x 10-1 for the wild-type 
strain to 2.24 x 10-2 for the cured strain. This increase was not as severe as that observed in 
C. acetobutylicum NI-4082, however, there was still a definite improvement. The host-
encoded mutation(s) in C. acetobutylicum NI-4082 are thought to be related to resolution of 
plasmid multimers as segregational stability should occur when most of the plasmid DNA is 
in the monomeric form. It is interesting to hypothesise that a similar mutation was selected 
in the curing of C. sporogenes NCIMB 10696. Conjugal transfer frequencies of pIM 13-
based plasm ids were also altered in the cured strain. This increase could be attributed to the 
aforementioned increase in segregational stability, as the plasmid should not be lost as fast 
during the seven-hour non-selective stage ofthe conjugation procedure. 
A second feature of the expression vector that was characterised was the relative strength of 
the fac2 promoter compared to other clostridial promoters. The ferredoxin promoter from 
C. pasfeurianum is known to be capable of over-expressing NfnB in C. beijerinckii to a level 
equating to 8% soluble protein (Minton et at.. 1995). Ho\\ e\Oer the promoter has not been 
characterised in Co sporogenes and may behave differently in this relatively dissimilar host. 
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Two reporter genes, GusA and CatP, were utilised to characterise a variety of clostridial 
promoters. Initial studies of available promoters identified the closI to be the 'strongest' 
available. One potential reason for this could be due to the close phylogenetic relationship 
of C. histolyticum to C. sporogenes. Also, clostripain is present in the C. botulinum A TCC 
3502 Hall A genome (CB01920) and is indicated to be present in C. sporogenes by 
microarray (Carter, A. personal communication). The alternative promoters are from 
solventogenic clostridia, which are not as closely related to C. sporogenes as the proteolytic 
C. histolyticum. 
The identification that the C. perfringens endogenous ferredoxin promoter is 'stronger' than 
the C. pasteurianum ferredoxin promoter prompted a study of the ferredoxin promoters in 
C. sporogenes. The CatP reporter data obtained highlighted an approximately 3-fold 
increase in reporter gene expression in C. sporogenes. The GusA reporter and CatP reporter 
data was combined for all the different promoters tested and the ferredoxin promoter from 
C. sporogenes proved to be the 'strongest' with a 3.1S-fold increase in reporter activity 
relative to fac2. Phased A-tracts in the C. perfringens pIc promoter sequences have been 
implied to be stimulate promoter activity through a curved DNA interaction of the promoter 
with the a-subunit C-terminal domain of RNA polymerase (Katayama et al., 1999; 
Katayama et al., 2001). Recent data on the analysis of the C. perfringens ferredoxin 
promoter identified three upstream phased A-tracts and two downstream phased A-tracts 
located within the promoter (Kaji et al., 2003). It is hypothesised that the phased-A tracts 
form a DNA curvature where the position of the bend centre appears critical for the 
stimulatory effect of DNA curvature on promoter activity. That the C. perfringens promoter 
was not the optimal promoter in C. sporogenes suggests that the DNA bend formed by the 
C. sporogenes ferredoxin promoter phased A-tracts is most suitable for interaction with 
C. sporogenes RNA polymerase. 
In parallel with the above studies, the potential of using pMTL5122 to obtain over-
expression of a gene, which has previously been successfully over-expressed, was studied. 
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Cloning nfnB into pMTL5122 resulted in over-expression as confirmed by SDS-PAGE and 
menadione assay. Conjugal transfer of the vector into C. sporogenes also resulted in over-
expression to a level equating to 7% soluble protein, a level similar to that obtained with 
C. beijerinckii. This proves that pMTL5122 is functional and capable of over-expressing 
protein to a relatively high level in C. sporogenes. Also, this highlights that expression is 
gene specific, with some genes proving easier to over-express than others. Over-expression 
to levels equivalent of 30% of the cells soluble protein have been reported using expression 
systems in E. coli (Chambers et al., 1988b). It was of interest to see what effects changing 
the plasmid replicon and/or promoter would have on protein expression, and to see if more 
elevated levels of expression could be obtained utilising the more stable pIP404 replicon 
and/or stronger C. sporogenes ferredoxin promoter. Interestingly there did not appear to be a 
significant increase in expression. Utilising pMTL5122, expression to a level equating to 
10.4% of the cells soluble protein was obtained. If the replicon was changed for the more 
stable pIP404 replicon a level of 11.0% soluble protein was obtained, a similar level (11.1 %) 
was obtained when the C. sporogenes fdx promoter was utilised. Based on the 3.18-fold 
improvement of the C. sporogenes fdx promoter over fac2 identified from the promoter 
reporter data, a level of expression of NfnB equating to approximately 30% soluble protein 
would be expected. As this was not seen, it suggests that a threshold for over-expression 
exists such that no greater than approximately 10% soluble protein can be over-expressed in 
the growth conditions tested. Alternatively, the potential toxicity associated with massively 
over-expressing a protein may prevent levels higher than approximately 10% soluble protein 
being obtained. Nevertheless, as it is an enzyme that is being expressed in the context of 
CDEPT current levels of over-expression may be sufficient to obtain a suitable anti-tumour 
effect and obtain tumour reduction. 
The effect that the cured strain had on expression of the nitroreductases was then studied. 
All the vectors were transferred at the previously found higher frequency. Lysates of the 
soluble fraction from nitroreductase recombinant cured strains were then visualised by SDS-
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PAGE. Expression of NfnB was apparent with higher levels in the plP404-based plasmids. 
This could be attributed to a potentially higher segregational stability and/or copy number of 
the plP404-based vector compared to the pIM13-based vector. Additionally, expression of 
HinNTR was observed, albeit at a lower level (4% soluble protein) than that observed for 
NfnB (5 - 10% soluble protein, according to the vector used). This could be due to the 
increased segregational stability of pIM I3-based vectors in the cured strain of C. sporogenes 
NCIMB 10696. This hypothesis was proven to be correct by the construction of a 
segregationally stable version of pMTL5I22::HinNTR-synth, pMTL5622::HinNTR-synth. 
Once pMTL5622::HinNTR-synth was transferred to the wild-type strain of C. sporogenes 
over-expression of HinNTR was obtained, indicating that plasmid stability does indeed 
influence the probability of obtaining expression of a particular gene. 
The identification of NTR-N as a novel improved nitroreductase, further added to the range 
of nitroreductases available for analysis. Cloning of this nitroreductase into pMTL5I22 did 
not result in expression of NTR-N protein. Based on G+C content of the genes alone 
expression of NTR-N would be predicted to occur as both nfnB and NTR-N have almost 
identical G+C contents. However, as expression of NTR-N was not obtained more specific 
factors appear to be influencing expression. 
Codon usage analysis of the nitroreductases highlighted that improvements could be made to 
NTR-N in order to increase the potential for obtaining expression. Also, there were some 
improvements that could be made to HinNTR-synth (now termed HinNTR-synth vI) to 
further improve the expression obtained in the cured strain. Once these improvements in 
codon usage had been generated NTR-N-synth and HinNTR-synth v2 were cloned into 
pMTL5I22. The aim being to identify the sole effect codon usage would have on expression 
as when the wild type NTR-N and HinNTR-synth vI were cloned into pMTL5122 no 
expression was obtained. Lysates from both wild type and cured strain recombinants 
harbouring pMTL5122::HinNTR-synth v2 and pMTL5I22::NTR-N-synth showed that 
expression of both genes could now be reliably obtained to relatively high levels in the 
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soluble fraction of both hosts. Thus, codon usage is also appearing to influence the potential 
of obtaining expression. This is confirmed by the findings of Musto et al (2003) where 
analysis of the C. perfringens and C. acetobutylicum genomes identified a strong bias 
towards low G+C contents. There was little variation in the mean G+C contents along the 
entire genome, with the exception of the ribosomal operons. For each amino acid the 
predominant triplet is A- and/or T -ended. This is particularly the case in highly expressed 
genes where the GC content is exceedingly low, in the range of 13-18%. 
To summarise, a variety of features appear to influence gene over-expression: 
1) Plasmid segregational stability; 
2) Codon usage of the gene to be expressed; 
3) Unknown features specific to each gene. 
However, the studies above indicate that if the gene is expressed on a segregationally stable 
plasmid or the codon usage is optimised then expression should be obtainable. There is, 
however, a more significant effect seen by optimising codon usage compared to plasmid 
stability, as NTR-N was not expressed when cloned into the segregationally stable plasmid 
pMTL5623. Optimisation of the codon usage of NTR-N, however, resulted in expression 
even though the gene was cloned in a segregationally unstable vector. This indicates the 
importance of eliminating rare codons in a particular sequence in order to obtain over-
expreSSIon. 
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CHAPTER 6 
DEVELOPMENT OF INTEGRATIVE TOOLS 
FOR C. SPOROGENES 
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6.1 INTRODUCTION 
Having obtained over-expression of HinNTR and a novel nitroreductase NTR-N, it was of 
interest to develop targeted gene integration systems for C. sporogenes. The ultimate aim of 
CDEPT being to have the prodrug converting enzyme integrated into the host chromosome, 
such that the gene can be stably maintained without the use of antibiotic selection. In this 
chapter, a variety of methods for obtaining gene integrants will be assessed in C. sporogenes 
NCIMB 10696. 
Obtaining mutants in clostridia is extremely difficult with current methods for gene 
inactivation remaining woefully inadequate. Suicide vectors remain the most common way 
of generating mutants in the two best-studied clostridia, C. perfringens and 
C. acetobutylicum. Since the initiation of these studies, suicide vectors have also been used 
to generate mutants by single crossover in the acidogenic Clostridium, C. tyrobutyricum 
(Zhu et aI., 2005), and by double crossover in C. septicum, the primary agent of spontaneous 
gas gangrene (Kennedy et al., 2005). The ability to generate mutants, albeit rarely, using 
'suicide' approaches appears relatively wide spread across the clostridial genus. In this 
chapter, the potential of using suicide plasm ids to generate both single and double crossover 
targeted gene knockouts in C. sporogenes will be explored. 
Conditionally replicating vectors are currently unavailable for use in clostridia. However, a 
replicative vector has been used to generate a sporulation mutant in C. acetobutylicum 
(Harris et al., 2002). The basis for integration is thought to be related to the method of 
replication of the vector used. The vector was based on the pIM13 replicon that replicates 
via a rolling circle mechanism. ssDNA intermediates are generated during rolling circle 
replication which are highly recombinogenic. pIMl3-based vectors are known to be 
segregationally unstable under non-selective conditions in a variety of clostridia, including 
C. sporogenes (see Chapter 5.0). A double crossover knockout system based on vectors 
containing the pIM 13 replicon will be developed in this chapter. 
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The E. faecalis transposon Tn916 has been used to generate anum ber of non-targeted 
mutants in C. acetobutylicum, C. botulinum, C. perfringens and C. difjicile. However, 
Tn916 has also been used to generate a targeted single crossover mutant in the sigma-factor 
(sigK) of C. difjicile (Haraldsen and Sonenshein, 2003). Additionally, in the work of 
Roberts et al (Roberts et aI., 2003) 50% of the cwp66 adhesin mutants screened had in fact 
integrated in the genomic copy of cwp66 (Minton, N.P. personal communication). As Tn916 
is capable of entering the genome at a variety of sites in both C. difjicile and C. botulinum, it 
may be possible to utilise Tn916 as an insertional mutagen in C. sporogenes. To identify 
this, in this chapter, pMTL900 will be assessed as a targeted mutational tool. 
Initially, knockouts will be attempted using vectors containing antibiotic selectable crossover 
cassettes. However, it is planned that any methods that prove successful would be repeated 
replacing the antibiotic marker for the C. sporogenes ferredoxin promoter and nitroreductase 
NTR-N. Thus, resulting in the generation of the 'final' strain. 
6.2 RESULTS 
6.2.1 Choice of knockout targets 
Two genes were identified as potential targets useful in the generation of a CDEPT integrant, 
either pyrF or spoOA. pyrF encodes the gene orotidine-5'-phosphate decarboxylase which is 
involved in the biosynthesis of pyrimidine ribonucleotides. PyrF converts orotidine-5 '-
phosphate to uridine-5'-monophosphate (UMP) with the evolution of CO2• UMP is then 
further converted by other enzymes to uridine-5'-triphosphate (UTP), cytidine-5 '-
triphosphate (CTP) and finally cytidine-5'-diphosphate (COP). As well as becoming uracil 
auxotrophs, pyrF knockout mutants can be positively selected for by resistance to 
5-fluoroorotic acid. pyrF has been successfully used as a target for the generation of mutants 
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in Mycobacterium smegmatis (Husson et aI., 1990). An additional safety aspect is also 
created by the generation of a uracil auxotroph, as the germinating spores will be confined to 
the tumour, a location expected to contain particularly high levels of pyrimidines. 
Auxotrophy has been utilised as a safe guard mechanism for the delivery of prodrug 
converting enzymes to tumours by Salmonella typhimurium. A S. typhimurium purl 
auxotroph strain, strain VNP20009, has been generated that requires an external source of 
adenine (Clairmont et aI., 2000). Once systemically administered, VNP20009 auxotrophs 
accumulated preferentially in tumours and' 41 days post-injection are cleared from all other 
organs screened. 
The second gene target is the major sporulation initiation factor spaDA. One of the overall 
aims of the EU consortium was to generate a conditionally sporulating mutant of 
C. sporogenes. Therefore the native spaDA gene would need to be inactivated such that 
mutant containing an inducible copy of spaDA would only be able to sporulate in vitro by 
addition of an exogenous inducer. 
6.2.2 Inactivation of pyrF by single crossover homologous integration 
Due to a lack of conditionally replicating vectors which function in Clostridium species as a 
whole, the first attempt at generating an insertion ally inactivated mutant in pyrF was based 
on a suicide plasmid, the type of which has been used to generate an assortment of mutants 
in a variety of clostridial species. 
pMTL31 is a mobilisable suicide plasmid which carries the RP41 RK2 oriT region, such that 
it can be transferred from a strain of E. coli which harbours a conjugative helper plasmid 
such as E. coli CA434 (E. coli HBI01 carrying the I n c P ~ ~ conjugative helper plasmid, R702). 
Also present on the plasmid are the erythromycin and ampicillin resistance markers (ermB 
and bla respectively), the Gram-negative ColEI rep licon, and LacZa to enable blue/white 
selection (Williams et al., 1990). pMTL31 has previously been used to successfully generate 
mutants in C. acetobutylicum, C. beijerinckii, and C. difficile by conjugal transfer of the 
suicide plasmid from an E. coli donor (Liyanage et al., 2001; Wilkinson and Young, 1994). 
The pyrF integrational plasmid was generated by PCR amplifyingpyrF from genomic DNA 
prepared from C. sporogenes NCIMB 10696. PCR primers against pyrF were designed 
based on the C. botulinum Hall A ATCC 3502 genome sequence 
(http://www.sanger.ac.uk/Projects/C_botulinum/private/). PCR amplification with primers 
PYRFF and PYRFR (designed to incorporate SphI and Pvull restriction sites at the 5' ends 
of the amplified fragment respectively) generated the expected product of 764 bp. The peR 
product was cloned into pCR2.I-TOPO prior to cloning into the suicide plasmid pMTL31. 
pMTL3I was digested with Sad (blunt-ended) and SphI. The C. sporogenes NCIMB 10696 
pyrFfragment was cloned from pCR2.I-TOPO on a Pvull / SphI fragment into the linearised 
pMTL31 fragment. The resulting plasmid was designated pMTL31 ::pyrF(Csp). 
High frequency gene transfer is desirable for obtaining gene knockouts usmg suicide 
plasmids as the frequency with which a mutant will be isolated is higher. Electroporation is 
usually the preferred method as large quantities of DNA can be electroporated, thus easily 
increasing the transfer frequency. An electroporation procedure has previously been 
developed for C. sporogenes NCIMB 10696 (Liu et al., 2002), however the method proved 
to be irreproducible in our laboratory. The development of a conjugal transfer procedure for 
C. sporogenes has negated this bottleneck in gene transfer (see Section 3.2.2). 
Plasmid pMTL31::pyrF(Csp) was transferred to C. sporogenes NCIMB 10696 by 
conjugation from E. coli CA434. As there is no Gram-positive replicon provided in 
pMTL31, the only way the plasmid can be maintained is by integrating into the host genome. 
Integration is regarded as a rare event, therefore a positive control conjugation with a 
replication proficient plasmid (pMTL5112) was included during every repeat of the 
conjugation to confirm that the conjugation procedure utilised was successful. Plasmid 
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pMTL31 ::pyrF(Csp) was repeatedly conjugated into C. sporogenes, with 15 independent 
conjugations being performed in total, and an estimated 7 x 108 cfu of C. sporogenes being 
used. Previous work using conjugal transfer of suicide plasmids to C. beij"erinckii NelMB 
8052 produced integrants at a frequency of 10-6 to 10-7 per recipient (Wilkinson and Young, 
1994). If a similar frequency is observed in C. sporogenes then it would be expected that 
approximately 70 to 700 integrants in total would have resulted from the repeated 
conjugations. However, no erythromycin resistant transconjugants were observed in any of 
the conjugations performed. 
If, however, integration in C. sporogenes is less efficient than in C. beij"erinckii then a more 
efficient means of delivering the crossover fragment is required. In the absence of 
conditional vectors for the clostridial genus as a whole, the conjugative transposon Tn916 
was assessed as a suitable alternative delivery tool. 
6.2.3 The conjugative transposon Tn916 
6.2.3.1 Conjugative transfer of Tn916 
The conjugative transposon Tn916 has previously been shown to be capable of mediating its 
own transfer from E. faecalis to C. botulinum at a frequency of approximately 10-6 
transconjugants per recipient (Lin and Johnson, 1991). Based on this observation, 
conjugative transfer of Tn916 was attempted in C. sporogenes using B. subtilis BS34A 
(B. subtilis CU2189 harbouring a single copy of Tn916) as the transposon donor (Roberts et 
aI., 2003). B. subilis BS34A transferred the tetracycline resistance determinant, Tn916, at a 
frequency of approximately 10-7 transconjugants per recipient, with an estimated 1,700 
tetracycline resistant C. sporogenes transconjugants obtained per filter mating. No 
spontaneous tetracycline resistant mutants of C. sporogenes were obtained in independent 
experiments involving plating of C. sporogenes onto filters without B. subtilis BS..l3A and 
160 
then, following incubation, plating onto TYG supplemented with cycloserine and 
tetracycline. Transconjugants were confirmed to be C. sporogenes rather than B. SUblilis as 
independent experiments highlighted that cycloserine at a final concentration of 250 IJ.g mrl 
was completely selective against B. sublilis BS34A. Furthermore, PCR analysis of genomic 
DNA isolated from selected tetracycline resistant transconjugants with primers specific to 
tetM (TETMF and TETMR) gave a product of the expected size (2.146 kb) for telM. As 
Tn916 was being utilised as a delivery tool rather than a mutational tool the specific location 
and frequency of Tn916 integration sites was not investigated. 
6.2.3.2 Integration utilising the conjugative transposon Tn916 as a delivery tool 
Following successful transfer of Tn916 from B. subtilis to C. sporogenes, its use as a 
delivery tool for single crossover knockout fragments could be assessed. Plasmid pMTL900 
was recently developed by Roberts et al (Roberts et al., 2003) for the expression of Tn916 
mediated integrated antisense RNA in C. difficile. pMTL900 is a B. subtilis suicide vector 
which contains the Tn916 tetM gene, into which a poly linker and the chloramphenicol 
resistance gene, catP, from the C. perfringens plasmid pCW3 have been cloned. The 
resultant plasmid can then be used to integrate genes cloned into the polylinker ofpMTL900 
by homologous recombination with the genome of B. subtilis carrying a single copy of 
Tn916 (strain BS34A). The recombinant transposon can then be transferred, by conjugation, 
from B. subtilis to the recipient of choice, in this case C. sporogenes. 
The pyrF fragment utilised in pMTL31 was again exploited for the Tn916 approach. pyrF 
was excised from pCR2.I-TOPO::pyrF on a PvuII / Sphl fragment and cloned into plasmid 
pMTL900 also digested with Pvull and Sphl, generating pMTL900::pyrF(Csp). To increase 
the frequency of double crossover recombination between tetM encoded on 
pMTL900::pyrF(Csp) and the genomic copy of tetM in B. subtilis BS34A, the plasmid was 
linearised with the restriction enzyme Agel and dephosphorylated to prevent recircularisation 
of the plasmid. 
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Approximately 1 I-lg of pMTL900::pyrF(Csp) was transformed into B. subtilis BS34A. 
Transformants were selected for on medium containing 5 I-lg mr] chloramphenicol. Since 
pMTL900 is replication deficient in B. subtilis, true chloramphenicol resistant clones should 
only arise if a double crossover event has occurred between the tetM gene of Tn916 and the 
homologous region in pMTL900 (see Figure 6.1). After 48 h incubation at 30°e. 
approximately five chloramphenicol resistant clones were observed on each selective plate. 
Four clones were randomly selected and screened further using a colony PCR with primers 
PYRFF, PYRFR, TETMF and TETMR (see Table 6.1). 
Forward primer Reverse primer Expected product size 
(kb) 
TETMF TETMR 4.7 
TETMF PYRFF 3.7 
TETMR PYRFR 1.6 
PYRFF PYRFR 0.76 
Table 6.1: PCR amplification ofpMTL900::pyrF(Csp) 
PCR was also performed on a pMTL900::pyrF(Csp) plasmid DNA positive control, and a B. 
subtilis BS34A untransformed negative control. 
The presence of the pyrF fragment in the B. subtilis donor was confirmed in all four 
randomly selected clones, and a single correct clone was used to conjugate the recombinant 
transposon into C. sporogenes NCIMB 10696. Plate filter matings were carried out between 
B. subtilis BS34A Tn916::pMTL900pyrF(Csp) and C. sporogenes NCIMB 10696. A 
positive control of B. subtilis BS38A (tetM interrupted with catP from pMTL900) was 
included. Transconjugants were selected for on 20 I-lg mr] thiamphenicol; the B. subtilis 
donor was counter-selected with 250 I-lg mr] cycloserine. Several thiamphenicol resistant 
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clones of C. sporogenes were obtained. Co lony PCR's were performed wi th primers PYRFF 
and CA TPR (see Figure 6.1) which generated a product of 2.4 kb prov in g Tn 916 had 
integrated into the genome. PCR screeni ng thiamphenicol resistant clones with prim ers 
PYRCF and CATPR (see Figure 6.1) did not y ield a product. PCR with PYRCF and 
PYRKR, however, gave the expected product size of 1.522 kb for an uninteITupted copy of 
pyrF. Thus it appears Tn916 had integrated at an alternative genomic location. 
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6.2.4 Inactivation of spoOA by double crossover 
Since a single crossover pyrF mutant was not obtained using both a standard suicide vector 
and a transposon mediated suicide vector then the target gene was altered to spoOA in which 
mutants have previously been made in C. acetobutylicum and C. perfringens (Harris et at., 
2002; Huang et al., 2004). Due to the innate instability of single crossover mutants and 
possibility of getting revertants, double crossover with spoOA was attempted. 
The ~ p o O A A gene plus regions up- and down-stream were PCR amplified from C. sporogenes 
NCIMB 10696 genomic DNA using primers based on the C. botulinum Hall A ATCC 3502 
genome sequence (work performed by C. Schwarz, University ofUlm, Germany). A 1.11 kb 
spoOA crossover cassette was constructed using primers located 237 bp downstream of 
spoOA with an EcoRI site generated by the primer, and a second primer located 33 bp 
upstream with a primer generated HindlII restriction site. The chloramphenicol resistance 
marker (catP) was then cloned into spoOA at a unique Pst! site in order to disrupt spoOA, thus 
creating a double crossover fragment. The spoOA double crossover fragment was then 
digested with EcoRI and HindIII and cloned into pMTL31 with the same two restriction 
enzymes generating plasmid pWG3 (C. Schwarz, University ofUlm, Germany). 
As with prevIous attempts with suicide vectors, p WG3 was repeatedly transferred by 
conjugation into C. sporogenes NCIMB 10696 this time selecting for thiamphenicol 
resistance (encoded by catP), using plasmid pMTL5112 (with selection for erythromycin) as 
a positive control for the conjugation process. The conjugation process was repeated fifteen 
times however no thiamphenicol resistant clones were ever obtained indicating that a double 
crossover event had not occurred. 
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6.2.5 Development of a single stranded DNA intermediate plasmid integration 
system 
Recently, Harris and colleagues (Harris et af. , 2002) deve loped a spoOA in activated strain of 
C. acelobutylicum ATCC 824 utilising a replication profi cient pl asm id based on the 
B. subtilis rolling circle plasmid pIM13 . Although the mutant generated was an imperfect 
double crossover (see Figure 6.2), it was of interest to develop a si mil ar procedure for 
generating double crossover mutants in C. sporogenes. As has been mentioned already, 
pIM 13 plasm ids are segregationally unstable in C. sporogenes (see Section 5.2.1.1.3 ). It is 
thought that this instability combined with the generation of single stranded DN A 
intermediates by rolling circle replication will aid in the homologous recombinati on process 
and generation of a double crossover mutant. 
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The segregationally unstable pIM13-based plasmids pMTL5122 and pIMP} ::OriT were 
utilised as the delivery tools for the spaOA double crossover cassette previously created for 
use in suicide plasmids. The spaOA crossover fragment was cloned from pWG3 as a blunt-
ended HindIII / EcaRI fragment and ligated to either pMTL5l22 or pIMP 1: :OriT, both being 
digested with BamHI (blunt-ended). The result being the spaOA double crossover cassette 
being cloned in either orientation into both delivery vectors. The plasmids were designated 
pMTL5122::spaOA:catP oril or ori2, and pIMPl::OriT::spaOA:catP oril or ori2. Problems 
were encountered conjugating the pMTL5122 derivatives into C. sparagenes however, 
transconjugants were obtained with the pIMPl::OriT derivative. These were studied further. 
Correct clones containing the pIMP 1: :OriT spaOA crossover vector were initially cultured 
overnight in selective media. This was followed by a passaging regime of subculturing 
every 24 hours non-selectively for 4 consecutive days, followed by plating onto media 
containing either thiamphenicol to select for the crossover cassette or erythromycin to select 
for the plasmid backbone. It was hoped that the cell counts for the plasmid backbone would 
be much lower than for the crossover cassette indicating that a potential crossover event 
could have occurred. However, colony counts of putative integrants revealed that there was 
a similar number ofthiamphenicol and erythromycin resistant clones (see Figure 6.3). 
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Figure 63: Colony counts for pIMPloriT-based spoOA crossover vectors. 
Potentially, all thiamphenicol resistant clones could be single crossover mutants with the 
plasmid backbone marker as well as the spoOA marker integrated into the host chromosome. 
50 colonies for each plasmid were picked onto media containing erythromycin and / or 
thiamphenicoL All 50 colonies grew on both selective plates . Plasmid extracts from several 
clones revealed that no crossover event had occurred as plasmid DNA could be detected 
when the DNA isolated was used to retransform E coli . Utilis ing the colony count data 
above the segregational stability of the plasmids was assessed and was not affected 
significantly by the introduction of the crossover cassette. 
6.3 DISCUSSION 
In this chapter the genetic tools that have previously been utilised to generate mutants III a 
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variety of clostridia were assessed in two different gene targets in C. sporogenes. 
Additionally, an unstable ssDNA intennediate based integrational vector was constructed 
and assessed. 
Attempts to utilise currently available mutational tools, both suicide vector and Tn916 based 
approaches, failed to yield a single crossover mutant in the pyrF gene of C. sporogenes 
NCIMB 10696. No erythromycin colonies were obtained using the pMTL31 suicide vector 
approach. Any thiamphenicol resistant colonies that were obtained with the Tn916 approach 
were shown to contain the transposon by PCR using transposon specific internal primers. 
However, PCR screening with primers flanking the target site resulted in a product of the 
expected size for an intact copy of pyrF. Therefore, it is probable that the transposon 
integrated into another location other than pyrF. Transposition of intact Tn916 was shown to 
be possible by conjugal transfer from B. subtilis BS34A to C. sporogenes. Tetracycline 
resistant colonies arose at a frequency of approximately 10-7 transconjugants per recipient. 
The exact location of integration of Tn916 was not studied. 
It is unclear why suicide vector systems that have proven to be capable of generating mutants 
in a variety of clostridia failed in C. sporogenes. Transfer frequency of plasmids is a 
determinant in the probability of mutant isolation. Transformation frequencies in the range 
of 3 x 105 cfu J.lg-1 plasmid DNA in C. perfringens (Scott and Rood, 1989), and up to 6 x 106 
cfu J.lg- 1 plasmid DNA in C. acetobutylicum (Azeddoug et aI., 1992) are amongst the highest 
reported frequencies of transfer for all clostridia. This correlates to the majority of reported 
mutants being obtained in C. perfringens and C. acetobutylicum using high-frequency 
electroporation-mediated transformation of replication deficient crossover vectors. Without 
a reliable electroporation protocol, vectors have to be introduced into C. sporogenes by 
conjugation. Conjugal transfer of replication deficient plasm ids is estimated to occur at an 
approximately 100-fold lower frequency than replication proficient plasm ids in 
C. beijerinckii (Young, M. personal communication). However, this is highly \·ariable 
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depending on the Gram-positive replicon used as a positive control and may vary on the 
clostridial host as well. Taking this into consideration, the lowest transfer frequency 
obtained in C. sparagenes with pMTL5122-like plasmids typically yielded approximately 50 
transconjugants per plate. If suicide plasmids transfer at a IOO-fold lower frequency then 
recombinants would not be obtained. However, during suicide plasmid conjugations the 
entire conjugation 'mix' was plated out on IO selective agar plates. If the reduced frequency 
were only IOO-fold then it would be expected that some integrants should be obtained. As 
no integrants were obtained then the transfer frequency of suicide plasm ids into 
C sparagenes may be lower than IOO-fold. 
Transfer frequency of Tn916 may be lower than that required in order to isolate a mutant. 
However, in the case of cwp66, 50% of thiamphenicol resistant colonies screened were 
cwp66 mutants. This suggests that the Tn916 mediated approach is highly efficient. Also, 
Tn916 has been successful at generating mutants in two different genes in C. diffic ile , yet 
mutants in spaOA of C. sparagenes could not be obtained. 
One factor known to influence the efficiency of integration into certain clostridia is the size 
of the gene fragment cloned into the delivery vector. This has proven to be a controlling 
factor as in C. perjringens, gene fragments in excess of 3kb have been required to obtain 
homologous recombination (Rood, 1.1. personal communication). Secondly, double 
crossover mutants have in some cases been easier to obtain than single crossover mutants 
(Minton, N.P. personal communication). To gain insight into the affects of this a 1.11 kb 
fragment containing spaOA was peR amplified from genes flanking spaOA to generate a 
double crossover fragment. However repeated transfer of the vector did not result in any 
thiamphenicol resistant mutants. Therefore in the future it may be necessary to utilise even 
larger fragments in order to obtain gene knockouts. 
Failed attempts at using both replication deficient vectors and Tn916 to generate integrants 
.. fi' I 'd h' h 'ould enable a laroer number l,r prompted the use of a replIcatIOn pro IClent p asml w IC \v t:" 
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cells to be targeted. The double crossover fragment from spoOA was used as the target as it 
is larger then pyrF and also is cloned as a double crossover cassette. Also, spoOA has 
previously been disrupted in C. acetobutylicum using replication proficient plasm ids (Harris 
et at., 2002). Repeated passage of the pIMP 1 oriT -based vectors did result in severe loss of 
the plasmid, however a similar number ofthiamphenicol and erythromycin resistant colonies 
were obtained. It appears that the plasmid had not integrated as thiamphenicol resistant 
clones were also erythromycin resistant, and plasmid DNA could be isolated from these 
clones and retransformed back into E. coli. 
One potential alternative explanation as to the failed attempts of obtaining integrants in 
either pyrF or spoOA is that homologous recombination appears to be very target specific 
with some genes being relatively easy to inactivate. For example, in the genetically 
amenable C. perfringens certain genes known to be non-toxic if knocked out have proven 
impossible to inactivate (1. Rood, personal communication). This'raises the question of the 
possible presence of specific gene targets in the form of Chi-like DNA sequences in the 
genome where recombination will preferentially occur (Myers and Stahl, 1994). In 
B. subtilis the gene AddAB protein complex behaves in an analogous way to RecBCD in E. 
coli (Kooistra et al., 1993). In vivo, AddAB responds to the five nucleotide sequence 
5'-AGCGG-3', or its complement (Chedin et al., 2000). RecA, AddA, and AddB have been 
identified in the C. botulinum genome and have been found to be present in C. sporogenes 
by microarray analysis, AadA is present but divergent from the C. botulinum gene. 
Therefore the requisite machinery is present to enable recombination to occur, although 
nothing is yet known about the relative activity of the recombination machinery of C 
sporogenes in relation to more genetically acquiescent clostridia such as C perfringens. 
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CHAPTER 7 
SUMMARY AND GENERAL DISCUSSION 
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7.1 Introduction 
DEPT-based cancer therapies rely on the targeted over-expression of prodrug-converting 
enzymes. The two main aims of this study were to obtain over-expression of prodrug 
converting enzymes and subsequently generate targeted mutants, in which the gene encoding 
the prodrug converting enzyme had been integrated into the genome. The work described 
here presents the first demonstrated over-expression in C. sporogenes NCIMB 10696 of two 
novel nitroreductases that have kinetic and enzymatic improvements over the nitroreductase 
currently used in alternative DEPT strategies, NfnB. A variety of approaches were 
investigated to generate targeted mutants. Unfortunately, all methods tried failed to yield a 
mutant in either of the designated spoOA or pyrF gene targets. 
7.2 Construction of a clostridial expression system 
Prior to the over-expression studies, the pMTL51 00 series of clostridial shuttle vectors were 
constructed. These are based on the widely used Gram-positive replicon from the B. subtilis 
plasmid pIM13. This replicon was chosen due to its segregational stability in the original 
CDEPT host of choice, C. acetobutylicum NI-4082. However, after the initiation of the 
project, early in vivo data on the varying colonisation potentials of different clostridia 
indicated C. sporogenes NCIMB 10696 to be the most suitable. At the outset of this study, 
the only published method for introducing DNA into C. sporogenes was by an 
electroporation procedure that proved to be irreproducible outside the author's laboratory. 
Conjugation is thought to be a way of negating transformation barriers such as extracellular 
endonucleases. Utilising the vector pMTL51 12, a previously published conjugal transfer 
method was adapted for use in C. sporogenes NCIMB 10696. This yielded transconjugants 
at a frequency of approximately 1.0 x 10-7 per donor cell. Using the pCD6-based plasmid 
pMTL9301, transconjugants were obtained at a frequency of 1.0 x 10-5 per donor cell. These 
levels of transfer frequency were similar to those obtained using a similar protocol in C 
difficile strain CD3 (Purdy et a/. , 2002). Higher conjugation transfer frequencies. in the 
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range of 10-3 to 10-4 recipients per donor, were obtained in C. botulinum, though a different 
protocol was used (Bradshaw et al., 1998). Therefore, the conjugation transfer frequencies 
obtained in C. sporogenes are comparable with other reported frequencies. The observed 
difference in transfer frequency of pIM 13- and pCD6-based vectors in C. sporogenes is most 
likely a consequence of the extreme segregational instability of pIM13-based plasm ids. 
Experiments performed in C. sporogenes NCIMB 10696 showed that plasmids based on 
pIM 13 were lost at a frequency equivalent to 17% per generation. Therefore, during the 
seven hour non-selective mating stage of the conjugation procedure, a significant proportion 
of the population will loose the plasmid due to poor segregation of the plasmid during cell 
division. 
7.3 Over-expression of CPG2 and HinNTR 
Codon usage is thought to be a major contributor to obtaining expression of heterologous 
genes. CPG2 and HinNTR were therefore synthesised based on the C. acetobutylicum 
ATCC 824 codon usage table. Once the wild type and synthetic DNA sequence prodrug 
converting enzymes were cloned, expression of both CPG2 and HinNTR was demonstrated 
in E. coli using pMTL51 00 series vectors. Interestingly, the synthetic DNA sequence CPG2 
was expressed to a much higher level than the wild-type sequence gene. This could be 
attributed to the high G+C content of the wild-type gene, which would result in less 
preferential codons being used for a particular amino acid. The HinNTR genes were both 
expressed to similar levels. 
Conjugal transfer of the genes encoding both enzymes into C. sporogenes resulted in low-
level expression of HinNTR only. The synthetic sequence HinNTR was expressed to 
marginally higher levels than the wild-type gene. In vivo studies on recombinant 
C. sporogenes NCIMB 10696 expressing HinNTR-synth resulted in a striking anti-tumour 
response. This is thought to be due to an additional bystander effect where apoptosis of 
aerobic non-targeted cells is also occurring. This phenomenon has been reported p r e v i o u s l ~ ~
1..,.., i _, 
for NfnB in combination with CB 1954 (Djeha et al., 2000; Wilson et al., 2002). The anti-
tumour response observed could also be being enhanced by the identified endogenous 
nitroreductase activity of C. sporogenes. The lack of expression of CPG2 was not 
investigated further due to time constraints and the potential for proteolytic cleavage of 
CPG2. 
7.4 Improving expression of prodrug converting enzymes 
Having identified a level of nitroreduction by the first generation recombinant, it was 
thought that improving expression could lead to an even greater anti-tumour effect. 
Additionally, as it is the final aim to have the nitroreductase integrated into the host genome 
as a single copy, expression needs to be as elevated as possible. Segregational stability and 
codon usage were found to affect expression, although, a more noticeable effect was seen 
when codon usage was altered. The reason for these differences appears to be gene specific 
as it is unclear why HinNTR-synth, which has near optimal codons, was not expressed to 
high levels in a segregationally unstable plasmid. The hypothesis that certain rare codons 
that occur only in HinNTR and NTR-N, and not in NfnB, are limiting expression was proven 
by the re-synthesis ofNTR-N. 
7.5 Assessment of current integrational tools 
During the course of this study a number of attempts to develop directed mutagenesis 
procedures for C. sporogenes have been made. The use of suicide vectors as a means to 
generate targeted mutants appears to be limited. They have been successfully used to 
generate mutants in a variety of clostridia including, C. beijerinckii, C. perfringens, 
C acetobutylicum, and C. difjicile (A wad et al., 1995; Liyanage et al., 2001; Wilkinson and 
Young, 1994; Wong and Bennett, 1996). More recently C. septic/{/}/, and C tyrobutyricum 
mutants have been generated (Kennedy et al., 2005; Zhu et al., 2005). However. unless 
significant improvements in gene transfer frequency or alternatively efficient electroporation 
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protocols are developed, the use of suicide vectors In C. sporogenes has so far has not 
proven fruitful. 
The exploitation of the conjugative transposon Tn916 as a mutational element is intriguing. 
Integration of the element has been proven to be both random and non-random in a species 
dependent manner. However, Tn916 has been used to obtain recombination within the sigK 
(Haraldsen et al., 2003) and cwp66 (A. Roberts personal communication) genes of 
C. difficile strains 196 and 79-685 respectively. Attempts to obtain Tn916 mediated 
recombination within the pyrF gene of C. sporogenes failed to yield any correct mutants. 
Tn916 was thought to have integrated into an alternative location in the genome as 
thiamphenicol resistant clones were proven to contain Tn916 using internal primers. 
However, using primers flankingpyrF gave a product of a size determined for an interrupted 
copy of pyrF. 
Finally, a ssDNA based integrative vector was constructed and assessed. No spoDA mutants 
were generated. Reasons for the failure of this approach, which successfully generated a 
spoDA mutant in C. acetobutylicum, are not known. The presence of species-specific Chi-
like DNA sequences which promote integration, are hypothesised to be a potential cause for 
the failure to generate mutants in the gene targets chosen in C. sporogenes. 
7.6 Latest advances of other clostridial anti-tumour therapies 
This work highlights the potential of using recombinant clostridial spores to elicit an anti-
tumour effect. Furthermore, the initial difficulty in obtaining over-expression of improved 
prodrug converting enzymes appears to have been solved. During the course of these studies 
work has been published on the progression of alternative clostridial therapies. 
The main clostridial alternative to CDEPT is the use of a strain of C. novyi, C. novyi-NT, in a 
process termed combination bacteriolytic therapy (shortened to the acronym COBALT) 
(Dang et aI., 2001). Following on from these initial studies on the use of C. n01yi-NT in 
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combination with conventional therapeutics, there has followed further work on reducing the 
toxicity observed in these initial studies. The combination of microtubule-synthesis-
inhibitors resulted in a reduction in toxicity although a tumour cell specific response was still 
observed (Dang et al., 2004). The administration of microtubule-stabilising drugs did not 
result in haemorrhagic necrosis but in slow regression of the tumour. When the microtubule-
stabilising drugs were combined with C. novyi-NT this improved the duration of tumour 
regression to the point where a cure was observed in mice bearing HCT116 colorectal 
carcinoma xenografts. Recently, combination of C. novyi-NT with an analogue of the most 
promising microtubule-stabilising drug led to a complete cure in 4 out of 5 mice harbouring 
HCT116 colorectal carcinoma xenografts (Smith et al., 2005). 
An alternative to the clostridial-derived expression of prodrug converting enzymes is the 
production of cytokines. Intratumoural injection of recombinant C. acetobutylicum 
expressing rat interleukin-2 (rIL-2) results in a significant growth delay of the tumour in 
rhabdomyosarcoma-bearing rats (van Mallaert et al., 2006). The rIL-2-mediated indirect 
activation of CDS+ T lymphocytes is proposed to be responsible for the observed growth 
delay (van Mallaert et al., 2006). This further highlights the potential of using expression of 
cytokines rather than prodrug converting enzymes to elicit anti-tumour effects. 
7.7 Future work 
Following on from these studies it is of primary interest to repeat the in vivo studies with 
both the HinNTR and NTR-N over-expression clones. Additionally, any anti-tumour effect 
resulting from the endogenous nitroreductase activity needs to be studied, such that the effect 
arising specifically from the expression of the novel nitroreductase can be quantified. 
It is paramount that the final strains have the prodrug converting enzyme integrated into the 
genome. To this aim, integrative technology needs to be developed. Indeed, it is vital to the 
clostridial research community as a whole. Recently, a mobile group II intron has been used 
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to generate an alpha toxin (PIc) inactivated mutant in C. perfringens (Chen et al., 2005). 
Mobile group II introns are site-specific retrohoming elements that are capable of targeting 
specific DNA sequences independently of host-encoded recombination machinery. It would 
be of interest to develop this method for the generation of mutants for use in CDEPT. This is 
due to the method being highly efficient and site-specific which avoids the random insertion 
of transposons, or low frequency of recombination associated with suicide plasm ids. 
Additionally, the major clinical advantage of this system is that no antibiotic resistant genes 
'-
are introduced into the chromosome making it ideal for applications such as CDEPT. 
In addition, it would be interesting to attempt to solve expression of carboxypeptidase G2, as 
CPG2 has yet to be expressed in a bacterial DEPT strategy. Initially RT-PCR performed on 
the recombinant clones created in this study would highlight if the expression was related to 
mRNA stability. If mRNA is being produced, expression of CPG2 could be attempted in the 
segregationally stable vector. If no CPG2 activity could be detected at this stage then the 
codon usage of CPG2 could be studied. Further work could also be performed on the 
proteolysis of CPG2. Expression in a less proteolytic saccharolytic Clostridium such as 
C. acetobutylicum would highlight if the level of protease secretion by C. sporogenes is 
hampering the extracellular production of CPG2. This would limit the choice of prodrug 
converting enzymes to intracellular enzymes such as nitroreductase. 
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APPENDIX I 
pMTL5 series of plasm ids - C. sporogenes and C. botulinum work 
1 st digit = replicon 
1 = pIMl3 
2 = pBPl 
3 = pCD6 
4 = pCBl02 
5 = pAMl3l 
6 = pIP404 
7= 
8= 
9= 
pMTL5 __ _ 
2 digit = feature 
0= nothing 
1 = oriT 
2 = oriT /lacZ 
3 = oriT/lacl 
4 = oriT /lacZ/lacl 
5= 
6= 
7= 
8= 
9= 
3 rd d" " 19lt = promoter 
0= nothing 
1 = fac 
2 = fac2 
3 = Cspofdx 
4= 
5= 
6= 
7= 
8= 
9= 
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APPENDIX II 
Prodrug converting enzyme DNA and protein sequences 
eglAss:CPG2 
MFSKIKKINFFKKTFSFLIAVVMMLFTVLGTNTYKAEAQKRDNVLFQAATDEQPAVIKTLEKLVNIETGTGDAEGI 
AAAGNFLEAELKNLGFTVTRSKSAGLVVGDNIVGKIKGRGGKNLLLMSHMDTVYLKGlLAKAPFRVEGDKAYGPGI 
ADDKGGNAVILHTLKLLKEYGVRDYGTITVLFNTDEEKGSFGSRDLIQEEAKLADYVLSFEPTSAGDEKLSLGTSG 
IAYVQVNITGKASHAGAAPELGVNALVEASDLVLRTMNIDDKAKNLRFNWTIAKAGNVSNIIPASATLNADVRYAR 
NEDFDAAMKTLEERAQQKKLPEADVKVIVTRGRPAFNAGEGGKKLVDKAVAYYKEAGGTLGVEERTGGGTDAAYAA 
LSGKPVIESLGLPGFGYHSDKAEYVDISAIPRRLYMAARLIMDLGAGK. 
CPG2 
ATGTTTTCAAAAATCAAAAAAATTAATTTTTTTAAAAAAACATTTTCTTTTTTAATTGCTGTTGTAATGATGTTGT 
TTACAGTATTAGGAACAAATACTTATAAAGCTGAAGCTCAGAAGCGCGACAACGTGCTGTTCCAGGCAGCTACCGA 
CGAGCAGCCGGCCGTGATCAAGACGCTGGAGAAGCTGGTCAACATCGAGACCGGCACCGGTGACGCCGAGGGCATC 
GCCGCTGCGGGCAACTTCCTCGAGGCCGAGCTCAAGAACCTCGGCTTCACGGTCACGCGAAGCAAGTCGGCCGGCC 
TGGTGGTGGGCGACAACATCGTGGGCAAGATCAAGGGCCGCGGCGGCAAGAACCTGCTGCTGATGTCGCACATGGA 
CACCGTCTACCTCAAGGGCATTCTCGCGAAGGCCCCGTTCCGCGTCGAAGGCGACAAGGCCTACGGCCCGGGCATC 
GCCGACGACAAGGGCGGCAACGCGGTCATCCTGCACACGCTCAAGCTGCTGAAGGAATACGGCGTGCGCGACTACG 
GCACCATCACCGTGCTGTTCAACACCGACGAGGAAAAGGGTTCCTTCGGCTCGCGCGACCTGATCCAGGAAGAAGC 
CAAGCTGGCCGACTACGTGCTCTCCTTCGAGCCCACCAGCGCAGGCGACGAAAAACTCTCGCTGGGCACCTCGGGC 
ATCGCCTACGTGCAGGTCAACATCACCGGCAAGGCCTCGCATGCCGGCGCCGCGCCCGAGCTGGGCGTGAACGCGC 
TGGTCGAGGCTTCCGACCTCGTGCTGCGCACGATGAACATCGACGACAAGGCGAAGAACCTGCGCTTCAACTGGAC 
CATCGCCAAGGCCGGCAACGTCTCGAACATCATCCCCGCCAGCGCCACGCTGAACGCCGACGTGCGCTACGCGCGC 
AACGAGGACTTCGACGCCGCCATGAAGACGCTGGAAGAGCGCGCGCAGCAGAAGAAGCTGCCCGAGGCCGACGTGA 
AGGTGATCGTCACGCGCGGCCGCCCGGCCTTCAATGCCGGCGAAGGCGGCAAGAAGCTGGTCGACAAGGCGGTGGC 
CTACTACAAGGAAGCCGGCGGCACGCTGGGCGTGGAAGAGCGCACCGGCGGCGGCACCGACGCGGCCTACGCCGCG 
CTCTCAGGCAAGCCAGTGATCGAGAGCCTGGGCCTGCCGGGCTTCGGCTACCACAGCGACAAGGCCGAGTACGTGG 
ACATCAGCGCGATTCCGCGCCGCCTGTACATGGCTGCGCGCCTGATCATGGATCTGGGCGCCGGCAAGTGA 
CPG2-synth 
ATGTTCTCAAAGATTAAGAAAATAAATTTTTTTAAGAAGACATTTAGTTTTTTAATAGCAGTAGTAATGATGTTAT 
TTACAGTATTAGGAACTAACACATATAAAGCAGAGGCTCAAAAAAGAGATAATGTATTATTTCAAGCAGCTACAGA 
TGAGCAACCAGCAGTTATTAAAACATTAGAGAAGCTAGTAAATATTGAAACAGGTACAGGAGATGCTGAAGGAATA 
GCAGCAGCAGGTAATTTTTTAGAGGCTGAACTAAAAAATTTAGGATTTACAGTAACTAGAAGTAAAAGTGCTGGTC 
TTGTTGTAGGAGATAATATAGTTGGAAAAATTAAGGGAAGAGGTGGAAAAAACCTTTTATTAATGTCACACATGGA 
CACTGTTTATCTAAAAGGAATATTAGCAAAAGCACCATTCAGAGTAGAAGGAGATAAAGCTTATGGTCCTGGAATT 
GCTGATGATAAGGGAGGAAATGCTGTAATTTTACATACATTAAAATTACTTAAGGAATATGGTGTTAGAGATTACG 
GAACAATTACAGTACTATTTAATACTGATGAAGAAAAAGGCTCTTTTGGTTCAAGGGACTTAATTCAGGAAGAAGC 
AAAATTGGCTGATTATGTACTATCATTTGAACCAACTAGTGCAGGAGATGAAAAACTTAGTCTTGGTACTTCAGGT 
ATTGCATACGTTCAAGTTAATATAACAGGAAAAGCAAGTCATGCTGGTGCTGCACCTGAGTTGGGTGTAAATGCAT 
TAGTTGAAGCTTCTGATCTTGTTCTTAGGACAATGAATATTGATGATAAAGCTAAAAATCTTAGATTCAACTGGAC 
TATAGCAAAGGCAGGTAATGTTAGTAATATAATACCAGCTTCTGCTACACTTAACGCTGACGTTAGATATGCAAGA 
AATGAAGATTTTGATGCAGCAATGAAAACTCTTGAAGAAAGAGCACAACAGAAAAAATTGCCAGAGGCAGATGTTA 
AGGTAATAGTTACTAGAGGAAGACCTGCTTTTAATGCAGGAGAAGGAGGTAAGAAATTAGTTGACAAAGCTGTTGC 
TTATTATAAAGAAGCAGGAGGAACTCTTGGAGTTGAAGAAAGGACTGGTGGAGGAACAGATGCAGCTTATGCTGCT 
CTTTCTGGTAAACCAGTTATAGAGTCTTTGGGTCTTCCAGGTTTTGGATACCATAGTGATAAGGCAGAATATGTTG 
ATATATCAGCTATACCTAGGAGATTATATATGGCTGCAAGATTGATAATGGATCTAGGTGCTGGTAAATAA 
198 
HinNTR 
MTQLTREQVLELFHQRSSTRYYDPTKKISDEDFECILECGRLSPSSVGSEPWKFLVIQNKTLREKMKPFSWGMINQ 
LDNCSHLVVILAKKNARYDSPFFVDVMARKGLNAEQQQAALTKYKALQEEDMKLLENDRTLFDWCSKQTYIALANM 
LTGASALGIDSCPIEGFHYDKMNECLAEEGLFDPQEYAVSVAATFGYRSRDIAKKSRKGLDEVVKWVG. 
HinNTR 
ATGACTCAACTTACTCGTGAACAAGTTCTTGAACTCTTCCATCAACGCAGCTCAACACGTTATTACGACCCAACAA 
AAAAAATCAGTGATGAAGATTTTGAATGTATTTTAGAGTGCGGTCGATTATCGCCGAGTTCTGTAGGCTCTGAGCC 
TTGGAAATTTTTAGTGATTCAAAATAAAACCTTACGCGAAAAAATGAAACCTTTTAGCTGGGGAATGATAAATCAG 
CTTGATAATTGCAGTCATCTTGTGGTAATTCTCGCGAAGAAAAATGCCCGTTATGATAGTCCGTTTTTTGTGGATG 
TGATGGCACGCAAAGGCTTGAACGCAGAGCAACAACAAGCCGCCCTCACAAAATACAAAGCCCTGCAAGAAGAAGA 
TATGAAATTACTCGAAAACGACCGCACTTTATTTGATTGGTGCAGCAAACAAACTTATATCGCCCTTGCAAATATG 
CTTACTGGAGCTTCAGCCCTTGGCATCGACTCTTGCCCAATTGAAGGTTTTCATTACGACAAAATGAATGAATGCC 
TCGCCGAAGAAGGATTATTCGATCCTCAAGAATATGCGGTTTCTGTCGCCGCAACCTTTGGCTATCGCTCACGCGA 
TATTGCGAAAAAATCCCGTAAAGGATTGGATGAAGTGGTGAAATGGGTGGGGTAA 
HinNTR-synth 
ATGACTCAATTAACAAGGGAACAAGTACTAGAATTATTTCATCAAAGAAGTTCAACAAGATATTACGATCCAACTA 
AGAAGATATCAGATGAAGACTTTGAATGTATATTAGAGTGTGGAAGATTAAGTCCTAGTTCTGTTGGATCAGAACC 
ATGGAAGTTCTTGGTAATTCAAAATAAAACTCTTAGAGAAAAAATGAAACCATTTAGTTGGGGTATGATTAATCAG 
CTTGATAACTGCTCACACCTAGTTGTAATTCTTGCAAAGAAGAATGCTAGATATGATTCTCCTTTTTTTGTTGATG 
TTATGGCTCGTAAAGGACTTAATGCTGAACAGCAACAAGCTGCATTAACTAAATATAAAGCATTACAGGAAGAAGA 
TATGAAACTTCTTGAGAATGATAGAACTTTATTTGATTGGTGTTCTAAACAAACATACATAGCATTGGCAAATATG 
TTAACAGGAGCTAGTGCATTAGGAATAGACAGTTGTCCAATAGAAGGTTTTCATTATGATAAGATGAACGAATGCC 
TTGCTGAGGAGGGATTATTTGATCCTCAAGAATATGCTGTATCAGTAGCTGCAACATTCGGATATAGATCTAGAGA 
TATAGCAAAAAAATCTAGGAAAGGTCTTGATGAAGTAGTAAAATGGGTTGGTTAA 
HinNTR-synthv.2 
A T G A C T C A A T T A A C A A G A G A A C A A G T A T T A G A A T T A T T T C A T C A A A G A A G T T ~ T A C T A G A T A T T A T G A T C C T A C T A A
AAAAGATAAGTGATGAAGATTTTGAATGTATATTAGAATGTGGAAGATTAAGTCCATCTAGTGTAGGATCTGAACC 
TTGGAAATTTTTAGTAATACAAAATAAAACTTTAAGAGAAAAAATGAAGCCATTTTCTTGGGGAATGATAAATCAA 
TTAGATAATTGTTCTCATTTAGTAGTTATATTAGCAAAAAAAAATGCTAGATATGATTCTCCTTTTTTTGTAGATG 
TTATGGCAAGAAAAGGATTAAATGCAGAACAACAGCAAGCAGCTTTAACTAAATATAAAGCTTTACAAGAAGAAGA 
TATGAAATTATTAGAAAATGATAGAACATTATTTGATTGGTGTAGTAAACAAACTTATATAGCTTTAGCAAATATG 
TTAACTGGAGCAAGTGCATTAGGAATAGATTCTTGTCCTATAGAAGGATTTCATTATGATAAAATGAATGAATGTT 
TAGCAGAAGAGGGATTATTTGATCCACAAGAATATGCTGTTTCAGTAGCTGCAACTTTTGGATATAGATCAAGAGA 
TATAGCTAAAAAAAGTAGAAAAGGATTAGATGAAGTTGTAAAATGGGTTGGATAA 
NfnB 
MDI ISVALKRHSTKAFDASKKLTPEQAEQIKTLLQYSPS STNSQPWHFIVASTEEG KARVAKSAAGNYVFNERKML 
DASHVVVFCAKTAMDDVWLKLVVDQEDADGRFATPEAKAANDKGRKFFADMHRKDLHDDAEWMAKQVYLNVGNFLL 
GVAALGLDAVPIEGFDAAILDAEFGLKEKGYTSLVVVPVGHHSVEDFNATLPKSRLPQNITLTEV. 
nfnE 
ATGGATATCATTTCTGTCGCCTTAAAGCGTCATTCCACTAAGGCATTTGATGCCAGCAAAAAACTTACCCCGGAAC 
AGGCCGAGCAGATCAAAACGCTACTGCAATACAGCCCATCCAGCACCAACTCCCAGCCGTGGCATTTTATTGTTGC 
CAGCACGGAAGAAGGTAAAGCGCGTGTTGCCAAATCCGCTGCCGGTAATTACGTGTTCAACGAGCGTAAAATGCTT 
GATGCCTCGCACGTCGTGGTGTTCTGTGCAAAAACCGCGATGGACGATGTCTGGCTGAAGCTGGTTGTTGACCAGG 
AAGATGCCGATGGCCGCTTTGCCACGCCGGAAGCGAAAGCCGCGAACGATAAAGGTCGCAAGTTCTTCGCTGATAT 
GCACCGTAAAGATCTGCATGATGATGCAGAGTGGATGGCAAAACAGGTTTATCTCAACGTCGGTAACTTCCTGCTC 
GGCGTGGCGGCTCTGGGTCTGGACGCGGTACCCATCGAAGGTTTTGACGCCGCCATCCTCGATGCAGAATTTGGTC 
TGAAAGAGAAAGGCTACACCAGTCTGGTGGTTGTTCCGGTAGGTCATCACAGCGTTGAAGATTTTAACGCTACGCT 
GCCGAAATCTCGTCTGCCGCAAAACATCACCTTAACCGAAGTGTAA 
199 
NTR-N 
MTVLSKEQVLSAFKNRKSCRHYDAARKISAEDFQFILELGRLSPSSVGSEPWQFIVVQNPEIRQAIKPFSWGMADA 
LDTASHLVVFLAKKNARSDSPFMLESLKRRGVTEPDAVAKSLARYQAFQADDIKILDDSRALFDWCCRQTYIALAN 
MMTGAAMAGIDSCPVEGFNYAEMERILSGQFGLFDAAEWGVSVAATFGYRVQEIATKARRPLEETVIWA. 
NTR-N 
ATGACAGTATTAAGCAAAGAGCAGGTTCTATCCGCATTTAAAAACCGTAAATCATGCCGGCATTACGATGCGGCAC 
GCAAAATCAGTGCCGAGGATTTTCAGTTTATTTTAGAACTCGGGCGTTTGTCGCCCAGTTCGGTCGGTTCGGAGCC 
TTGGCAGTTTATTGTGGTTCAAAACCCTGAAATCCGACAGGCAATCAAGCCGTTTTCTTGGGGTATGGCGGATGCT 
TTGGATACCGCCAGTCATTTGGTGGTGTTTTTGGCGAAGAAAAATGCCCGCTCCGACAGCCCGTTTATGTTGGAAA 
GCCTCAAACGGCGCGGCGTTACCGAACCGGATGCCGTAGCAAAATCTTTGGCAAGGTATCAGGCGTTTCAAGCTGA 
CGACATCAAGATTTTGGACGATTCTCGCGCCTTGTTTGACTGGTGTTGCCGTCAGACCTATATCGCGTTAGCCAAC 
ATGATGACGGGTGCGGCGATGGCAGGTATCGATTCCTGCCCGGTGGAAGGTTTCAACTATGCCGAGATGGAGCGCA 
TATTGTCCGGGCAGTTTGGTTTGTTCGATGCGGCAGAATGGGGCGTGTCCGTCGCCGCGACATTCGGCTACCGCGT 
TCAGGAAATCGCCACGAAAGCGCGTAGGCCCTTGGAAGAAACCGTTATTTGGGCATAA 
NTR-N-synth 
ATGACAGTATTATCTAAAGAACAAGTATTATCTGCATTTAAAAATAGAAAAAGTTGTAGACATTATGATGCTGCTA 
GAAAAATAAGTGCAGAAGATTTTCAATTTATATTAGAACTTGGAAGATTATCTCCTTCTAGTGTAGGATCTGAACC 
TTGGCAATTTATAGTAGTACAAAATCCAGAAATAAGACAAGCAATAAAACCTTTTTCATGGGGAATGGCTGATGCA 
TTAGATACAGCATCTCATTTAGTAGTTTTTTTAGCAAAAAAGAATGCAAGATCTGATTCACCATTTATGTTAGAAA 
GTTTAAAAAGAAGGGGAGTTACTGAACCAGATGCAGTAGCTAAAAGTTTAGCAAGATATCAAGCTTTTCAAGCTGA 
TGATATAAAAATTTTAGATGATAGTAGAGCATTATTTGATTGGTGCTGTAGACAAACTTATATAGCTTTAGCTAAT 
ATGATGACAGGAGCAGCAATGGCTGGAATAGATTCTTGTCCTGTAGAAGGATTTAATTATGCAGAAATGGAGAGAA 
TATTATCTGGACAATTTGGTTTATTTGATGCAGCTGAATGGGGAGTATCAGTTGCTGCAACTTTTGGATATAGAGT 
TCAAGAAATAGCTACAAAAGCAAGAAGACCATTAGAAGAGACTGTAATATGGGCTTAA 
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